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ABSTRACT 

Bipolar disorder (BPD), previously known as manic depression, is a severe, debilitating, 
mental illness. Characterized by cyclical swings between mania (elation) and 
depression (despair), BPD is common, estimated to affect 1 - 1.5 % of the population, 
and often aggregates in families. Suicide is a common phenotype and endpoint for 
about 20% of patients diagnosed with BPD. Twin, adoption and family studies provide 
strong support for a complex genetic aetiology that may involve multiple interacting 
susceptibility genes and an environmental component. The aim of this study is to 
identify susceptibility loci for BPD and attempted suicides (sub-phenotype), in South 
African families, integrating recent developments in statistical, computational and 
bioinformatics methods. 
Based on prior international reports of linkage, ten candidate regions (1 q32, 2q33.3, 
4p16.1, 7q11.23, 10q23.31, 12q24, 13q32, 15q12, 16p13.3 and 22q12.1) were selected 
and assessed for evidence of linkage in 22 multiplex South African families, under 
affection status model (ASM) I (BPI and BPII) and ASM " (BPI, BPII and MDE). To 
investigate the genetic component of BPD, this study included (i) analyses involving 
single locus and the jOint action of two loci, and (ii) the application of model-free/non­
parametric linkage methods, u ing the programs MERLIN, Simwalk2, Allegro and 
TWOLOC. A modest linkage signal was found on 1 q32, and we report evidence for 
interaction between 1 q32 and 10q23.31. USing bioinformatics the candidate genes 
flagged in region 1q32, included neuron navigator-1 (NAV) and adenosine A1 receptor 
(ADORA 1), whereas in region 10q23.31, the candidate genes serotonin receptor 7 
(HTR7) and phospholipase C epsilon 1 (PLCE1) were identified. 
This study went on to investigate the genetics of suicide attempts, owing to the high 
rates reported in individuals with an affective disorder. Two different approaches were 
used. In the association study the frequency of candidate gene (TPH, DRD4, BDNF, 
HTR2A and 5-HTT) polymorph isms were compared between 46 cases of attempted 
suicides and 160 controls. The only promising finding was the decreased frequencies of 
the 4/4 genotype and 4-repeat allele in the Caucasian subset, suggesting that the 4­
iv 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
repeat allele may confer a possible 'protection' against susceptibility to development of 
an affective disorder and/or attempted suicide. Of the 46 cases, 9 extended families 
were available for a linkage study. The presence of genetic vulnerabilities, which 
predispose individuals with mood disorders to suicidal behaviour, were investigated. 
Single locus analyses were carried out under ASM I (to assess the genetic 
predisposition to suicide attempts), ASM II (to assess the genetic predisposition to mood 
disorders) and ASM III (to determine whether inclusion of suicide attempts in the group 
of mood disorders had any effect on linkage). 
Single locus analysis provided statistical evidence in support of linkage between 
tryptophan hydroxylase (TPH1) and brain-derived neurotrophic factor (BDNF) in mood 
disorders. Evidence of linkage to BDNF, but not TPH1 was significant in suicide 
attempts. It therefore appeared that BDNF predisposes susceptible individuals to both 
mood disorders and suicide attempts, whereas TPH predisposes to mood disorders but 
not to the risk of suicide, suggesting a possible protection factor against suicidal 
behaviour in this group of mood disorder patients. Two-locus interactions showed 
evidence of interaction between BDNF and TPH, HTR2A and TPH, and 5-HTT and TPH, 
in the group of mood disorders. The single-locus linkage findings are consistent with 
international reports implicating BDNF, TPH, HTR2A and 5-HTT, in the pathophysiology 
of mood disorders. However, none of the two-locus interactions described here have 
been reported before. 
Due to the complex nature of BPO, it is clear that researchers cannot rely on classical 
genetics alone to identify genes for this conditiofl. To this end, the present study 
integrates classical genetics methodologies, statistical modelling of two-locus 
interactions and bioinformatics, to identify genes in common pathways, that may be 
involved in BPO and suicidal behaviour. 
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GLOSSARY 

Apoptosis 
Also known as programmed cell death, is the way in which cells that are induced to 
commit suicide 
Gene 
A sequence of DNA that codes for a particular protein. 
Genotype 
The genetic constitution of an individual either overall or at a specific locus. 
Heredity 
Transmission from generation to generation through the process of reproduction in 
plants and animals of factors which cause the offspring to resemble their parents. 
Heterogeneity 
Anyone of multiple genes may underlie similar phenotypes in different families, such as 
a wide concert of genes interacting in a common biochemical pathway 
Informed consent 
Consent given by a patient allowing research to be undertaken on his/her biological 
material. 
Linkage analysis 
A technique, designed to search for co-occurrence of a marker locus and a putative 
disease gene, using all the available inheritance information from families 
Lod score 
A measure of the likelihood of genetic linkage between loci. The log (base 10) of the 
odds that the loci are linked (with recombination fraction 8) rather than unlinked. For a 
Mendelian character, a lod score of +3 is evidence of linkage, one that is -2 is evidence 
against linkage. 
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Microsatellite 

A small run of tandem repeats (usually less than 0.1 kb) of a very simple DNA sequence, 

usually 1-4bp e.g. (CA)n. 

Multifactorial 

Traits are determined by interactions between a gene or genes and the environment, 

and do not exhibit Mendelian ratios 

Non-parametric analysis 

Is model-independent and therefore tests the deviation of inheritance pattern from 

random Mendelian segregation under independent assortment 

Oligogenic 

A phenotypic trait produced by two or more genes working together, but distinct from 

polygenic inheritance in that smaller number of total loci thought to be involved. 

Parametric analysis 

Proposes a specific model to explain the inheritance pattern of a trait-causing gene 

Penetrance 

Is genotype specific and is the probability of being affected given the genotype. 

Polymorphism 

The existence of two or more variants at significant frequencies in the popUlation; any 

sequence variant present at a frequency of more than 1 % in a population. 

Prevalence 

The proportion of individuals in a population having a disease. 

Proband 

The family member whose disease led to ascertainment of family for study. 
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PLAN OF THESIS 

This dissertation is comprised of five chapters, and the layout is as follows: 
Chapter 1 is a review of the literature, providing a context for BPD, that is a general 
theoretical background on various aspects of BPD. This is in order that the reader 
understands the concepts as they are introduced, and is aware of their importance. The 
work-related chapters 2 to 4 provide the relevant literature pertaining to these specific 
chapters. 
Chapter 2 provides perspective for the subsequent research, drawing primarily on the 
BPD research archive in the Division of Human Genetics, at the University of Cape 
Town South Africa, with some input from international archival resources. 
Chapter 3 and Chapter 4 present the laboratory-based research and each consists of 
an introduction, the experimental approach, followed by results and discussion. Chapter 
3 describes the investigation of the candidate regions that were chosen for linkage 
analysis, involving single and two-locus interactions, in bipolar disorder multiplex 
families. This chapter also describes the development and application of bioinformatics 
tools to identify candidate genes in linked and other regions. Chapter 4 details a pilot 
study in the genetics of suicidality in a subset of the cohort outlined in Chapter 2. 
Chapter 5 concludes the dissertation, providing a general discussion of the present and 
international investigations. 
xvi 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CHAPTER 1 

REVIEW OF BIPOLAR DISORDER 
Based on the Mendelian principles of genetic transmission, the heritability of 
polymorphisms in DNA has been used in families to map inherited diseases to the 
genome. The successful application of these techniques to several hereditary 
diseases including Duchenne Muscular dystrophy (Monaco et aI., 1985; Kunkel et 
aI., 1986), cystic fibrosis (Kerem et aI., 1989) and Huntington disease (Gusella et 
aI., 1983) has naturally evolved to the use of mapping to even non-Mendelian 
disorders and indeed to psychiatric disorders. Thes~ common disorders do not 
follow a monogenic pattern of inheritance, but are generally influenced by both 
genetic and environmental components (Ghosh and Collins, 1996). This thesis 
outlines an attempt to identify genetic elements predisposing to bipolar disorder 
(BPD). 
The intensity of research dedicated to BPD reflects the degree of scientific and 
public recognition of its 'burden of disease' in society. This introductory chapter (1) 
provides an overview of BPD, starting with the long and well recorded history of the 
disease. Following the historical perspective, the epidemiology of the disease is 
presented. Detailed descriptions of the clinical aspects of BPD, neurobiology of 
mood and pharmacological intervention all provide necessary background 
information on the status of research to date. The understanding of BPD as a 
multifactorial disorder is presented and the concept of a genetic or hereditary 
component is introduced. Molecular genetic research and analytical strategies 
adopted in BPD to date, and as they relate more directly to the proposed research, 
are described. In light of this historical context, the epidemiological status of the 
disease, and the current research status, the present study is motivated, and the 
aims and objectives of the research made explicit. 
1.1 HISTORY OF BIPOLAR DISORDER 
The deeds and accounts of the classical Greek physicians chronicle the recognition 
of BPDs even in ancient times (reviewed by Angst and Marneros, 2001). In the first 
century AD, Aretaeus of Cappadocia, cited in Angst and Marneros (2001), 
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categorically described the inherent connection between mania and melancholia. 
Notwithstanding the fundamental contributions made by these ancient physicians 
and subsequent psychiatrists of the 19th century, BPD was first classified as a 
distinct entity in 1951 by Jean-Pierre Falret (cited in Angst and Marneros 2001). 
Falret observed BPD, which at the time he termed 'folie circulaire', which is 
characterised by a continuous cycle of depression and mania with lucid intervals of 
varying length. Succeeding Falret and with opposing views, Jules Baillarger, in 
1854, submitted his judgement 'folie a double forme', that is a disease in which 
mania and melancholia vacillated, but where the interval was of no consequence 
(cited in Angst and Marneros 2001). 
The German psychiatrist, Emil Kraepelin (1856-1926), upon whose findings 
contemporary distinctions of psychiatric disease depend, defined manic depressive 
disorder thus: "As a rule the disease runs its course in isolated attacks more or less 
sharply defined from each other or from health. Accordingly we distinguish first of 
all manic states with the essential morbid symptoms of flight of ideas, exalted mood, 
and pressure of activity, and melancholia or depressive states with sad or anxious 
moodiness and also sluggishness of thought and action. These two opposed 
phases of the clinical state have given the disease its name. But besides them we 
observe also clinical 'mixed forms', in which the phenomena of mania and 
melancholia are combined with each other" (Angst and Marneros 2001). 
Kraepelin's immense contribution to the comprehension, diagnosis and prognosis of 
manic depressive illness (BPD), qualifies his recognition as the 'father of modern 
psychiatry' (reviewed by Angst and Marneros, 2001). However, two of Kraepelin's 
impressions have motivated strong counterarguments from German scholars in 
psychiatry. Firstly, Kraepelin's unitary concept of BPD included not only attenuated 
forms, but also much of the sphere of major depressive disorders (Akiskal, 2003). 
Secondly, in 1899, his binary theory separated manic depressive insanity and 
dementia praecox (schizophrenia) as distinct disease entities, based on clinical 
symptoms, course, and prognosis (Crow, 1986; Angst, 2002). However, the more 
descriptive trend in modern psychiatric classification is in favour of a continuum 
from BPD to schizophrenia (Crow, 1986; 1990; Angst, 2002), including 
schizoaffective disorder as an intermediate phenotype (Angst and Marneros, 2001; 
Benabarre et aI., 2001). The vast range of research of BPDs and schizophrenia 
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internationally, showed similarities in age at onset, lifetime risk, course of illness, 
world-wide distribution, suicide risk, gender influence and genetic susceptibility 
(Berrettini, 2000). 
In 1966, Perris put forward the nosological distinction between unipolar and BPO, 
thereby confirming Falret's and Baillarger's concepts of cycling mania and 
depression in BPD (Perris, 1966; Angst and Marneros, 2001). This binary 
conceptualisation removed a large portion of depressive disorders from BPO 
(Akiskal, 2003), and is currently reflected as official nosology in the fourth edition of 
the Diagnostic and Statistical Manual for mental disorders (DSM-IV, American 
Psychiatric Association (APA), 1994). 
1.2 EPIDEMIOLOGY OF BPD 
Over recent decades the clinical definition of BPD has been revisited extensively. 
giving rise to the disparity in reported prevalence even in the same population 
groups (Greil and Kleindienst, 2003). Although earlier epidemiological studies 
reported a lifetime prevalence of 0.5-1.5% for BPD (Hwu et aI., 1989), more recent 
population-based investigations indicate a much higher prevalence of this disorder. 
The reported increase in prevalence is attributed to the improved ascertainment 
through the development of diagnostic manuals and diagnostic practices (Greil and 
Kleindienst, 2003). For example (with the exception of the DSM-IV), a patient 
initially diagnosed as either schizophrenic, unipolar depressive or exhibiting a 
personality disorder (PO), is now presumed to belong to the BP spectrum (Stoll et 
aI., 1993; Angst and Marneros, 2001; Akiskal and Benazzi, 2003). 
The burden of neuropsychiatric disorders, which includes mental and nervous 
system disorders, was highlighted in the 'Global Burden of Disease Study' (GBD) 
(Murphy and Lopez, 1997a). In 1990, this cluster of conditions was reported to 
account for 0.3% of deaths and 10.5% of the burden of disease and injury world­
wide. Estimates of the global burden of disease calculated in terms of disability­
adjusted life years (DAL Ys) placed unipolar major depression (UMD) as the fourth 
most disabling disorder world-wide, preceded by, in descending order, lower 
respiratory tract infections, diarrhoeal diseases and perinatal disorders. With the 
inclusion of suicide in the primary tabulations, the burden of UMD was elevated by 
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nearly 40% (Murphy and Lopez, 1997a). Alcohol use, schizophrenia and BPD were 
the other neuropsychiatric conditions in the 30 leading contributors to burden of 
disease. As part of the GBD, projected health scenarios of (future) mortality and 
disability, predict a rise in the burden of neuropsychiatric disorders, including BPO, 
from 10.5% in 1990 to 14.7% in 2020 (Murray and Lopez, 1997b). 
In South Africa the "National Burden of Disease study" excluded the category of 
neuropsychiatric conditions per se, but included the categories of mental disorders 
and nervous system disorders, to make Lip the category of neuropsychiatric 
conditions (Bradshaw et aI., 2003). Remarkably, this category of neuropsychiatric 
conditions ranked as the second most burdensome of all medical conditions, after 
HIV/AIDS, thereby justifying the present research into this group of disorders. 
1.3 CLINICAL ASPECTS OF BPD 
1.3.1 Clinical phenotype and diagnostic guidelines 
Much of the current understanding of the clinical phenotype of BPD is based on the 
DSM-IV (APA, 1994). Aimed at presenting a unified and comprehensive 
nomenclature/nosology for psychiatric illness, more than 300 mental, behavioural 
and addictive disorders, as well as other psychopathologies, are described and 
grouped into broad diagnostic categories in the most recent edition of this 
publication. The DSM-IV uses a multi-axial approach, where the axes are levels of 
diagnoses that assist the clinician in the planning of treatment and prognostication. 
Axis I comprises the major groups of clinical disorders, including eating, anxiety, 
substance-related and mood disorders, amongst others. Of these, the mood 
disorders comprise those conditions where the predominant feature is a disturbance 
in mood (affect), such as BPD and major depressive disorder (MDD). 
Characteristically, individuals affected with BPD (often not recognised by relatives, 
friends, physicians or even the patients themselves) vacillate between states of 
major depression, hypomania and frank mania; whereas individuals affected with 
MDD, experience one or more major depressive episodes (MDE). 
According to DSM-IV guidelines, during a IVIDE the patient experiences a loss of 
interest or pleasure in his/her normal activities, weight loss or gain, insomnia or 
hypersomnia, fatigue, psychomotor agitation or retardation, diminished ability to 
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think or concentrate and a feeling of worthlessness. In order to meet the criteria for 
diagnosis of a MOE, symptoms must be present nearly everyday for at least two 
weeks. Furthermore, patients may be plagued by recurrent thoughts of death or 
suicidal ideation, or they may attempt suicide. A hypomanic episode typically lasts 
at least four days, during which the patient's symptoms include: elation or irritation, 
inflated self-esteem or grandiosity, decreased need for sleep, psychomotor 
agitation, recklessness, impulsivity, incoherent thoughts, distractibility and a flight of . 
ideas. A manic episode, a more extreme case of hypomania, lasts for a minimum 
period of one week, when the patient experiences all the symptoms of a hypomanic 
episode as well as difficulty in performing their daily functions. 
On account of the different phases that. patients with BPO may experience, the 
OSM-IV has defined two different forms of the condition, BP type I (BPI) and BP 
type "(BPII). A subject diagnosed with BPI disorder may express one or a 
combination of the following symptoms: 
(i) 	 one manic episode with no history of MOEs, 
(ii) 	 currently or most currently in a hypomanic episode, preceded by at least one 
manic or mixed episode, 
(iii) 	 currently or most currently in a manic episode following at least one previous 
MOE, 
(iv) 	 manic or mixed episode, or currently in a mixed episode having had at least 
one previous MOE, manic episode or mixed episode. 
The diagnosis of BPII disorder is based on the presence or history of one or more 
MDEs and at least one hypomanic episode; without any prior experience of manic 
or mixed episodes. Often people experience a mixed state, i.e. when the criteria for 
both a manic and a depressive episode are met everyday for at least one week. 
OSM-IV criteria also include rapid cycling, a variant of BPO, during which patients 
experience four or more mood episodes within a 12-month period. 
Some individuals endure fluctuating disturbances of mood that involve numerous 
periods of hypomania and depression, whilst the symptoms do not meet the full 
criteria for classification of a manic episode or a MOE. If symptoms persist for at 
least two years, patients are diagnosed with· cyclothymic disorder. When a patient 
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appears to present features of BPO, yet does not meet the "full" criteria for BPO, a 
diagnosis of BPO "not otherwise specified" (NOS) is given. 
Patients with BPO commonly have at least one other (co-occurring) Axis I disorder, 
such as anxiety and substance abuse, with eating disorders diagnosed to a lesser 
extent (McElroy et aI., 2001; 2004). Co-occurring disorders, such as BPO and 
substance abuse, or BPO and anxiety disorders, have important clinical 
implications, because of the prevalence and negative impact on the course, 
treatment and prognostic response to both disorders (McElroy et aI., 2001; Myrick 
and Brady, 2003; Boylan et aI., 2004). Substance use, for example, aggravates 
bipolar symptoms and functionality, as evidenced by its association with an earlier 
age of onset of BPO (Feinman and Dunner, 1996), increased rates of psychiatric 
hospitalisation, delayed remission from acute mania (Goldberg et aI., 1999), poor 
response to lithium among bipolar patients (O'Connell et aI., 1991), and higher rates 
of suicide attempts (Feinman and Dunner, 1996; Potash et aI., 2000). 
BPO can also present with an Axis II disorder, which includes personality disorders 
(POs) such as paranoid PO, borderline PO, obsessive-compulsive PO, and mental 
retardation. Kraepelin, cited in Cloninger et al. (1998), was the first to identify the 
existence of enduring/rudimentary personality variants that are essential for the 
development of psychotic or mood disorder states. In 1999, Henry and colleagues 
demonstrated the impact of temperament on the clinical evolution of BPO, 
su pporting the existence of a continuum between personality and affective 
disorders. The three most frequent POs associated with BPO, as evidenced by the 
independent studies of Rossi et al. (2001) and Brieger et al. (2003), were 
obsessive-compulsive PO, borderline PO and avoidant PD. 
Variance in personality can arise from four temperament dimensions (harm 
avoidance, novelty seeking, reward dependence and persistence) and three 
character dimensions (self-directedness, cooperativeness and self-transcendence) 
(Cloninger et aI., 1993). Based on these dimensions, the Temperament and 
Character Inventory (TCI), one of a number of rating scales, was developed as a 
reliable and efficient test for the assessment of personality. TCI traits were found to 
be related to mood states (Cloninger et aI., 1998). More recently, using the TCI, it 
was reported that patients with BPO scored significantly higher in harm avoidance 
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and lower in reward dependence, self-directed ness and cooperativeness, than a 
control group (Engstrom et aI., 2004). These BPD patients were wearier, less 
sentimental, more independent, less purposeful and resourceful, less empathetic 
and had less impulse control than the control subjects. Engstrom and co-workers 
(2004) noted the possibility that specific personality dimensions may predispose 
individuals to BPD or alter the natural history of illness and response to treatment. 
Personality traits are a significant theme of BPD research internationally, and may 
further contribute to sub-phenotypes within a heterogeneous phenotype. 
Based on the number of overlapping diagnostic and syndromic entities observed in 
families with BPD, a number of clinical practitionersiresearchers have contributed to 
the construction of a bipolar spectrum (Gershon et aI., 1982; Weissman et aI., 1984; 
Coryell et aI., 1984; Kelsoe 2002; Akiskal, 2003). Ranging in decreasing symptom 
severity and detriment, the spectrum includes the following: BPI - BPII - recurrent 
unipolar depression - single episode unipolar depression - cyclothymia - dysthymia ­
affective personalities. Adding to the complexity of the BPD phenotype, Crow 
(1986) proposed the concept of a continuum of psychosis with increasing severity 
and impairment, extending from unipolar, through bipolar affective illness and 
schizoaffective psychosis, to typical schizophrenia. The observed aggregation of 
psychotic symptoms, defined as hallucinations or delusions (originally thought to 
typify schizophrenia), in families with BPD lends support in favour of Crow's 
continuum of psychosis (Potash et aI., 2001; Tsuang et aI., 2004). It is currently 
unresolved as to whether the all-inclusive bipolar spectrum depicts a clinical or 
genetic continuum (Akiskal, 2003). 
DSM-IV does not accurately distinguish between BPI and BPII disorder, except for 
the difference between mania and hypomania, since age of onset and the duration 
of episodes are very similar. Furthermore the current diagnostic gold standard, the 
Structured Clinical Interview for DSM-IV (SCID), classifies the bipolar spectrum 
conditions as Type II and NOS (Ghaemi et aI., 2003) and omits depressive mixed 
states, MDE and hypomania of less than four days duration, which are commonly 
found in clinical practice (Akiskal and Benazzi, 2003). Therefore the bipolar 
spectrum disorders often go unrecognised, or they may be misdiagnosed as 
symptoms of either impulsive behaviour or alcohol and substance abuse (Ush et aI., 
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1994). Misdiagnosis or delayed diagnosis can be damaging. as it complicates drug 
treatment strategies and contributes to suicidal behaviour (Kasper, 2003). 
Recognising the need for more descriptive screening instruments or measures for 
BPD, researchers have sought to develop sufficiently sensitive diagnostic tools to 
supplement DSM-IV guidelines. The Mood Disorder Questionnaire (MDQ), a brief 
self-report scale, was developed to screen for a lifetime history of a manic or 
hypomanic syndrome (Hirschfeld et aI., 2000). The MDQ yielded good sensitivity 
and specificity scores for the bipolar spectrum disorders in a psych iatric. outpatient 
population. Moreover, the MOQ improved the diagnosis of the so-called 'soft' 
phenotype (Akiskal, 2003), towards the diagnosis of BPI! disorder, which frequently 
stays undetected in psychiatric care. (Isometsa et aI., 2003). Another instrument, 
the Bipolar Spectrum ~iagnostic Scale (BSOS), aimed at identifying BPII and NOS 
conditions, was demonstrated to be highly sensitive and specific for bipolar 
spectrum conditions (Ghaemi et aI., 2003). The combined administration of MOQ 
and BSOS promises to be a powerful screening tool. Well-validated and 
comprehensive, the Brief Psychiatric Symptom Rating scale-24 item version 
(BPRS24) (cited in Dennehy et aI., 2004). assesses symptom changes in psychiatric 
patients. including manic phase symptoms for patients with BPO. A subset of 10 
BPRS24 items was incorporated into the Brief Bipolar Disorder Symptom Scale 
(BOSS), which was developed to measure the critical dimensions and symptoms 
seen in patients with BPO (Dennehy et aI., 2004). In preliminary investigations the 
BOSS was sensitive to symptom change, suggesting its use as an invaluable 
su pplementary tool in clinical settings for the purposes of assessing symptom 
severity and treatment response. 
While various formal rating scales exist for the assessment of a range of clinical 
expressions of bipolar spectrum disorders, not all of these tools appear to be well 
suited for use in everyday clinical practice. The area of diagnosis is therefore an 
area that is in need of considerable further research. It is likely that once genes are 
identified in at least a subset of BPOs that the confusing issues of genetic and 
clinical heterogeneity will begin to be logically defined. 
Another reported feature of BPD, is greater neurological dysfunction, predominantly 
in the region of sequencing of complex motor acts (Negash et aI., 2003). It is 
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possible that these early neurological "soft signs" are stable manifestations of BPD 
and represent a stable disease process. Furthermore, cognitive abnormalities have 
been detected in symptomatic BPD patients with trait-related deficits present in 
verbal recall and sustained attention (Quraishi and Frangou, 2002). The research 
into personality traits, neurological and cognitive dysfunction has contributed to the 
understanding of the disease pathology of BPD, however, these neuropsychological 
aspects are not discussed any further in this thesis. 
Along the behavioural dimension, suicide is a serious complication of BPD and a 
common endpoint for many patients (Barraclough, 1974; Mann, 1998; Jamison, 
2000). Over 90% of suicide victims are reported to have suffered a significant 
psychiatric illness in their lifetime (Isometsa et aL, 1995; Harris and Barraclough, 
1997; Mann, 1998; Sher et aL, 2001), predominantly major depression and BPD 
(Guze and Robins, 1970; Oquendo et aI., 2000; Jamison, 2000; Sher et aI., 2001). 
An estimated 25-50% of patients with BPD admit to at least one suicide attempt in 
their lifetime (Jamison, 2000; Oquendo et aI., 2000; Grunebaum, 2001). 
Consequently, the mortality rate in BPD is two to three times higher than that of the 
general population (Muller-Oerlinghausen et aI., 2000). Amongst the 20 leading 
contributors of premature mortality in South Africa, suicide is ranked 10th in males 
(1.9%), 19th in females (0.7%) and 11th in general (1.4%) (Bradshaw et aI., 2003). 
l\Jo definitive epidemiological information is available on the contribution of 
neuropsychiatric illness to suicide. 
Comorbid substance abuse (Tondo et aI., 1999), borderline PD, hopelessness and 
a history of impulsive aggression all increase the risk of suicide attempts and 
ideation in BPD (Oquendo et aL, 2000; Soloff et aI., 2000). It is estimated that the 
lifetime mortality due to suicide is approximately 20% in BPD patients, 15% in 
individuals suffering from unipolar depression, 18% in alcoholics, 10% in 
schizophrenics and 5-10% in individuals with some type of PDs. The latter include 
both borderline and antisocial PDst characterised by emotional liability, aggression 
and impulsivity. Furthermore, with the TCI, individuals who scored low in both self­
directedness and cooperativeness were at an increased risk of both attempted and 
completed suicide (Cloninger et aI., 1998). Therefore, suicide is not merely a 
serious consequence of a personal crisis or a psychosocial impediment, but occurs 
at a significantly elevated incidence in the context of a psychiatric condition, 
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particularly in the mood disorders. The relationship between suicidality and BPD 
and specific genetic loci is investigated in Chapter 4 of this current study. 
1.3.2 Gender and Age 
The influences of gender and age on the clinical manifestation of BPD have been 
reported in the literature, and deserve a mentioning at this stage. According to 
McGuffin and Katz (1989), in order to give a sufficient account of the complex 
relationship between the influences of "nature" (genes) and "nurture" (environment) 
one has to consider gender differences in the aetiology of affective disorders. 
There are differences in the clinical course of BPD in men and women (Rasgon et 
aI., 2005). Women have higher rates of depression and larger fluctuations in mood 
than men, and are about two times as likely as men to describe a lifetime history of 
MDEs (Kessler et aI., 1993; Weissman et aI., 1993; Bierut et aI., 1999; Visscher et 
al. 2001; RClgson et aI., 2005). Furthermore and in line with mood disorders 
generally, Silberg et al. (1999) reported increased heritability of depression among 
adolescent girls (aged 8 to 16 years). 
Characteristically, BPD manifests at a relatively early age and late onset cases are 
reported to be rare (Nath et aI., 2001; Visscher et aI., 2001). Schurhoff et al. (2000) 
defined early and late onset as before 18 and after 40 years of age, respectively. 
The most severe manifestations of BPD are generally observed in the early onset 
group. Commonly, severely affected patients experienced increased psychotic 
features, increased mixed episodes, greater co-occurrence with panic disorder and 
inferior prophylactic lithium response. In addition, a reported association exists 
between early age at onset of BPD and suicidal behaviour and substance use 
disorders, rapid cycling course (Carter et aI., 2003; Ernst and Goldberg, 2004) and 
a family history of affective disorders (Johnson et aI., 2000). Owing to differences in 
clinical expression and familial risk, it has been implied that early and late onset 
BPDs may be considered to be distinct sub-forms of BPD (Schurhoff et aI., 2000). 
As probable as the existence of these sub-forms may be, there is still debate in the 
literature on defining their accurate age at onset thresholds. 
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1.4 NEUROBIOLOGY OF MOOD 
The underlying biology of mood disorders, which might aid surer and faster 
diagnosis, is gradually being exposed. As BPD is a neuropsychiatric condition, 
involving the central nervous system (eNS), the next two sections of this chapter 
provide relevant background on the normal functioning of neural circuitry. This is 
followed by a description of the reported neurological abnormalities underlying the 
clinical phenotype of BPD, an area that has been extensively studied over the last 
decade. 
1.4.1 Neural basis of emotion perception 
Emotion perception is based on three processes: (i) identification of the emotional 
importance of the stimulus; (ii) production of a specific affective condition in 
response to the stimulus; and (iii) the management of the affective condition and 
emotional behaviour (Phillips et aI., 2003). Findings from recent human lesion 
(Adolphs et aI., 1994; Bechara et aI., 1995; Scott et aI., 1997) and functional 
neuroimaging studies (Anderson and Phelps, 2001; Davis and Whalen, 2001; 
Drevets et aI., 2001) suggest that these processes may depend on the functioning 
of two neural systems: a ventral, and a dorsal system. The ventral system, 
including the amygdala, insula, ventral striatum, ventral regions of the anterior 
cingulate gyrus and prefrontal cortex, is responsible for the rapid appraisal of the 
emotional significance of the stimuli and the subsequent production of the affective 
state. The dorsal system, including the hippocampus and dorsal regions of the 
anterior cingulate gyrus and prefrontal cortex, is responsible for executive functions, 
including selective attention, planning, and laborious rather than automatic 
regulation of resliiting affective states (Scott et aI., 1997; Davis and Whalen, 2001; 
Drevets et aI., 2001). The functioning of these two neural systems involves 
complex signalling networks elicited by neurochemical transmission. 
1.4.2 Neurochemical transmission 
Neurochemical transmission is the process by which an electrical impulse in the 
presynaptic neuron is converted to a chemical signal (Stahl, 2000). This conversion 
involves the release of chemical messengers called neurotransmitters at the 
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synapse between the pre- and postsynaptic neuron. The released neurotransmitter 
molecules (first messenger) selectively bind to appropriate receptors on the surface 
of the post-synaptic neuron. This binding action leads to the postsynaptic events of 
chemical neurotransmission, starting with the production of second messengers, 
which include cyclic adenosine mono phosphate {cAMP} and phosphatidylinositol 
(PI) (Stahl, 2000). Through a biochemical cascade, these second messengers 
instruct the postsynaptic neuron to execute numerous actions (for example, to 
modify its ionic fluxes, to generate or stop neuronal electrical impulses, and to 
phosphorylate intracellular proteins). These postsynaptic events ultimately extend 
to the cell nucleus, where they regulate the expression of certain genes. This 
process initiates a second biochemical cascade, which is dependent on the manner 
in which specific genes in the previous cycle have been regulated. 
Termination of the initial signal occurs when the neurotransmitters detach from the 
receptor and either diffuse through the extracellular fluid. undergo re-uptake, or are 
broken down by enzymes (Kandel et aI., 2000). Neurotransmitter receptors are 
also found on the presynaptic neuron (autoreceptors) and function as inhibitors of 
further neurotransmitter release. Each neurotransmitter has a variable number of 
receptor subtypes that function in association either with G-proteins, protein 
kinases, or by the receptor itself in the form of a ligand-gated ion channel (Stahl, 
2000). 
Neurotransmitters such as the three major monoamines: serotonin, norepinephrine, 
and dopamine can modify and shape human behaviour (Stahl, 2000). Serotonin, 
present in both the central nervous and peripheral nervous systems, is formed by 
the hydroxylation and decarboxylation of tryptophan and then released by 
serotonergic neurons (Mendes de Oliveira et aI., 1998). In turn, serotonin (S-HT) 
exerts its function upon interaction with specific receptors of which several have 
been cloned and identified (SHT1 to SHT7). each with its own subtypes. With one 
exception. the serotonin receptors are G-protein coupled receptors. Synaptic 
actions of serotonin are terminated by the re-uptake of serotonin by the serotonin 
transporter protein (Hoehe et aI., 1998), and the destructive enzyme. monoamine 
oxidase (MAO). 
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Dopamine and norepinephrine, further classified as catecholamines, are chemical 
compounds formed from tyrosine (Furlong et aI., 1999). These neurotransmitters, 
apart from their excitatory and inhibitory affects in the peripheral nervous system, 
are active in the CNS. In the CNS, dopamine receptors effect brain processes that 
control movement, cognition, emotion, in addition to neuro-endocrine secretion 
(Grandy et aI., 1992; Emilien et aI., 1999). The dopamine receptors belong to a 
superfamily of seven transmembrane domain G-protein coupled receptors 
(Sherrington et aI., 1993). At least six dopamine receptors have been cloned from 
brain tissue (Emilien et aI., 1999; Hiroi et aI., 2002). These receptors include the D1 
class, divided into D1 and D5 receptor subtypes, which, when activated, stimulate 
adenylate cyclase, the enzyme that converts ATP to cyclic AMP (Emilien et aI., 
1999). The D2 class, consisting of the D2, D3 and D4 subtypes, generally inhibit 
adenylate cyclase activity. Termination of dopamine synaptic activity involves the 
uptake of dopamine by the dopamine transporter into the presynaptic terminal 
(Giros et aI., 1996). Dopamine is also destroyed enzymatically, by MAO and 
catechol-o-methyl transferase (COMT). 
Dopamine, when transported into norepinephrine-producing neurons, is rapidly 
transformed into norepinephrine (Kandel et aI., 2000). In the CNS, the locus 
coeruleus of the brain stem is concentrated with norepinephrine-containing cell 
bodies. Following release into the synaptic cleft, postsynaptic activity involves the 
excitatory alpha 1 and beta adrenergic receptors and the inhibitory alpha 2 receptor 
(reviewed in Ressler and Nemeroff, 1999). Norepinephrine activity can be 
terminated by the norepinephrine transporter, which rapidly returns norepinephrine 
to the synaptic terminals. The same enzymes that destroy dopamine (MAO and 
COMT) destroy norepinephrine. 
In addition to monoamines, the nervolJs system makes use of multiple other 
neurotransmitters, including amino acids of which y-aminobutyric acid (GABA) is the 
most important inhibitory neurotransmitter. 
As neurochemical transmission is the process that underpins emotion and 
behaviour, the neurochemical control of any component of this highly regulated 
matrix may be a potential cause of neuropsychiatric disorders. 
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1.4.3 Cellular phenotype of BPD 
In light of the intricacy of brain function, it is not surprising that the aetiology and 
pathophysiology of BPO is not well understood. However, distinct imbalances in 
neurochemical control, including reduced glial cell number, excess signal activity, 
neuropeptide aberrations and monoamine alterations, have been observed in the 
brains of patients with BPO (reviewed by Vawter et aI., 2000). This area of 
research carries much credence and has guided the selection of candidate loci in 
the present study. 
1.4.3.1 The neurotransmitters 
Based largely on pharmacological observations, the mo oamine model 
(Schildkraut, 1965) implicates serotonin, dopamine and norepinephrine in BPO. It is 
possible that patients with BPO have diminished neurotransmitter transport into the 
synaptic vesicle and/or presynaptic neuron (Freis, 1954; Schildkraut, 1965). 
Consequently, the synaptic vesicles are non-functional and a surplus of the 
respective neurotransmitter exists, resulting in a higher concentration of transmitter 
in the synaptic cleft. This may also be responsible for the corresponding fluctuation 
in mood. In their study, Potter and Manji (1994) corroborated the monoamine 
hypothesis, which generally showed a rise in monoamine turnover occurring in 
mania and a fall in depression. Serotonin has been implicated in a variety of traits 
and behaviour such as mood, anxiety, aggression, sleep, appetite and suicidality 
(Mendes de Oliveira et aI., 1998). Imbalances in the dopaminergic system are 
involved in manic depression, schizophrenia, Parkinson disease and Tourette 
syndrome (Grandy et aI., 1992; Ernilien et aI., 1999). Irregularities in 
norepinephrine circuits have been shown to possibly interfere with concentration, 
attention, memory, arousal states and sleep regulation (Ressler and Nemeroff, 
1999). Further clarification, however, is needed on which of the three monoamines, 
, are predominantly involved in depression and mania. 
In addition to the roles of these monoamines, the GABA receptor genes may be 
involved in the pathogenesis of affective disorders (Petty, 1995). Sanacora and 
colleagues (1999) reported a significant reduction in cortical GABA concentrations 
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in the brains of depressed patients, with the idea that diminished amounts of this 
neurotransmitter could lead to the "uncontrolled" phenotype of BPD. 
1.4.3.2 Beyond the neurochemical origin 
The monoamine model of BPD (Schildkraut, 1965) fails to explain the mechanism 
underlying the therapeutic action of antidepressant drugs. Furthermore it does not 
provide an holistic view of the pathophysiology of depression (Hindmarch, 2002). In 
addition, it seems as though medications work by modifying synaptic connections 
and therefore alternative mechanisms, other than the monoamine model, have 
been investigated to help elucidate the pathophysiology of BPD. 
Emerging evidence implicates impairments of structural plasticity and cell survival in 
the pathophysiology of mood disorders (Duman et aI., 1997; Manji et aI., 2001; 
Rohlff and Hollis, 2003). Neuronal plasticity is pivotal to the process by which the 
brain gathers information and facilitates the execution of the suitable adaptive 
responses to anticipated situations (Duman, 2002). Disruption of these primary 
processes can thereby lead to the pathobiology of mood disorders. Recent studies 
have demonstrated structural changes in the brain in response to stress and in 
patients with mood disorders (Duman et aI., 2000; Duman, 2002; Spedding et aI., 
2003). 
The neuroprotective effects of lithium are mediated through the brain-derived 
neurotrophic factor (BDNF)/receptor tyrosine kinase (TrkB) signalling pathway 
,(Hashimoto et aI., 2002). BDNF, a neurotrophic factor for both the norepinephrine 
and serotonin neurotransmitter systems (Mamounas et aI., 1995), is involved in cell 
survival and synaptic plasticity (Thoenen, 1995), and is one of the targets of 
antidepressant treatment (Duman et aI., 1997; Duman et aI., 1999). Over the past 
decade, investigation into the pathophysiology of BPD and unipolar depression has 
focussed on second messenger systems (for example, cAMP and PI) within cells. 
The cAMP second messenger pathway, including the cAMP response element 
binding protein (CREB) and G proteins, has been implicated in BPD (Manji et ai, 
1995; Thome et aI., 2000). Furthermore, altered levels of catalytic subunits of 
cAMP-dependent protein kinase (PKA), a central component of the cAMP signalling 
cascade, and one of its substrates, RAP1, were reported in the platelets of bipolar 
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patients (Perez et aI., 2000). Abnormalities of the PI system, another second 
messenger pathway, were found in post-mortem brains of subjects with BPO (see 
Gould and Manji, 2002 for review). The second messenger system is considered a 
credible area of research with support, further than that listed above. 
Further research points to the disruption of inherent biological rhythms, such as the 
sleep-wake cycle, hormonal rhythms, temperature regulation and circadian rhythms, 
as an underlying mechanism in BPO. This is supported for example by the study 
which showed the secretion of the hormone melatonin, an indolarnine derivative of 
serotonin, which is involved in the timing of circadian rhythm information, as 
frequently abnormal in patients with BPI (Nurnberger et aI., 2000). While this points 
to the diversity of proposed etiologic mechanisms and the breadth of BPO research, 
it is not an aspect which is pursued beyond this chapter. 
1.4.4 Functional and structural brain abnormalities in BPD 
Extricating the disease pathology of BPO from the rest of the mood disorders {so 
that etiologically distinct categories can be formed), as well as defining its link with 
brain structure and function, is a challenging task. In addition to neuro-anatomical 
and clinical data, the explosion of brain-imaging technologies in the last decade 
{such as magnetic resonance imaging (MRI) and positron emission tomography 
(PET» is adding considerably to the area of functional neurobiology. 
PET images of cerebral blood flow and the rate of glucose metabolism, in bipolar 
and unipolar depressive patients, identified abnormally decreased activity in the 
prefrontal cortex (PFC) ventral to the genu of the corpus callosum in the left 
hemisphere (Orevets et aI., 1997). The implicated neuronal region forms part of the 
multiplex circuitry of emotion and is critically involved in the dysfunctional states of 
depression and mania. Importantly, the subgenual PFC has been shown to be 
involved in the regulation of neurotransmitter systems. 
Analysis of lesions of the subgenual PFC in humans and experimental animals, 
implicated this area in the regulation of visceral responses to stimuli incited by 
stressful and emotional experiences. MRI indicated a corresponding reduction in 
the mean volume of grey matter of the subgenual PFC in BPO subjects (Orevets et 
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aI., 1997}. Furthermore, MRI images of patients with BPD suggested subregion­
specific grey matter volume reductions in the PFC (Lopez-Larson et aI., 2002). 
Information gathered from post-mortem brain studies could supplement and guide 
neuro-imaging studies in psychiatric patients. Preliminary post-mortem 
histopathological assessments of subgenual PFC tissue from subjects with MOD 
and BPD suggest that the abnormal reduction in grey matter volume is associated 
with a reduction in glia (Drevets et aI., 1998). However, no decrement in neuronal 
number was observed. Recently, Uranova and co-workers (2004) reported a 
significant reduction in the density of oligodendroglial cells in the PFC of post­
mortem human brain specimens of BPD patients. 
Despite the notable body of neuro-imaging and neuropathology studies indicating 
the occurrence of brain changes in BPD, their aetiology and their relation to 
phenotypic characteristics are yet to be established. Malfunctioning of the 
subgenual PFC may upset autonomic, neurotransmitter, neuroendocrine, motor and 
somatosensory responses, which together bring about human emotion (Damasio, 
1997). It is through the understanding of the process of neurochemical 
transmission that psychopharmacology aims to unravel the mechanism of drug 
action on the brain (Stahl, 2000). 
1.5 PSYCHOPHARMACOLOGY 
The advent of the anti-psychotic drug, chlorpromazine, in 1952, marked the 
beginning of psychopharmacology (Catalano, 1999). Psychopharmacology heeds 
the impact of diseases on the CNS, and explains the behavioural effects of 
psychiatric medicines. While this project does not focus on treatment, but rather on 
the genetic susceptibility of the disease, it is important to note that an increase in 
genetic understanding could aid treatment. 
The treatment of BPD is variable and reflects the heterogeneity the clinical 
phenotype of the disease. Treatment modalities in BPD include electroconvulsive 
therapy, psychotherapy, sleep deprivation, phototherapy and psychopharmacology 
(reviewed in Compton and Nemeroff, 2000). One of the main aims in the treatment 
of BPD is mood stabilisation (Griel and Kleindienst, 2003). The desired effects of 
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mood stabilisers are antimanic, antidepressant (Goodwin et aI., 1972), and 
prophylactic efficacy. It has been proposed that the therapeutic agent should 
improve at least one phase of illness, without worsening another (Keck and 
McElroy, 2003). 
Amongst the most established mood stabilisers (lithium, valproate and 
carbamazepine) (Gould et aI., 2002), lithium comes the closest to meeting the 
criteria of a comprehensive mood stabiliser. Since its discovery, lithium is 
considered the cornerstone of pharmacologic treatment of persons affected with 
BPD (reviewed in Manji et aI., 1999; Lenox and Hahn, 2000). Lithium has been 
shown to deplete inositol (Berridge et aI., 1989), inhibit the enzyme glycogen 
synthase kinase (GSK3) (Klein and Melton, 1996), and has the neuroprotective 
effect of rendering cells less susceptible to apoptosis (Hashimoto et aI., 2002; 
Brunello,2004). In addition, the anticonvulsants, valproate and carbamazepine, are 
effective antimanic agents in the treatment of patients with BPD (Keck et aI., 1998; 
Keck and McElroy, 2003). In an experiment of explants of rat sensory neurons from 
dorsal root ganglia cultured in lithium, valproate and carbamazapine, not only was 
growth cone collapse inhibited, but an increase in growth cone area was observed 
(Williams et aI., 2002). Upon the addition of inositol, these effects were abolished, 
thereby implicating inositol phosphate signalling in the actions of lithium, valproate 
and carbamazapine (and also in BPD). Furthermore, the treatment of BPD patients 
with lithium, valproate or carbamazapine has been shown to be associated with 
reduced risk of suicidal behaviour (Yerevanian et aI., 2003). 
Mood stabilisation is also important in the treatment of the disabling depressive 
phases of BPD, which may sometimes be dominated by mixed episodes (Kasper, 
2003). Antidepressants include selective serotonin inhibitors (SSRls) (for example 
fluQxetine, paroxetine and setraline) and MAO inhibitors (for example 
tranylcypromine, imipramine and moclobemide) (reviewed in Compton and 
Nemeroff, 2000). However, the latter may induce mania and psychosis in 
vulnerable individuals (Stoll et aI., 1994; Preda et ai, 2001). The Expert Consensus 
Guidelines (Francis et aI., 1998) prefer bupropion, which is believed to have a lower 
risk of switching the patient into a manic phase, and SSRls as first-line treatment for 
depression in BPD (Frances et a!., 1998). The anti-epileptic drug lamotrogine has 
emerged as a promising new prophylactic treatment for bipolar depression 
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(Calabrese et aI., 1999). In addition to its anti-psychotic properties, olanzapine 
also has antidepressant effects (Rothschild et aI., 1999). 
Antidepressant treatment and stress have been shown to target signal transduction 
and gene expression circuits associated with neuroplasticity in patients with mood 
disorders (Duman, 2002; Shimizu et aI., 2003). Two such targets include CREB and 
BDNF, a major gene regulated by CREB (Duman et aI., 1997). Antidepressant 
administration has been reported to increase the expression of CREB and BDNF in 
rat hippocampus (Nibuya et aI., 1996). 
Appropriate drug therapy for BPD is complicated, as the usefulness of psychotropic 
drugs in the treatment of patients has proved to be variable in outcome and side 
effects. Tohen and co-workers (2002) reported that up to 40% of patients with BPD 
respond poorly to either lithium or valproate. Thus, monopharmacological (one 
drug) treatment strategies appear to have different degrees of efficacy (Calabrese 
et aI., 1999; Greil and Kleindienst, 2003), with some displaying notable effects on 
the depressive phase, the manic phase, psychotic symptoms, or decreasing risk of 
suicidal behaviour. Instead of treating patients with one mood stabilizer, 
psychiatrists commonly prescribe combination therapy, combining anti-psychotics 
(for example olanzapine and risperidone), anti-epileptics (for example lamotrigine 
and carbamazepine) or anti-depressants (for example imipramine and paroxetine) 
with mood stabilizers (reviewed by Bowden, 2004). Dependent on the individual 
patient's manifesting symptoms, disease history and comorbid illness, successful 
management of BPD needs both acute and chronic (maintenance) treatments of 
both mania and depression. 
1.6 BPD: A MULTIFACTORIAL DISORDER 
Only a few decades ago psychologists were convinced that human behavioural 
characteristics and aberrancies could be explained entirely by environmental 
influences (Sherman et aI., 1997). In addition, and classically, psychiatry has 
focussed its attention on the pathogenicity of the disorder, rather than taking the 
contributions of heredity into account (Barondes, 1999). In more recent years 
heredity and the possibility of having a multifactorial pathology (Le. not a single but 
many genes with varying effect and interacting with exogenous influences) to the 
19 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
aetiology of psychiatric conditions has been considered. Several aetiological 
mechanisms, as discussed in the following sections 1.6.1-1.6.3, are thought to 
contribute to BPD, owing to the observed bipolar spectrum of clinical phenotypes 
together with non-Mendelian inheritance patterns in families with the disorder 
(Lander and Schork, 1994; Craddock and Owen, 1996; Craddock and Jones, 1999). 
1.6.1 Environmental stimuli 
Several studies have implicated psychosocial stressors in the timing, type and 
outcome of bipolar episodes (Glassner and Haldipur, 1983; Bidzinska, 1984; 
Miklowitz et aI., 1988). These stressors include health, marital and family conflicts, 
work overload, and emotional and ambitional failures (Bidzinska, 1984). Previously, 
it was reported that post discharge from hospital, important predictors of the bipolar 
patient's subsequent clinical course of illness may include: (i) the emotional quality 
of the family environment (Miklowitz et aI., 1988), (ii) the season of the year, (iii) 
variation in endocrine status, and (iv) dnJg treatment (Silverstone and Romans­
Clarkson, 1989). The onset of mania has also, interestingly, been reported in 
association with unpleasant life events, in the form of loss or threat (Ambelas, 1979; 
Ambelas, 1987; Bebbington et aI., 1993). This response to stress is immediate and 
selective, possibly providing a transient shield or buffer which makes the 
succeeding depression tolerable or even ineffectual (Ambelas, 1987). As observed 
by Glassner and Haldipur (1983), stressful life events may constitute different 
etiological components in early and late onset BPDs. The contribution of 
environmental components to illness is further compounded by the underlying 
biological predisposition. 
1.6.2 Evidence of heredity 
Genetics offers the ability to dissect the "heritable" aspects/components of disease 
towards identifying the underlying genes and biology. The measure of heritability 
describes the relative genetic contribution to any complex trait (Ellsworth and 
Manolio, 1999a). In the broad sense, heritability is the estimated percentage of the 
total phenotypic variation owing to genetic influences, relative to environmental 
factors and measurement error. 
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Twin studies offer the most compelling evidence for the presence of genetic effects 
in complex disorders (McGuffin and Katz, 1989; Ghosh and Collins, 1996; Kelsoe, 
2003). It has been shown that the concordance rate for BPO, on average, in 
monozygotic twins is 65%, and 14% in dizygotic twins (McGuffin and Katz, 1989), 
reflecting an estimated heritability as high as 80%. In these studies, both 
monozygotic and dizygotic twin subjects were reared together which suggested that 
sharing all (as opposed to 50%) genes elevates the risk of disease over twofold 
(Kelsoe, 2003). Twin data have also suggested a genetic component to suicide that 
may represent a predisposition to the associated psychiatric illness (Roy et aI., 
1991 ). 
Adoption studies provide another means of separating the hereditary (nature) and 
environmental factors (nurture) interacting in the aetiology of the disorder 
(Mendlewicz, 1977; Mitchell et aI., 1993; MacKinnon et aI., 1997). These 
inve~tigations have shown that in the presence of genetic effects, the biological 
parents of an individual with BPO exhibited relatively high BPO rates compared with 
the adoptive parents. 
Another effective measure to describe the genetic contribution to a trait is relative· 
risk, AR (Risch, 1990a; Ghosh and Collins, 1996). AR is defined as the recurrence 
risk for a relative (R) {such as sibling (S) and offspring (0» of an affected individual, 
divided by the recurrence risk fo  the general population (Lander and Schork, 1994). 
The greater the value of AR, the greater the scale of concordant inheritance for 
genetic elements is, in affected relative pairs. For BPO, Gershon and colleagues 
(1982) suggested an increase in the AR for siblings by a factor of about eight to 
nine. However, because of BPO's multigenic aetiology, in which many loci add to 
the inflated AR, it is predicted that the locus-specific AR would be much less than 
nine, owing to their minor to moderate effects. 
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1.6.3 Genetic mechanisms involved in BPD 
Several genetic mechanisms are known to generate complex patterns of 
inheritance, including: 
(i) Heterogeneity 
Anyone of multiple genes may underlie similar phenotypes in different families, 
such as a wide concert of genes interacting in a common biochemical pathway 
(Lander and Schork, 1994; Craddock and Owen, 1996). 
(N) Epistasis 
Two or more products of disease genes may interact to produce a phenotype 
(Craddock and Owen, 1996). 
(iii) Incomplete penetrance 
The inheritance of a predisposing allele (genotype) does not result in the 
manifestation of the phenotype (Lander and Schork, 1994; Craddock and Owen, 
1996). Some individuals, however, are phenocopies, that is they do not inherit a 
predisposing allele but nonetheless express the phenotype due to 
environmental/random influences (Lander and Schork, 1994), or could simply be 
due to the effects of other genes. 
(iv) Anticipation 
A clinical phenomenon of increasing severity of disease phenotype observed at an 
earlier age in successive generations (Lander and Schork, 1994; Craddock and 
Owen, 1996; MacKinnon et aI., 1997). 
(v) Imprinting 
Given the same genetic defect, variation in phenotype between family members 
may occur due to differential activity of the maternal and paternal copies of a gene 
(Lander and Schork, 1994; Craddock and Owen, 1996; MacKinnon et aI., 1997), the 
so-called parent-of-origin effect (McMahon et aI., 1995; Gershon et ai, 1996). 
(vi) Mitochondrial inheritance 
Another plausible genetic mechanism is that of mitochondrial inheritance, which can 
explain the maternal inheritance pattern of BPD, since mitochondria are transmitted 
exclusively from a mother (Craddock and Owen, 1996). 
(vii) Variable expressivity 

A variety of related clinical phenotypes can result from the same genes (Kelsoe, 

2003). 
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Some of these genetic mechanisms have been suggested as possible explanations 
for BPD (Table 1.1). 
Table 1.1: Genetic mechanisms involved in BPD 
Genetic mechanism References 
Heterogeneity Hodgkinson et aI., 1987 
Epistasis Craddock et aI., 1995 
Anticipation Mci n nes et aI., 1993; Nylander et aI., 1994 
Imprinting McMahon et aI., 1995 
Mitochondrial inheritance McMahon et aI., 1995 
It is possible that two or more of these potential genetic mechanisms interact in a 
single individual, thereby adding to the complexity of the disease. 
1.7 MOLECULAR GENETICS OF BPD 
1.7.1 Models of BPD inheritance 
Unlike disorders with Mendelian patterns of inheritance, such as Huntington 
disease, BPD is unlikely to have a specific mode of inheritance (Barondes, 1999). 
This is mainly attributed to the spectrum of disorders characteristic of BPD. 
However, several genetic models for inheritance, as discussed in this section of the 
dissertation, have been proposed for the complex phenotype of BPD. 
In psychiatric disorders, including BPD, an at-risk individual does not inherit the 
certainty of becoming ill, but instead may be predisposed to illness as a result of 
environmental and genetic components, termed "liability" (McGuffin and Katz, 1989; 
Mitchell et aI., 1993). Therefore, people whose liability surpasses a certain 
threshold value, present with the disorder. The simplest form of "liability threshold" 
model is the single major locus (SML) model, which states that a single gene is 
responsible for all the genetic variation in liability (McGuffin and Katz, 1989; Mitchell 
et ai, 1993). However, the effect of the major contributing locus can be influenced 
by reduced penetrance, variable expressivity and phenocopies (Kelsoe, 2003). 
Fu rthermore, different major genes may function in each family. 
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Alternatively, the multifactorial polygenic (MFP) model, assumes that the combined 
effect of multiple genes and environmental factors contribute to an at-risk 
individual's liability in an additive fashion (McGuffin and Katz, 1989; Mitchell et ai, 
1993). Galton first proposed this polygenic or quantitative transmission model (as 
cited by Kelsoe, 2003). Risch (1990a) described two types of multilocus models: (i) 
an additive model, which closely approximates genetic heterogeneity, characterised 
by no interlocus interaction, and (ii) a multiplicative model with locus interaction. 
The multiplicative or epistatic model serves as a basis for the methodologies 
implemented in the present study. Such genes that underlie scores on continuous 
measures, including blood pressure, weight, height, serum cholesterol levels and 
body-mass index, have been termed quantitative trait loci (QTLs) (Ghosh and 
Collins, 1996; Craddock and Owen, 1996). Simplified, quantitative traits derive from 
many genes, each of modest effect (Kelsoe, 2003). Traditionally, psychiatric 
genetics has focussed its attention on categorical phenotypes (Craddock and 
Owen, 1996). However, if it can be shown that a suitable continuous measure 
exists that is biologically associated with the disorder, a QTL approach will prove to 
be practical and possibly impart valuable information about the disorder itself. 
In the multiple threshold model, Reich et al. (1972) extended the quantitative trait 
model to include qualitatively different phenotypes lying on a spectrum. Assuming 
that these phenotypes are quantitatively ranked in relationship with each other, as 
in the case of the bipolar spectrum disorder (Kelsoe, 2002), different thresholds of a 
latent quantitative trait lead to different disorders. 
Yet another and a fourth possible mechanism for the complex inheritance pattern of 
BPO is the mixed model. This model favours the presence of a single major locus 
against a multifactorial background, which could include the effects of birth cohort 
and age of onset (Rice et aI., 1987). All these genetic models point to the highly 
variable approaches adopted, to elucidate the specific genetic factors that may 
explain the familial transmission of BPO, and other complex diseases. 
1.7.2 Genes implicated in BPD 
A number of susceptibility genes have been implicated in BPO (Table 1.2), either by 
genome-wide scans or the candidate gene approach. Failure to detect major gene 
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effects may indicate that individual BPD susceptibility loci represent small to 
moderate effects. and are required in combination (multiplicative or epistatic 
inheritance) (Stoltenberg and Burmeister, 2000). and this is what the present study 
hopes to build on. 
Molecular genetic studies have also displayed evidence for overlapping genetic 
vulnerabilities in BPD and other psychiatric conditions. particularly schizophrenia 
(Table 1.3). Recently, Mazaide and co-workers (2004) identified a novel 
susceptibility locus on chromosome 15q26 shared by schizophrenia and BPD. 
Their findings support the concurrent investigation of schizophrenia and BPD in the 
same study. Based on studies. such as those listed in Table 1.3. BPD and other 
psychiatric conditions are likely to be expressions of the same genetic susceptibility, 
creating a phenotypic spectrum. This implies that current nosology of these 
disorders will require substantial redefinition during the next decade to model their 
shared genetic vulnerability. as specific genes and their derived biologies are 
identified (Berrettini, 2000). 
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Table 1.2: Summary of candidate loci implicated in BPD 
Locus and Reference Source Population" Etnicity" SM" Type of Findings· 
analysisd 
1q32 
Turecki G et aI., 1995 10 cases, 10 cons Bra CA CC BPI was associated with a fragile site on 1q32 
Oetera-Wadleigh et al., 22 tams Nam+OOA G8 Non-par. Lod= 2.67, P= 0.00022 at 0181660-0181678 
1999 
1q42 
Blackwood €It aI., 2001 1 large tam Sr CR Par. Max lod= 4.5 at translocation at 1q42 
Macgregor €It aI., 2004 45 tams 8cot G8 Par. lod= 2.63 at 018103 
2p13-16 
Lui €It aI., 2003 40 tams Nam+ls G8 Par. 2P lod= 3.2 at 028441 
Mcinnis et aI., 2003b 65 fams Am G8 Non-par. NPL= 2.54 at 02899 
2q 
Zubenko et.al., 2003 81 tams Am CG MA CREB1 associated with depressive disorders 
Papiol et aI., 2004 88 cases, 176 cons Spanish CG bc Interleukin-1 cluster is associated with BPO 
3q 
Schosser €It al.. 2004 5 tams Austrian CR Non-par. NPL score Z aU = 4, P= 0.000128 at 0381265 on 3q29 
Bailer €It aI., 2002 5 tams Austrian G8 Non-par. NPL score Z all = 3.74, P=.0003 at 0381265 
Benedettietal.,2004 185 cases Italian CG Assoc. GSK3-be/a associated with age at onset in BPO 
4p16 
Blackwood et aI., 1996 12 families Scot G8 Par. 2P Lod= 4.1 at 048394 
Ewald €It aI., 1998 2 tamilies Dan CR Par. 2P Lod- 2.0 at 048394 
Oetera-Wadleigh €It aI., 22 fams Nam+OOA G8 Non-par. P= 0.0022 at 0482408·0482632 
1999 
Als et aI., 2004 17 cases, 44 cons Faroese LOM P= 0.0162 at two-marker segment 048394·0482983 
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TABLE 1.2: Continued 
Locus and Reference 
4q35 
Adams et al.. 1998 
Source Population" 
1 tam 
Etnicity" 
Aust 
SMc 
GS 
'rye of 
analysisd 
Non-par. 
Findings' 
NPL- 3.74. P=.0003 
Willour et al.. 2003 56 fams Nam GS Non-par. allele-sharing lod- 2.49 between 0453335-04S2390 
Mcinnis et aI., 2003b 65 fams Am GS Non-par. NPL- 2.8 at 04S1629 
Lui et al.• 2003 40 fams Nam+ls GS Par. 2P lod: 3.16 at 04S1625 
5p15.3 
Kelsoe et aI., 1996 25 fams Nam+OOA+lsl CR Par. Max lod- 2.38 at 058392 
Greenwood et aI., 2001 50 trios Nam+OOA CG TDT LO between Oopamine transporter and. BPO 
ter5q-q35 
Coon et al.• 1993 8 tams Nam GS Par. Max lod >1 at 05839, 05S43, 05862 
Edenberg et aI., 1997 97 fams Nam G8 ASP P= 0.008 at 0551456 
Oetera-Wadleigh et aI., 
1999 
22 tams Nam+OOA GS Non-par. Lod- 1.7, P= 0.0026 in the region of 05S498-05S408 
6pter-p24 
Ginns et aI., 1996 5fams OOA GS Non-par. P= 0.0003 at 06S7 
8q24 
Cichon et aI., 2001a 75 fams Ger+lt+ls GS Par. 2P lod- 3.619 at 08S514 
Mcinnis et aI., 2003b 65fams Am GS Non-par. NPL: 3.13 at 08S256 
Avramopoulos et aI., 2004 65 fams Nam CR Par. lod: 3.32 at 088256 
9q31-34 
Badenhop et al., 2002 13 tams Brllrish G8 Par. Hlod: 1.74 at 0981776 
Mundo et al.. 2003 288 trios Eur CG TOT GRIN1 confers susceptibility to BPO 
Lui et aI., 2003 40 fams Nam+ls GS Par. 2P lod> 1.9 at 098938 
27 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
-
TABLE 1.2: Continued 
Locus and Reference Source Population· Etnicity" SM" Tye of Findings· 
analysisd 
10p 
Foroud et aI., 2000 97 fams Nam GS Non-par. lod: 2.5 at 010S1423 
10q21-26 
Cichon et aI., 2001 b 75 fams Eur Non-par. Max NPL(all) score= 3.12, P:: 0.0013 at segment 010S1483-010S217 
Lin et aI., 2003 100 cases, 106 cons Taiwanese CG CC Association between 5HT7 and BPO 
11p15 
Bellivier et aI., 1998 152 cases, 94 cons France CG CC Association between TPH and BPO 
Neves-Pereira et aI., 2002 283 nuclear fams Eur CG Assoc. 
Sklar et aI., 2002 136T Nam+Br CG TOT BDNF potential risk locus for BPO 
12p 
Faroane et aI., 2004 97 fams Nam GS VC lod> 2.5 near 012S1292 
Wille it et aI., 2003 172 cases, 143 cons Austrian CG CC Association G-protein coupled signal transduction in the aetiology of affective 
disorders 
12q23-q24 
! 
Oawson et al., 1995 45fams Br+Ger+Wel CR Non-par. P< 0.053 at 012S78 , 
Oetera-Wadleigh et aI., 22 tams Nam+OOA GS Non-par. Lod= 1.24, P:: 0.0084 in the region ot 012S1343-012S2070 
1999 
Shink et al.. 2004 20 fams Can GS Par. lod;::: 3.35 at 012S378 
13q12-q13 
Ginns et al.. 1996 5 fams OOA GS Non-par. P= 0.0003 at 01381 
Mcinnis et aI., 2003b 65 fams Am GS Non-par. NPL- 2.53 at 013S1493 
13q32-q34 
Liu et al. 2001 22 fams Nam CR Non-par. max lod;::: 3.25. P- 0.00546 around 0138779-013S225 
Hattori e\ aI., 2003 557 samples Eur CG TOT Association between G721G30 ad BPO 
Shaw e\ aI., 2003 32 fams Nam CR Par. lod: 2.26 at 013S154 
Schumacher et aI., 2004 300 cases, 300 cons Ger CG CC G72 was associated with BPO 
L_ 
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TABLE 1.2: Continued 
Locus and Reference Source Population" EtniClty" SM" Tye of 
analysisd 
Findings· 
14q 
Luietal.,2003 40 fams Nam+ls G8 ASP lod::: 2.36 at 048306 
Faroane et al., 2004 97 fams Nam G8 VC lod- near GATA50C 
15q 
! 
Ginns et aI., 1996 5fams OOA G8 Non-par. P= 0.0003 at 015845 i 
Papadimitriou et aI., 48 cases, 50 cons Greek CG CC Association between GABRA5 and BPO 
1998 , 
Maziade et aI., 2004 21 fams Can GS Par. Z- 4.59 at 015S122 
Faroane et aI., 2004 97 fams Nam GS VC lod- 3 near GATA31B 
16p13 
Ewald et aI., 1995 2fams Oan CR Par. 100- 2.65 at 016S510 
Nyegaard et aI., 2002 80 cases, 144 cons Oan CG CC Association between Somatostatin receptor 5 and BPO 
Itokawa et aI., 2003 96fams Nam CG POT Association between GRIN2A and BPO 
Maziade et aI., 2004 21 fams Can G8 Par. Z- 4.10 at 016S1145 
17q 
-Dick et aI., 2003 250 fams Nam G8 Non-Par. max lod score:::3.63 at 0178928 
Lui et aI., 2003 40 fams Nam+ls G8 Par. 2P fod> 1.9 at 017S921 
18p11 
Berrettini et aI., 1994 22 fams Nam+OOA CR ASP P< 0.001 at 018821 
Sjoholt et aI., 2004 44 cases, 48 cons + 75 T Nor+Arabian CG Assoc. Association between IMPA2 and BPO 
Washizuka et aI., 2004 189 cases, 222 cons + 105 T Jp+Nam CG Assoc. association between NDUFV2 and BPO 
18q 
McMahon et aI., 1997 58 fams Am CR Non-Par. NPL = 2.84, P<0.0019 at 018S38 
Mcinnis et aI., 2003b 65 fams Am GS Non-par. NPL= 2.9 at 018S878 
Maziade et aI., 2004 21 fams Can GS Par. Z= 4.05 at 0188410 
19q12-q13 
Badenhop et aI., 2002 13 fams Brllrish G8 Non-par. NPl= 4.55, P= 0.0002 between 0198414 and 019S220 
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TABLE 1.2: Continued 
Locus and Reference Source Population" Etnicity" SMc Tyeof Findings· 
analysisd 
20p 
Willour et al.. 2003 56fams Nam GS Non-par. allele-sharing lod- 1.82 at D20S162 
21q 
Detera-Wadleigh et al.. 22 fams Nam CR ASP P< 0.01 between D21S270-D21S171 
1996 
Aita et aI., 1999 57 fams Am+ls CR Non-par. 2P heterogeneity lod= 3.35 at D21S1260 
I 
22q11 
Lachman et al.. 1997 17 fams Nam+OOA CR Par. Max lod= 2.51 at D22S303 
Kelsoe et al .• 2001 20 tams Nam GS Par. Max lod- 3.8 at D22S278 
Barrett et al.. 2003 153 nuclear tams + 275 T Nam+Eur TDT P= 0.0019 at P-5 variant 
Shifman et al.. 2004 217 cases, 4050 cons Is CG Assoc. association between COMT and BPD 
Xq24 
Ekholm et al.. 2002 41 tams Finnish CR Par. max lod- 2.78 at DXS1047 
Lin et al.. 2003 100 cases. 106 cons Taiwanese CC Association between 5HT2C and BPD 
: cons = controls. fams = families. T = trios 
b: Am ::: American. Aust = Australian. Bra = Brazilian. Br = British, Can = Canadian. Dan = Danish. Eur = European, Fin = Finish. Ger = German. lsi = Islandic, Is = Israeli, It = Italian. Jp =Japanese, 
Nam North American, Nor::: Norwegian, OOA ::: Old Order Amish. Scot = Scottish 
c: SM = screening method, CG = candidate gene, CR candidate region, GS = genome scan 
d: 2P = two point, Assoc = association, CC ::: case-control. LDM == linkage disequilibrium mapping, Non-par non-parametric. Par. = parametric. PDT= pedigree disequilibrium test, TDT == 

transmission disequilibrium test. VC =variance components 

e: 5HT2C =serotonin receptor 2C, 5HT7 =serotonin receptor 7. COMT = catechol-o-methyltransferase, CREB1 == cAMP response element-binding protein 1. GABRA 1 = gamma-aminobutyric acid 

receptor. alpha-1, GABRA5 = gamma-aminobutyric acid receptor. alpha-5, GABRA6 = gamma-aminobutyric acid receptor, alpha-6. GRIN1 =glutamate receptor. ionotropic, n-methyl-d-aspartate, 

subunit 1, 

GRIN2A =glutamate receptor. ionotropic. n-methyl-d-aspartate. subunit 2A, GSK3-beta = glycogen synthase kinase beta, 

IMPA2 = myo-inositol monophosphatase 2, LD == linkage disequilibritun, NDUFV2 = NADH-ubiquinone oxidoreductase flavoprotein 2, TPH = tryptophan hydroxylase 
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Table 1.3: Overlap of genetic regions and candidate genes implicated by 
linkage and association respectively in psychiatric disorders. 
Locus Phenotype Reference 
BPD Sr.7 4nHD ALC. NS AT OCD 
1q21 
· · 
Chandy et al.. 1998 
1q32-q41 
· t= Hallmayer. 1999 1q32 · Detera-Wadleigh et al.. 1999 
1q42 
· · 
Macgregor et aI., 2004 
1 p22.3-1 p21 
· 
Rice et al.. 1997 
Hallmayer.1999 
2p22.1 
· 
Hallmayer.1999 
2p22.1 . Hallmayer.1999 
2p13-16 
· 
Uu et aI., 2003 
2q31-q33. . Rabionet et al.. 2004 
2q33-35 
· 
Zubenko et aI., 2002 
3q13.3 
· 
Parsian et al., 1995 
3q13 
· ±± Maziade et aI., 2001 3q27-28 · Uu etal., 2003 3q29 
· · 
Schosser et al.. 2004 
4q31 
· 
Kennedy et al.. 1999 
4q31 * Uu et al.. 2003 
4p16.1 
· 
* Als et al.. 2004 
DRD5 (4p16.1-15.3) * Bobb et al.. 2004 
5p15.31-15.1 
· 
Shink et aI., 2002 
OAT (5p15.3) . Bobb et aI., 2004 
11.2-q13.3 * Sherrington et al.. 1993 
5q11 
· I 
Mcinnis et aI., 2003a 
5q23.3-q31.1 
· 
I Crowe et aI., 1999 
5q31.3-q35.1 
· 
Crowe et al.. 1999 
5q33.3 * Arcos-Burgos et aI., 2004 
6p24-p22 
· 
Straub et al.. 1995 
MOG (6p21.3) . Zaletal..2004 
6p * Schwab et al.. 2000 
6p • Schulze et aI., 2004 
6p22-p24 * Maziade et aI., 2001 
8p23.1-p22 • ~et"2000 
8p23.1-p22 
· 
net aI., 1998 
8p23 I • 
=f .2003 8p21-p22 Wildenauer et al.. 1999 8p21-p22 I Brzustowicz et aI., 1999 
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Table 1.3: Continued 
Locus Phenotype Reference 
BPD SCZ ADHD ALC. NS AT OCD 
10p12 * Mcinnis et aI., 2003a i 
I 10p11-p14 • Maziade et aI., 2001 
10q • Wildenauer et aI., 1999 
10q • Levinson et aI., 1998 
10q24 
· 
Liu et aI., 2003 
11p15 
· 
Mcinnis et aI., 2003 
DRD4 (11p15.4-15.5) * Ebstein et aI., 1996 
DRD4 (11 p15.5) . Bobb et aI., 2004 
DRD4 (11p15.4-15.5) * Hemmings et aI., 2004 
BDNF (11p13-15) * Hall et aI., 2003 
BDNF (11p13-15) * Matsushita et aI., 2004 
I 
13q32 * Blouin et aI., 1998 
, 13q32 * Detera-Wadleigh et aI., 1999 
15q13-q15 * Turecki et aI., 2001 
15q13-q15 * Leonard et aI., 1998 
15q11-q13 * Cook et al ., 1998 
16p13 
· 
Ewald et aI., 1995 
16p13 • Detera-Wadleigh et al. 1999 
16p13 
· 
Mcinnis et aI., 2003 
17q11-12 
· 
Liu et aI., 2003 
5-HTI (17q11.1-q12) . Bobb et aI., 2004 I 
18q21 
· 
McMahon et al. 1997 
18q21.1 
· 
Van Broeckhoven et al. 1999 
18q12-q21 
· · 
Maziade et aI., 2004 
22q11 
· 
Karayiorgou et al. 1995 
22q11 
· 
. Lachman et al. 1997 
22q11 . Schindler et al. 2000 
MAOA (Xp11.23) * ~OOO I 
Xp11 * Wei and Hemmings 2000 
MAOA (Xp11.23) . I Karayiorgou et al. 1999 
..Key: BPD- bipolar disorder; SCZ- schizophrenia; ADHD- attentlon-deficlt hyperactivity disorder, ALC.- alcohol abuse, NS- novelty­
seeking; AT- autism; OCD- obsessive compulsive disorder 
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1.8 ANALYTICAL STRATEGIES 
Gene identification can involve one of two approaches. The first is a general survey of 
the entire human genome, i.e. genome-wide scans (Elsworth and Manolio, 1999b). The 
second is the candidate gene approach, which considers genes based on their location 
in a previously identified genomic region or because they are suspected to have a role 
in the physiology of a phenotype/trait (Glatt and Freimer, 2002). The identification of 
genes via the candidate gene approach has not been fully realised, because the biology 
underlying many complex diseases, including physical processes and biochemical 
pathways, is not yet known (Ellsworth and Manolio, 1999b). 
In the case of a phenotype with an unknown inheritance pattern, identification of 
susceptibility genes over a range of genetic models requires the type and size of study 
sample to be chosen in a manner that will provide optimal statistical power (Craddock 
and Owen, 1996). Power is a function of the number of genes present and the manner 
in which these contribute to the disease (Weeks and Lathrop, 1995). Linkage analysis 
provides the method of measuring the genetic contribution to disease. 
1.8.1 Linkage analyses 
Statistical power to detect linkage in BPD is determined by the locus-specific value of AR 
(Risch, 1990b). Moreover, in the case of multiple loci, the ease or difficulty of mapping 
loci for a given phenotype depends on the value of the largest of the locus-specific AR 
values for the contributing loci. In other words, a disorder with a moderate value of AR 
may have only loci with individual small effect sizes, which will be quite difficult to map, 
or it may have one or a few loci accounting for most of the familial effect, and those loci 
will be relatively easier to map. For example cystic fibrosis has a value for As (the risk 
to a sibling of an affected individual compared to the population prevalence) of about 
500, much larger than the As values of 15 for type I diabetes, 3.5 for type II diabetes and 
8.6 for schizophrenia (Lander and Schork, 1994). 
Linkage analysis is a technique, designed to search for co-occurrence of a marker locus 
and a putative disease gene, using all the available inheritance information from 
affected subjects and their families (Kruglyak et aI., 1996). This technique involves 
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either parametric analysis, which proposes a specific model to explain the inheritance 
pattern of a trait-causing gene, or non-parametric analysis, which is model-independent 
and therefore tests the deviation of inheritance pattern from random Mendelian 
segregation under independent assortment (Kruglyak et aI., 1996; Lander and Schork, 
1994; Ott and Hoh, 2000). 
1.8.1.1 Parametric linkage analysis 
Traditionally, parametric (model-based) linkage analysis, commonly known as the 
logarithm of odds (LaD) score method (Morton, 1955) was performed on large, multiply 
affected, multigenerational pedigrees (Holmans and Craddock, 1997). The LaD score 
is the logarithmic expression of the likelihood (odds) ratio of the estimated 
recombination fraction (calculated under the alternative hypothesis of linkage, 9<0.5) 
and the recombination fraction of 0.5 (calculated under the null hypothesis of no 
linkage) (McGuffin and Katz, 1989; Mitchell et aI., 1993; Nyholt, 2002). Recombination 
fraction (9), refers to the number of observed recombination events divided by the total 
number of informative meioses (McGuffin and Katz, 1989; Ghosh and Collins, 1996). 
For small distances, the extent of 9 is related to the physical distance between the 
marker locus and the disease locus. By testing across differel1t values of 9, the 
maximum LaD score (MLS) is obtained. Traditionally, a LaD score of >3, with odds of 
1000 to 1 for linkage, was accepted as firm evidence to declare significant linkage 
(Morton, 1955; Nyholt, 2000). However, if one selects any two loci in the human 
genome, those loci are -50 times (Le., 46 chromosomes) more likely to reside on 
different chromosomes (Nyholt, 2000). Even with odds of 1000 to 1 in favour of linkage 
compared with non-linkage, the reality that non-linkages occur 50 times more often than 
linkages, it stands to reason that a LaD score of 3 corresponds to odds of -20 to 1 in 
favour of linkage. That is, a LaD score of 3 will show to be false in -1/20 events 
(P=0.5). 
With few models for the disease locus, the LaD score method has been successfully 
applied to diseases with Mendelian patterns of inheritance (Lander and Schork, 1994). 
These models incorporated parameters such as the number of loci involved, allele 
frequencies, penetrances of each genotype, and recombination fractions (Olson et aI., 
1999; Ott and Hoh, 2000). Given good estimates for these parameters and therefore a 
correct disease model, the LaD score method takes full advantage of the available 
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pedigree data, thereby rendering it the most powerful linkage analysis technique (Guo 
and Lange, 2000; Ott and Hoh, 2000). If the assumed model is at least roughly 
accurate, then mapping of the disease locus becomes relatively straightforward (Guo 
and Lange, 2000). Using different phenotypic models, LOO score analysis has led to 
the identification of several genes implicated in BPO (see Table 1.2). Currently, in 
complex inheritance, a LOO score ~3 is still necessary although not adequate enough 
to render a linkage test reliable (Morton, 1998). LOO score methods are sensitive to 
genetic heterogeneity and can lead to spurious results if the disease model is 
misspecified (Guo and Lange, 2000). 
1.8.1.2 Nonparametric linkage analysis 
In the instance of complex traits, it is not possible to model with certainty all the 
parameters of familial aggregation (Elston, 1998). Therefore, recent non-parametric 
(model-free) methods that do not require prior specification of such parameters have 
become increasingly popular in behavioural genetiCS (Kruglyak et ai, 1996). Non­
parametric methods have been used extensively in the identification of susceptibility 
genes in BPO (Table 1.2), and it is the method of choice in the present study. These 
include allele-sharing methods, association studies and the transmission disequilibrium 
test (TOT) (Lander and Schork, 1994; Ghosh and Collins, 1996). 
(i) Allele-sharing methods, aim to determine whether affected relative pairs share the 
same chromosomal region identical-by-decent (IBO), i.e. inherited from a common 
ancestor, more often than expected by chance (Lander and Schork, 1994; Kruglyak and 
Lander, 1995). With the tendency to be more robust than linkage analysis (Kruglyak 
and Lander, 1995), allele-sharing methods are often less powerful, when compared to a 
correctly specified linkage model. 
The most common and simplest form of allele-sharing methods use affected sib pairs 
(ASP), who in a randomly mating population can share 0, 1 or 2 alleles identical by 
decent (IBO), with corresponding sharing probabilities (z) of 0.25 (zo) 0.5 (Z1) and 0.25 
(Z2) , respectively (Lander and Schork, 1994). If the marker under investigation is linked 
to a locus underlying a trait of interest, then affected sibs will tend to share more alleles 
IBO than expected (Ghosh and Collins, 1996). In some cases the founder alleles may 
not be informative, Le. parents are not heterozygous with different genotypes. 
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Consequently, restriction of the ASP test to such families will undoubtedly result in a 
loss of information (Nyholt, 2000). In order to deal with data for which IBO status, in the 
presence of ambiguous marker information, cannot be unequivocally determined for all 
ASPs, likelihood methods were introduced. 
The main approach of current ASP analysis is the likelihood-ratio (LR) or maximum 
likelihood score (MLS) method of Risch (1990b, 1990c), which tests the null hypothesis 
Ho: (zo, Z1, Z2) =(0.25, 0.50, 0.25), 
MLS = 10glO L(~) 
L(0.25, 0.50, 0.25) 
where the maximum likelihood estimate (MLE) ~ = (zo, Z1, Z2), the values of (zo, Z1, Z2) 
that maximise the likelihood (probability) of the data. For the unrestricted MLS method 
the only constraint on the MLE is that ZO+Z1+Z2 =1. The null hypothesis is rejected if the 
resulting MLS is greater than the test criterion of 3 (with 2 degrees of freedom) which 
corresponds to a P value of 0.001. Not all sharing vectors (z) correspond to a plausible 
genetic model (Holmans, 1993). For example a sharing vector (zo, Z1, z2)=(0.9, 0.05, 
0.05) would imply that ASPs are not very likely to share disease alleles. This would 
seem doubtful, as the sibs are both affected, and therefore would have both inherited 
the same disease allele(s) from their parents. Risch (1990b) demonstrated that the 
sharing proportions (zo, Z1 and Z2) for affected siblings can be expressed in terms of 
relative risks, given by the equations, Zo =0.25/As, Z1 =0.5AoIAs and Z2 =0.25Am/As. The 
symbol As represents the relative risk for a sibling of a proband, where 
As = Risk for sibs of a proband 
Population prevalence 
and Ao and Am are the relative risks for offspring and MZ twins of a proband, 
respectively. By stating the relative risks in terms of population additive and dominance 
variances it can be shown that Ao :-:; As and Am ~ As (Risch, 1990b). Thereby restricting 
the sharing vector (zo, Z1, Z2) to realistic genetic models, with the following restrictions 
imposed on the sharing probabilities: 
Zo, Z1, Z2~ 1, zo+ Z1 + Z2= 1, Z2 + zo~ Z1, Z1 ~ 2zo 
Holmans (1993) showed that plotting these restrictions graphically in the (zo, Z1) plane, 
defines a 'possible triangle', bounded by the lines Zo = 0, Z1 = 0.5 and Z1 = 2zo. 
Maximisation of the MLS is restricted to the set of sharing probabilities defined by Z1 :-:; 
0.5 and 2zo :-:; Z1 within the possible triangle, which is more powerful than the 
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unconstrained method. Restriction to the possible triangle follows a multiplicative 
model, which describes epistasis (interaction) among loci, has been shown to increase 
the power of the LR test and allows for dominance variance. Dominance variance 
occurs when alleles at a locus display dominance-recessive interactions, i.e. when the 
effect of one allele at a locus masks the effect of the other allele. For the possible 
triangle restricted test an MLS of 2.3 corresponds to a P value of 0.001, whereas for an 
unrestricted test an MLS of 3 corresponds to a P value of 0.001. 
Other restrictions on the sharing probabilities are possible (Risch, 1990a). By 
restricting Z1 = 0.5 and Zo ~ 0.25, the test follows an additive model and assumes no 
dominance variance. An additive model assumes that the genetic contribution to the 
phenotypic variance of a trait results from the additive effects of genes at unlinked loci. 
This model is a good approximation of genetic heterogeneity, allowing for no interaction 
between loci (Risch, 1990a), and an MLS of 2.07 corresponds to a P value of 0.001. 
Another possible restriction is the 'multiplicative model' restriction, which expresses (zo, 
Z1, Z2) in terms of a single parameter p such that zo=(1- p l, Z1 =2 P (1- P ) and Z2= p 2 
(MLS=2.07, P value of 0.001 ). 
ASP methods make use of nuclear families containing affected sibling pairs, which 
makes it easier to collect large samples necessary to map susceptibility genes 
(Holmans and Craddock, 1997). Unlike large, densely affected pedigrees, affected sib 
pairs are more informative for linkage under oligogenic epistatic models (Risch and 
Merikangas, 1996). However, ASP methods also have some drawbacks: a relatively 
large proportion of the inheritance information contained in the pedigree structure is 
lost, making affected sib pair analysis inefficient (Kruglyak et aI., 1996) and they do not 
produce estimates of recombination fractions (Holmans and Craddock, 1997). 
MLS is very flexible and easily extendable to more complex situations. Recently, the 
MLS method has been extended to; (i) allow the consideration of the joint effects of two 
loci using ASPs (Cordell et aI., 1995), and (ii) affected relative pairs (ARPs) (Cordell et 
aI., 2000). 
An alternative approach, the affected pedigree member (APM) method, has been 
developed to include information from all affected pedigree members (Weeks and 
Lange, 1988; 1992). This is not a true linkage method as it uses identical-by-state (18S) 
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relations, i.e. affected relatives share a common allele at a locus regardless of whether 
it is inherited from a common ancestor in the pedigree. Excess IBS allele sharing 
among affected relative pairs and deviation from Mendelian expectation under the 
hypothesis of non-linkage, are investigated. The APM method, however, lacks a true 
multipoint formulation, i.e. it only adds together statistics from several marker loci 
(Weeks and Lange, 1992), and thereby tests for linkage to an extended chromosomal 
region rather than to a locus (Kruglyak et aI., 1996). It therefore cannot be used to 
confine a specific locus relative to a map of markers. 
Linkage mapping is the superior method for localisation of genes of moderate-to-Iarge 
effect, although some genes of modest effect can also be uncovered (Concannon et aI., 
1998; Baron, 2001 ). 
(ii) Association studies, unconcerned with familial inheritance patterns, are case­
control studies examining the co-occurrence of a marker and disease at the population 
level (Lander and Schork, 1994; Baron, 2001). The gene is implicated in disease 
susceptibility if the frequency of occurrence of a marker allele is significantly different 
between unrelated patients and controls, both carefully matched for ethnicity and other 
factors (Parsian et aI., 1991; Lander and Schork, 1994). Such disease-marker 
association can arise if the marker allele (like single nucleotide polymorph isms, SNPs) 
at the candidate locus directly influences the risk of disease or if it is in linkage 
disequilibrium with the actual cause. Association mapping, using a dense genome-wide 
collection of SNPs (see section 1.8.2.2 Linkage Disequilibrium/HapMap), has been 
heralded the method of choice in the study of the genetic basis of common complex 
disorders (e.g. Risch and Merinkangas, 1996). However, population substructure 
(heterogeneity) presents a serious problem, in that it can induce spurious associations 
between a candidate marker and a phenotype (Lander and Schork, 1994). The 
transmission disequilibrium test (family-based methods of association) was proposed in 
response to this problem (see next section on Linkage disequilibrium). Despite the 
success and popularity of family-based association tests, however, case-control studies 
are once again being extensively used with either direct analysis of population 
substructure (with correction if necessary) through the techniques developed by 
Pritchard and colleagues (2000), or the use of genomic control developed by Devlin, 
Roeder and Wasserman (2001). Each of these methodologies involves genotying 
rather large number of unlinked markers in the cases and controls, particularly for 
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admixed populations in which there may be slight variations in population substructure 
between case and control samples. 
(iii) Linkage disequilibrium (LD) occurs when the marker allele, on the ancestral 
chromosome, lies close to the trait-causing locus in question, so that these are 
transmitted together through successive generations (MacKinnon et al., 1997). 
Therefore LO is most inclined to occur in young, genetically-isolated populations 
(Lander and Schork, 1994). In finite populations LO can arise from random drift, 
selection, mutation and non-random mating (Hill and Weir, 1994). Moreover, the 
recombination fraction between the loci influences the extent of LO, such that LO 
decays with time in proportion to the recombination fraction (Weeks and Lathrop, 1995). 
In other words, LO between closely linked loci will decay slowly, whereas LO, as a 
result of admixture, selection or drift, between unlinked loci will decay very rapidly. 
Spurious association can occur as an artefact of population admixture (Lander aQd 
Schork, 1994), as a result of inappropriate matching of patients and controls (Weeks 
and Lathrop, 1995), or due to the choice of the candidate gene (Saron, 2001). 
When population stratification is an issue, association studies depend on the 
transmission disequilibrium test (TOT) (Spielman et aI., 1993), incorporating family­
based control data, to overcome the problem. This test tracks the distorted transfer of 
disease susceptibility alleles in family triads, i.e. from parents to their affected child. 
The TOT relies on the assumption that a parent heterozygous for a disease associated 
allele should transmit that allele or its alternate at a greater frequency to the affected 
child compared to the unaffected child (Spielman et aI., 1993; Lander and Schork, 
1994; Sham 1996; Morton and Collins, 1998). Therefore the TOT is specific for 
association between linked loci and is preferred because of its robustness to population 
stratification, migration and admixture. 
Martin and colleagues (2000) developed the pedigree disequilibrium test (PDT), for 
analysis of LO in general pedigrees. The PDT uses all potentially informative data, from 
related nuclear families and discordant sibships from extended pedigrees. Whilst 
retaining its validity in the presence of population substructure, PDT is more powerful 
than TOT even in case of misclassification of unaffected individuals. 
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1.8.1.3 Computationalanalysis 
To provide adequate background to the challenges of analysis of complex disorders, it 
is necessary, at this stage, to review the range of available computational methods, 
including those used in the present study. 
Given the genotype data obtained from a genome-wide scan, test statistics may be 
calculated in a single-point (or two-point) or a multipoint manner. When calculating the 
test statistic in a single-point analysis each marker is analysed independently of all the 
other markers, whereas a multipoint analysis uses the information from multiple 
markers when testing for linkage at any particular marker or at any location between the 
markers. The multipoint approach makes full use of all the available genotyping 
information, which can increase the power. 
A variety of computation programs have been developed for calculating often 
mathematically intensive linkage statistics, however two main algorithms underlie the 
calculations. The Elston-Stewart algorithm (Elston and Stewart, 1971) scales linearly 
with non-founders, individuals whose parents are in the pedigree, and exponentially 
with the number of loci used in the analysis. This algorithm is most commonly used in 
parametric linkage analysis, particularly in programs such as LlNKAGE/FASTLINK 
(Lathrop et aI., 1984; Cottingham et aI., 1993) and VITESSE (O'Connell and Weeks, 
1995). Depending on the pedigree size, LlNKAGE/FASTLINK and VITESSE programs 
are best suited to analyse only a handful of loci (Ott and Hoh, 2000). Thus complete 
multipoint analyses remain a point of contention for general pedigrees (Kruglyak et aI., 
1996). Numerous families are frequently necessary to gain sufficient power to give 
significant evidence for linkage (Ellsworth and Manolio, 1999a). 
An alternative to the Elston-Stewart algorithm is the Lander-Green algorithm (Lander 
and Green, 1987), which scales linearly with the number of loci and exponentially with 
non-founders. Most commonly utilised for non-parametric linkage analysis, the Lander­
Green algorithm is equally well suited for parametric linkage analysis (Cox, 2001). 
Substantial improvements have been made to the algorithm, to extract all the available 
inheritance information from pedigrees (Kruglyak et aI., 1996). The improved Lander­
Green algorithm, incorporated into the GENEHUNTER computer program, when 
applied to parametric linkage analysis, provided rapid multipoint LOD score 
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calculations, including dozens of highly polymorphic markers. In non-parametric 
analysis, the same multipoint algorithm provided a new and powerful approach to 
pedigree analysis. Compared to parametric linkage analysis, loss of power in the non­
parametric linkage (NPL) analysis was insignificant. More robust than the ASP and 
APM methods, the non-parametric linkage (NPL) approach is powerful in the face of an 
uncertain mode of inheritance. GENEHUNTER utilises two useful scoring functions, 
Spairs and Sail (Whittemore and Halpern. 1994) to measure whether affected individuals 
share alleles IBO more often than expected under random segregation. Spairs refers to 
the number of pairs of alleles from distinct affected pedigree members that are IBO. 
When considering larger sets of affected relatives. such as three or more, the Sail 
function puts extra weight on those individuals sharing the same allele IBO. In general. 
Si can be any function to include further information about sharing or lack of sharing, 
among affected and unaffected individuals. The normalised form of Si is defined as, Z ;:;: 
[S -).t]/cr. Under the null hypothesis, i.e. under the uniform distribution over the possible 
inheritance vectors, Z has mean (fl) 0 and variance (cr) 1. To analyse m pedigrees, the 
scores are combined in the following linear combination, Z = .L Yi Zi, where Zi is the 
normalised score for the ith pedigree, and Yi are weighting factors. 
Kruglyak et al. (1996), added the constraint .L Y/ =1, so that Z has mean 0 and variance 
1 under the null hypothesis of no linkage. Z is referred to as the NPL score, and 
NPLpairs and NPLau are used to denote the scoring function under investigation. With 
the concurrent use of multiple markers, in a region or along an entire chromosome, 
multipoint linkage analysis methods can infer IBO status at every point along the 
genome, as well as perform information content mapping and reconstruction of 
haplotypes. In addition GENEHUNTER allows the researcher to carry out LO analysis 
(by incorporating TOTs) and variance component analysis (for the detection of linkage 
to quantitative traits). However, GENEHUNTER is still somewhat encumbered by the 
size of the pedigree under investigation, Le. only pedigrees of moderate size can be 
analysed (twice the number of nonfounders, 2N - the number of founders, F::;;20, ::;;16 by 
default) (Kruglyak et aI., 1996; Ott and Hoh, 2000). Furthermore, the P value 
(computed by the comparison of the observed NPL score with its complete data 
distribution) is usually conservative when information on decent is incomplete (Kong 
and Cox, 1997). This problem is circumvented by the likelihood approach of Kong and 
Cox (1997) by calculating the test statistic Zir. Under the null hypothesis 6=0, where 6 
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is the parameter to be estimated representing the magnitude of deviation from null 
sharing, Zir == ..J2 [log likelihood(o) - log likelihood(O)]. 
When IBD sharing is ambiguous, this allele-sharing model still maximises an exact log 
likelihood. This allele-sharing model has been incorporated into the program 
ALLEGRO (Gudbjartsson et aI., 2000). Much of the functionality of GENEHUNTER has 
been included in ALLEGRO, such as the calculation of multipoint parametric lod scores, 
NPL scores and allele-sharing lod scores, the reconstruction of haplotypes, estimated 
recombination count between markers and entropy information. ALLEGRO has several 
advantages over GENEHUNTER, such as the allele-sharing models that it provides, a 
much shorter execution time and there is no fixed limit on the number of marker loci or 
the number of non-founders. Unlike GENEHUNTER, that assigns equal weights to 
large and small families when tabulating the overall score, ALLEGRO allows the user to 
specify the weighting scheme. This property can also be used to execute conditional or 
two locus analyses in which the weight of a family relies on the linkage score of the 
family at a second locus (Cox et aI., 1999). 
Another program for linkage analysis at the postulated second locus is TWOLOCARP, 
which implements a likelihood-ratio analysis, based on the two-locus IBD sharing 
probabilities of affected relative pairs (Cordell et aI., 1995; Farrall, 1997; Cordell et aI., 
2000). This likelihood ratio is a generalisation and extension of the maximum lod score 
(MLS) method (for a single locus) originally described by Risch (1990c) to overcome the 
problem of detecting the influences and modelling the action of many disease loci, 
using all affected relative pairs. TWOLOCARP generates various two-locus models, 
including a multiplicative (MUL), an additive (ADD) and a general (GEN) model. The 
MUL model, is an epistatic model (Risch, 1990a), where the two-locus MLS for two 
unlinked loci is equal to the sum of the individual single-locus MLSs at the two loci; the 
ADD model, is a good approximation of a heterogeneity (HET) model (Risch, 1990a), 
where the two loci are considered to be independent causes of the disease; both the 
MUT and ADD models are embedded in the GEN model, i.e. may be considered as 
special cases of the GEN model. 
Other computer packages for multipoint analysis include, Multipoint Engine for Rapid 
Likelihood Inference, MERLIN (Abecasis et aI., 2002) and SIMWALK2 (Sobel and 
Lange, 1996; Sobel et aI., 2001; Sobel et aI., 2002). The algorithms implemented in 
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MERLIN (Abecasis et aI., 2002) use sparse inheritance trees to summarise the gene 
flow within pedigrees and efficiently calculate exact likelihoods for single markers or for 
multiple linked markers. MERLIN uses the Whittemore and Halpern (1994) NPLpairs and 
NPLall statistics to test for allele sharing among affected individuals, by generating a Z 
score, and its associated p value: The program also uses the Kong and Cox function 
(delta) to convert this Z score into LaDs and calculate p values. MERLIN carries out 
common single-point and multipoint analyses, including IBD and kinship calculations of 
pedigree data, non-parametric and variance component linkage analyses, rapid 
haplotyping, genotype error detection, affected pair linkage analyses and can deal with 
more markers than other pedigree analysis programs. In addition, simulation studies 
can be carried out in MERLIN and many of the other software packages commonly 
used in linkage studies. By simulating data a more pragmatic estimation of the 
genome-wide significance of a finding is permitted, by taking into consideration the 
existing information content in the observed data (Wiltshire et aI., 2001). The simulate 
option in MERLIN can generate random chromosomes that is unlinked to any of the 
traits of interest, the so-called gene-dropping simUlations. The authors reported 
increases in computational speed for MERLIN relative to GENEHUNTER and 
ALLEGRO, software packages implementing related Lander-Green algorithms. 
SIMWALK2 (Sobel and Lange, 1996; Sobel et aI., 2001; Sobel et aI., 2002), uses the 
Markov chain Monte Carlo (MCMC) algorithm which is able to analyse large pedigrees 
(>200 individuals) because it heeds the underlying configurations in proportion to their 
likelihood. Thus SIIVlWALK2 calculations are estimates and not exact. The program 
measures the degree of clustering, among affecteds, of the marker alleles descending 
from the founders, at each marker locus. The NPL_PAIR statistic (formerly known as 
STAT D) (Sobel and Lange, 1996, Whittemore and Halpern, 1994) is roughly the sum 
of conditional kinship coefficients for all affected relative pairs and is similar to the 
Whittemore and Halpern Spairs statistic as implemented in GENEHUNTER. Both these 
statistics were designed for traits best modelled by additive inheritance. Simwalk2 
performs haplotype, parametric and non-parametric linkage, IBD and mistyping 
analyses. In instances where the pedigrees under investigation are of varying sizes 
(small and large), the utility Mega2, Manipulation Engine for Genetic Analysis 
(Mukhopadhyay et aI., 1999) ~an be used to generate, from data stored in linkage­
format files, all the input files required for a combined MERLIN (for small pedigrees) and 
SIMWALK2 (for large pedigrees) analysis. 
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There are a large number of computational resources for the linkage mapping of 
candidate loci, however, the outcome of these strategies are influenced by many 
factors. 
1.8.1.4 Factors contributing to the outcome ofanalyses 
With the availability of various computational resources, the identification of candidate 
loci, by linkage methods, has seen few loci unambiguously classified. The reasons for 
this lack of progress are reviewed in this section. 
1.8.1.4.1 Misclassification of BPDs 
It is not clear which phenotypic denotation best describes the underlying genetics of 
BPO (Segurado et aI., 2003). It is plausible that there exist subtypes of BPO, owing to 
the presence of heterogeneity. The issue of phenotypic spectra is critical in molecular 
genetic studies, especially in linkage analysis of relatives that need to be classified as 
either affected or unaffected. It is therefore possible that diagnostic categories in the 
initial bipolar linkage studies may have been (i) too inclusive in some instances, thereby 
presuming that a particular phenotypic spectrum marked a unitary genetic disorder 
being inherited within families; or (ii) too exclusive of certain diagnoses, which may 
reduce statistical power (Pauls, 1993; Aida, 2004). 
Co-morbidity, often seen with BPO, could lead to the misdiagnoses of these patients. 
This was illustrated, for example, where patients presenting with both BPO and 
alcoholism, were diagnosed as alcoholic, instead of BPO, and therefore led to the 
misclassification as "unaffected" in linkage analysis of BPO (Mitchell et aI., 1993). 
1.8.1.4.2 Statistical power 
Genetic analysis of complex traits requires a strong statistical power, to ensure credible 
evidence of association (Glatt and Freimer, 2002). The genetic mapping of complex 
traits involves searching for those chromosomal regions that tend to be shared among 
affected relatives. This is followed by the calculation of an appropriate linkage statistic, 
S, and identification of the region in which the deviation, from what one would expect to 
occur under independent assortment, is significant (Lander and Kruglyak, 1995). The 
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following guidelines, based on simulation studies, illustrate the Lander and Kruglyak 
(1995) statistical thresholds for significant linkage: 
- a LOD score of 3.3 (pointwise P value of 0.000049) in parametric linkage analysis 
a pointwise probability (P =0.000022) in sib-pair analysis 
a LOD score of 3.6 in non-parametric LOD score analysis 
- a P =0.00005-0.00001. in affected-pedigree-member analysis 
When significant linkage has been obtained, its credibility has to be confirmed in an 
independent replication study (P<0.01). Modest p:'values, and failure to replicate initial 
findings in recent candidate gene association studies and genome wide linkage scans, 
has lead to controversy within the field of complex trait analysis (Mein et aI., 1998; 
Lernmark and Ott, 1998; Concannon et aI., 1998). 
The effects of locus heterogeneity across samples and across families within samples 
may contribute to several of the conflicting results (Lander and Kruglyak, 1995; 
Segurado et aI., 2003). Prathikanti and McMahon (2001) concluded that ascertainment 
and methodological differences across linkage· studies might contribute to the 
inconsistent findings. These differences can be seen in the use of multiplex extended 
pedigrees and parametric linkage analyses by some investigators, whilst others 
advocate the use of nuclear families with affected sib-pairs and non-parametric linkage 
approaches (Table 1.3). Further possible explanations for inconsistencies in linkage 
findings include population heterogeneity, which may lead to incidental sample variation 
across studies, and statistical outcomes such as inflated linkage results due to multiple 
comparisons (Lander and Kruglyak, 1995) and appropriate thresholds for significance in 
replication studies (Lernmark and Ott, 1998). Reduction in power may be due to 
stringent correction of multiple testing, as these procedures tend to be conservative and 
therefore impede reproducibility (Bohringer et al., 2003). A requirement for increased 
power in the disease gene mapping and subsequent replication studies is an adequate 
sample size (Lander and Kruglyak, 1995; Lernmark and Ott, 1998). With a 
hypothesized decrease in genetic effect of a locus, there is a near exponential increase 
in sample size required for high-resolution mapping (Weeks and Lathrop, 1995). 
In order to circumvent the statistical problems in human linkage analysis in pedigrees, 
computer simUlation (Monte Carlo) methods can be used to assess the potential for 
linkage before actual marker typing of family members proceeds (Boehnke, 1986). 
Furthermore, Monte Carlo procedures can be used to predict genotypes or risks before 
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gathering the relevant information and to evaluate and compute the significance of 
information accumulated (Ott. 1989). It is expected that further refinement of the 
human genome map, in addition to multipoint analysis of closely linked marker loci. will 
magnify the power of linkage and association tests (Baron. 2001). A more efficient 
strategy perhaps. involves the combined (rather than separate) search for linkage and 
association between marker loci and disease. 
1.8.2 Advances in molecular genetics 
Despite the widespread recognition that complex disorders are oligogenic, researchers 
have been mapping genes one at a time, thereby vastly understating both the number 
of contributing susceptibility loci and the genetic and molecular complexities underlying 
complex disorders. Both the power and the resolution of linkage mapping may increase 
substantially, once genetic approaches include the gene-gene and gene-environment 
interactions that almost surely distinguish the genetic element of complex disorders 
(Cox et aI., 1999; Cordell et aI., 2000). The joint effects of two loci have been 
considered in insulin-dependent diabetes mellitus (Cordell et aI., 2000), non-insulin 
dependent diabetes mellitus (Cox et aI., 1999), obesity (Dong et aI., 2005), and only 
recently have statistical analyses considered potential genomic interactions (epistasis) 
in BPD. With the application of conditional analyses, Mcinnis and co-workers (2003a) 
reported evidence of epistasis between chromosomes 16p13 and 9q21. In a different 
study, based on the National Institute of Mental Health Genetics Initiative pedigrees 
(USA). it was shown that loci on chromosomes 6q and 6p interact to increase 
susceptibility to BPD (Schulze et aI., 2004). In addition to improved statistical analyses, 
Le. to model potential gene-gene interactions, as in the present study, other promising 
strategies/approaches have come to the fore, to aid the identification of genetic 
components involved in complex disorders, and particularly BPD. These advanced 
strategies are summarised next, in sections 1.8.2.1 - 1.8.2.7, and (with the exception of 
bioinformatics) a're not described further beyond this chapter. 
1.8.2.1 Endophenotypes 
The incorporation of more phenotypic parameters into the analysis of behavioural and 
psychiatric traits, might improve the chances of identifying genetic loci involved in the 
disorder, by improving the statistical power of linkage and association studies (Inoue 
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and Lupski, 2003). These so-called endophenotypes are biological or psychological 
features and are generally quantitative in nature. Such quantitative traits could be 
influenced by fewer genetic and environmental factors than the disease trait itself and 
therefore possibly more agreeable to identification of susceptibility loci or disease­
causing variants (Weeks and Lathrop, 1995). For example, Cloninger et al. (1998) 
reported an association between both temperament and character personality 
dimensions and mood disorders. Yoon and colleagues (2001) observed significantly 
reduced mRNA levels of inositol monophosphatase 1, IMPA1, with an associated 
increase in basal intracellular calcium concentrations in B lymphocyte cell lines from 
males with BPI and not in healthy male controls. Both, reduced IMPA 1 activity and 
elevated basal intracellular calcium concentrations may reflect cellular endophenotypes 
of bipolar disorder. A recent report has shown an association between genetic risk for 
BPD and decreased gray matter volume in the right anterior cingulate gyrus and ventral 
striatum (McDonald et aI., 2004). 
1.8.2.2 Linkage disequi/ibriumlHapMap 
Single nucleotide polymorph isms (SNPs) have been acclaimed as the 'markers of 
choice' for disease mapping (Xiong and Jin, 1999). Highly abundant and accounting for 
90% of sequence variation in humans, SNPs are stable genetic markers (Collins et aI., 
1998). A SNP database has been developed by the international SNP Consortium, in 
an effort to characterise at least 300 000 SNPs (http//:www.ncbLnih.nlm.gov/SNP/). 
With the construction of high-density SNP maps (Wang et aI., 1998) conventional 
candidate gene association studies can be substituted with genome-wide linkage 
disequilibrium (LD) mapping, using thousands of candidate-SNPs (Risch and 
Merinkangas, 1996). LD mapping of complex disease traits depends on detecting an 
association of SNPs, either individually or as haplotypes, with disease-causing 
mutations (Tishkoff and Verrelli, 2003). According to simulations by Kruglyak (1999), 
approximately 500 000 SNPs would be required to capture any disease associations in 
a full genome-wide scan. In addition to marker density, other parameters that affect the 
success of LD mapping include sample size, population subdivision, demography, and 
disease incidence (Clark, 2003). Identification of an association relies mainly on the 
underlying genomic patterns of LD in the population under investigation (Tishkoff and 
Verrelli, 2003). 
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More recently, the genome has been depicted as being made up of discrete high LD 
segments (haplotype blocks) interspersed with very low LD regions (Daly et aI., 2001; 
Gabriel et aI., 2002). These haplotype blocks, characterised by low haplotype diversity, 
may cover as little as one third of a chromosome (Clark, 2003). Johnson and 
colleagues (2001) determined the common haplotype blocks for nine genes in subjects 
of European origin and selected a set of 'tagging' SNPs within each block. These 
haplotype tags not only scanned the common variation of a gene sensitively and 
comprehensively, but also significantly reduced the number of SNPs from 122 to 34 
SNPs (thereby reducing genotyping costs). The National institute of Health (NIH, USA) 
Haplotype map (HapMap) project is underway to catalogue common haplotype blocks 
and patterns of LD across the human genome, to assist the mapping of complex 
disease genes (Couzin, 2002). 
1.8.2.3 Pharmacogenomics 
One of the major issues with the management of patients with BPD is patient non­
compliance with drug therapy, reported at rates of 51 to 64% (Keck et aI., 1998). A 
further complication is that 30-40% of patients do not respond adequately to the early 
treatment therapy (Doris et aI., 2001; Bradbury, 2003). Moreover, time required in 
proving the ineffectiveness of a therapy and, accordingly, the identification of non­
responders could take up to six weeks. It would, therefore, be highly desirable to have 
a test that will distinguish the patient as a responder or a non-responder, prior to 
starting therapy and so eliminate the method of trial and error (Spear et aI., 2001; 
Steimer at aI., 2001). The principal, yet un-elucidated, explanation for erroneous drug 
response remains a patient's individual genetic predisposition (Spear et aI., 2001). 
Hence the origin of the biomedical discipline of pharmacogenetics, which refers to the 
investigation of inherited variations in the metabolism and activity of xenobiotic agents 
and drugs (Catalano, 1999; Weber, 2001; Serretti et aI., 2002; McCarthy, 2001). The 
term pharmacogenetics is often used interchangeably and confused with 
pharmacogenomics, where the latter deals with the impact of a patients' genetic 
constitution on the efficacy and toxicity of drugs (Peet and Bey, 2001; Schmitz et aI., 
2001). Pharmacogenetics and pharmacogenomics hold great promise for clinical 
medicine, where the aim of both is to determine the effect of genetic variation on drug 
response, with the ultimate goal of finding better and safer therapies for an individual 
patient, i.e. so-called personalized medicine. 
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SNPs and their analysis have been synonymous with the concept of 
pharmacogenomics (Meyerson, 2003); Over the past few years, several groups have 
reported possible susceptibility genes (see Serretti et aI., 2002 for review). Certain 
studies found an association of the short (s) allele, in the promoter region of the 
serotonin transporter gene, with a poor response to selective serotonin re-uptake 
inhibitors (SSRls). Serretti et al. (2001) reported an association between the AlA and 
AlC genotypes of the A218C variant in TPH and poor response to paroxetine. Variants 
in the 5-HT2a receptor (Minov et aI., 2001) and G-protein p3 (Zill et aL, 2000) have 
been associated with a response to SSRls. The near completion of the human genome 
project will provide a wealth of information on the nature and extent of genetic variation 
in human drug response and so transform the practice of medicine (Weber, 2001; 
Gurwitz et aI., 2003). 
Turecki and co-workers (2001), using a pharmacogenetic approach, mapped 
susceptibility genes for bipolar disorder. Their genome scan of 31 families ascertained 
through excellent lithium responders, found evidence for linkage with loci on 
chromosomes 15q14 and 7q11.2 and interesting findings were observed with markers 
on chromosomes 6 and 22. These findings highlight the potential of 
pharmacogenomics, in contributing to the elucidation of the genetic aetiology of BPO. 
1.8.2.4 Meta-Analysis 
The need for large sample sizes in the study of complex traits, has led investigators to 
see existing data in the literature in a new light (Johnson and Todd, 2000). Pooling of 
former linkage studies of BPO would increase the power of the combined data to detect 
linkage (Merinkangas and Yu, 2002). Meta-analysis represents one strategy for 
determining the significance of findings from multiple, independent and related studies 
(Segurado et aI., 2003). In a genome scan meta-analysis (GSMA) of bipolar disorder, 
data from 18 BPO genome scans were combined, in an effort to identify regions with 
significant support for linkage (Segurado et aI., 2003). Three such regions were 
identified on chromosomes 9p22.3-21.1, 10q11.21-22.1 and 14q24.1-32.12, using 
stringent disease models. 
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1.8.2.5 Variance component analysis 
Variance component-based linkage analysis, provide an attractive tool for the mapping 
of quantitative trait loci influencing complex phenotypes and for accurately estimating 
. their relative effect sizes, using all the available information in extended pedigrees of 
varying complexity (Blangero et aI., 2000). In addition to analysing large pedigrees, the 
variance component approach is able to analyse multiple loci simultaneously, examine 
gene-environment interaction, epistasis and calculate multipoint IBD probabilities. 
These properties have been implemented in the SOLAR (Sequential Oligogenic 
Linkage Analysis Routines) computer software package (Almasy and Blangero, 1998). 
1.8.2.6 Expression studies 
In the hope of identifying individual genes and/or functionally related genes that 
contribute to complex disease, molecular profiling/expression studies, such as high­
density array screens and differential display technologi s, have started to impact on 
the understanding of BPD and schizophrenia. 
Recently, genome-wide expression analysis, using microarrays, revealed decreased 
expression of myelin-related and oligodendrocyte-related genes in post-mortem 
dorsolateral PFC of schizophrenic patients (Hakak et aI., 2001). In an independent 
study, using differential display and quantitative PCR, Tkackev et al. (2003) found that 
key oligodendrocyte and myelination genes were down-regulated in post-mortem brain 
samples of BPD and schizophrenia (including transcription factors that co-ordinate 
these genes), thus lending support for common pathophysiological pathways for these 
two disorders. Using DNA microarray analysis, Kakiuchi and colleagues (2003) showed 
down-regulation of expression of genes involved in the endoplasmic reticulum (ER) 
stress response in Iymphoblastoid cells of bipolar patients. Upon further investigations, 
a polymorphism, -116C-7G, in the promoter region of XBP1 was significantly 
associated with bipolar disorder in Japanese case-control samples, causing impairment 
in the XBP1 positive-feedback system. 
Bosetti and et al. (2002), using cDNA micro-arrays, examined brain expression of 
genes in rats fed with lithium. Expression of 50 genes were decreased at 42 days of 
oral lithium administration, coding for a number of receptors, protein kinases, 
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transcription and translation factors, markers of energy metabolism, signal transduction 
and stress response. The finding of lithium's widespread depressive effects proposes 
that bipolar disorder, in comparison, may be associated with a stimulatory effect on 
gene expression and brain functional activity. Microarray analysis of human 
neuroblastoma flat cells exposed to valproate (a mood-stabilizing drug) showed 
decreased expression of dopamine decarboxylase, dopamine beta-hydroxylase and 
dihydropyrimidinase-related protein 3 (Jurata et aI., 2004). 
cDNA array analysis of post-mortem frontal cortex tissue from patients with BPD and 
controls revealed gene expression differences between the two groups (Bezchlibnyk et 
aI., 2002). This study identified genes encoding the signal transduction proteins, 
including transforming growth factor-beta 1 (TGF-beta1), caspase-B precursor (casp-B) 
and transducer of erbB2 (Tob). 
Using oligonucleotide GeneChip microarrays, Niculescu and colleagues (2000) 
examined gene expression in specific brain regions of rats, treated with 
methamphetamine. Several novel candidate genes were identified, including signal 
transduction molecules, transcription factors and metabolic enzymes that may be 
involved in the pathogenesis of mood disorders and psychosis. Moreover, decreased 
protein levels of GRK3, were observed in a subset of patient Iymphoblastoid cell lines 
that related to disease severity. Recently, Iwamoto and co-workers (2004) performed 
oligonucleotide microarray analysis on post-mortem tissue from patients with bipolar 
disorder and control subjects. The genes encoding receptor and channels (or 
transporters) were down regulated and those that encode the stress response proteins 
were up regulated in bipolar disorder. 
Yoon and colleagues (2001) examined the mRNA levels of TRPC7 in B lymphoblast 
cell lines (BLCLs) from BPI patients and healthy controls. Significantly lower TRPC7 
mRNA levels were found in BPI patients with high BLCL intracellular Ca2 + 
concentration, thus implicating reduced TRPC7 gene expression in pathophysiological 
disturbance of Ca2 + homeostasis in a subset of BPI patients. 
Expression studies, using human and animal systems, augment efforts to characterise 
the structure and function of the genetic factors involved in complex disease processes. 
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1.8.2.7 Bioinformatics 
The successful completion of the Human Genome Project,· HGP (Guttmacher and 
Collins, 2003), has led to the harnessing of genomics and proteomics in human disease 
studies. Simply put, genomics is the study of the interaction of genes, whereas 
proteomics is the study of all the proteins expressed in a cell or tissue. The HGP and 
its spin-offs, i.e. genomics and proteomics, are yielding unprecedented quantities of raw 
sequences, polymorphisms and gene expression data for thousands of genes, including 
those of the central nervous system in humans (Baron, 2002). Bioinformatics, the 
application of computer science to molecular biology, comparative genomics, structural 
genomics, and proteomics, has emerged as a fundamental tool to, (i) cope with the vast 
amount of genomic data stored in databases (Baron, 2002), and (ii) analyse information 
through data mining tools (Debes and Urrutia, 2004). Several different databases 
allowing universal access, with a sophisticated website as a primary means of 
presenting the data, are available and these include: 
1. 	 The Serial Analysis of Gene Expression (SAGE) database, at the National Centre 
for Biotechnology Information (NCBI). is a public resource that provides a 
quantitative profile of cellular gene expression. This quantitation does not measure 
the expression level of a gene, but measures a 'tag' which marks a gene transcript 
(Lash et aI., 2000). 
2. 	 The Gene Ontology (GO) site is a database and informatics resource that provides 
controlled and structured vocabularies (ontologies) to describe properties of gene 
products, including molecular function, biological process and cellular component 
(Gene Ontology Consortium, 2004). 
3. 	 Databases such as Ensembl (http://www.emsembl.org), the University of California, 
Santa Cruz (UCSC) Genome browser (http://www.genome.cse.ucsc.edu) and the NCBI 
(http://www.ncbLnlm.nih.gov/mapview) store and display annotated sets of genes, their 
chromosomal locations, and derived proteins from a range of genomes. 
Further tools at Ensembl, including BlastView and MartView, provide the user with 
access to inter-species comparisons at both the genomic and protein sequence levels 
and a rich series of links to external databases, such as the Genetic Association 
database (http://geneticassociationdb.nih.gov/cgi-binlindex.cgi), UNIPROT 
knowledgebase (http://www.expasy.uniprotorg/) and PUBMED 
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(http://www.expasy.uniprot.org/) amongst others, thereby accommodating a wide range 
of possible queries (Hammond and Birney, 2004). 
In order to gain maximum benefit from the wealth of information deposited in various 
databases, researchers require powerful computational tools to effectively integrate, 
clarify and apply it to drive hypothesis-based laboratory research and devise genetically 
derived benefits for clinical medicine. 
1.9 THE PRESENT STUDY 
Despite the current diagnostic techniques, diagnosis of BPO is complicated and 
misdiagnosis is commonplace. Nonetheless, BPO has long been recognised and 
continues to be well researched. Over the last decade intensive efforts have been 
made to explicate the genetic basis of BPO, in the hope of gleaning valuable insights 
into the structural and functional pathology, which remains to be fully explained. The 
genetic findings have, however, been unsatisfactory as investigators struggle with the 
problems of dealing with phenotypically and genetically heterogeneous conditions, 
controlling for gene-environment interactions and revealing the contributions of several 
interacting loci of small individual effect. Motivated by the current understanding of 
BPO, its impact on the global and South African burden of disease, the present study 
proposes, to some degree, to address the aforementioned problems, using an 
integrative approach, in contributing towards a better understanding of the specific 
neuropathology that underlies BPO. The practical benefits of identifying susceptibility 
genes for BPO include; 0) making diagnosis surer and faster, (ii) pinpointing 
biochemical pathways involved in pathogenesis, (iii) the facilitation of rational and more 
effective treatment strategies and, (iv) the implementation of clinical management 
strategies to prevent suicide and other morbidities in susceptible individuals. 
1.9.1 Aims 
The aim of this study is to identify susceptibility loci influencing BPO and attempted 
suicides (sub-phenotype), in South African families, integrating recent developments in 
statistical, computational and bioinformatics methods. 
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1.9.2 Project Objectives 
The specific objectives of this study are to: 
i) select candidate loci for genetic investigation 
ii) perform linkage analysis, using parametric and non-parametric methods 
iii) investigate the association between suicide attempts (sub-phenotype) and 
candidate loci (SNP) 
iv) investigate gene-gene interactions, using statistical and bioinformatics 
methods 
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CHAPTER 2 
THE SOUTH AFRICAN PERSPECTIVE 
In the presence of no substantial molecular pathophysiological knowledge, linkage 
analysis is one of the finest available methods to identify chromosomal regions 
concealing genes that promote the development of BPD. Successful linkage studies of 
BPD will require very large samples of informative bipolar families drawn from diverse 
populations, and/or samples drawn from genetically isolated populations. Such a 
resource, if made readily accessible to the scientific research community, would not 
only permit researchers to test various linkage hypotheses (Blehar et aI., 1988), but 
also allow findings of linkage in one family to be investigated speedily in other families. 
In due course, such an archival resource may favour the determination of (i) the 
proportion of BPD in which a specific chromosomal locus is involved, and (ii) the 
various loci contributing to genetic heterogeneity. 
In 1988, the National Institute of Mental Health (NIMH, USA) initiated a nation-wide 
program to establish an archival resource for genetic studies in BPD (Blehar et aI., 
1988). Known as the NIMH genetics initiative for BPD, four sites were selected for 
participation, including Indiana University (John Nurnberger, PI), Johns Hopkins 
University (Raymond DePaulo, PI), the NIMH Intramural research program (Elliot 
Gershon) and Washington University at St. Louis (Theodore Reich, PI). By 1995, using 
a common ascertainment and assessment strategy, around 140 families with 1200 
individuals had been ascertained and recruited. This national biological resource is 
complemented by diagnostic information and transformed cell lines from members of 
multiple families with BPD, providing an inventory or a living "library" of DNA and 
pedigree data. Based on their informativeness for linkage, 97 families with 540 
subjects, enriched for affected relative pairs and parents (where available) were chosen 
for genotyping. This is one of the largest uniformly ascertained and assessed samples 
available for genetic studies of BPD. Over the past few years several other groups 
have recruited large series of families with BPD, for linkage studies (Table 2.1). 
Families, containing multiple affected individuals, typically had patients diagnosed with 
BPI and BPI!. In some studies, the diagnostic criteria were extended to also include 
recurrent unipolar depression (RUP), major depression and schizoaffective disorder. 
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Table 2.1: International archival resources for genetic studies of families with BPD 
Reference Resource Diagnoses 
NIMH Genetics 
Initiative Bipolar group, 
1997 
97 pedigrees (540 individuals) of 
North American origin 
232 BPI, 72 BPII, 88 RUP, 
Schizoaffective bipolar illness 
32 
McMahon et aI., 1997 30 pedigrees (259 individuals) of 
North American origin 
56 BPI, 38 BPII and MDE-R, 38 
RUP, 4 Sch izoaffective bipolar 
illness 
Kelsoe, et aI., 2001 20 pedigrees (164 individuals) of 
North American origin 
33 BPI, 15 BPII, 28 MDE-R 
Cichon et aI., 2001 75 pedigrees (445 individuals) of 
German, Israeli and Italian origin 
respectively 
128 BPI, 40 BPII, 14 32 
Schizoaffective bipolar illness, 40 
RUP 
Bennett et aI., 2002 151 nuclear families (509 
individuals) of British and Irish 
origins 
288 BPI, 12 Schizoaffective bipolar 
illness, 25 BPII, 8 BNOS, 34 MDD 
Ekholm et aI., 2002 41 families (341 
Finnish origin 
individuals) of 92 BPI, 9 Schizoaffective bipolar 
illness, 6 BPII/BNOS, 15 MDD 
Dick et aI., 2003 250 pedigrees (1152 individuals) 
of North American origin 
537 BPI/ Sch izoaffective 
illness, 51 BPII, 98 RLiP 
bipolar 
In South Africa (SA), the Medical Research Council (MRC) conducted a survey in 2000, 
in order to obtain initial estimates of the burden of disease nation-wide (Bradshaw et aI., 
2003). In this survey the combined categories of mental and nervous system disorders, 
referred to as neuropsychiatric conditions, had the second highest disability-adjusted 
life years (DALY) ranking. These conditions could be the cause of mortality due to 
suicide (part of the injuries category). Furthermore, neuropsychiatric illness is ranked 
19th out of the 24 disease categories contributing to premature mortality in SA, making it 
an essential category of healthcare problems. In 1996, the Division of Human 
Genetics, at the University of Cape Town (UCT), SA, initiated an investigation into the 
genetics of familial BPD with the establishment of a BPD archive. 
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2.1 MATERIALS AND METHODS 
2.1.1 Ascertainment scheme 
BPD families were recruited through the systematic screening of local psychiatric 
hospitals as well as through advocacy groups and advertisements. During the period of 
1997 - 1999, three clinically trained interviewers undertook several visits to 4 of the 9 
provinces in South Africa (Gauteng, Free State, Eastern Cape and Western Cape). 
The criteria for ascertainment required a proband and an available first-degree relative, 
both with a BPI or BPII diagnosis. Interaction with healthcare professionals and 
advocacy groups resulted in the recruitment of two or more family members with a 
diagnosis of BPI, BPII, or recurrent MOE. Through further genealogical assessment, 
additional affected family members were identified and included in the study. All 
subjects were entered into the research programme after signing the UCT Research 
Ethics Committee-approved (study approval UCT ERC 081/96) written informed 
consent forms. In addition, 20 ml of peripheral blood was obtained from each 
participant and processed to DNA in the molecular genetics laboratory in the Division of 
Human Genetics. 
Individuals from the South African Mixed Ancestry and Caucasian population groups 
were recruited for the BPD resource. In SA, the Mixed ancestry population is derived 
from San, Khoi-Khoi, West Africa, Madagascar, Java and Western Europe origins. The 
South African Caucasian population is of Western European origin, mainly from 
European and British stock. 
2.1.2 Diagnostic assessment 
Probands and their relatives were interviewed by means of the Structured Clinical 
Interview for DSM-IV1 Axis I Disorders (SCID) 2. Borderline and anti-social PO were the 
only Axis " personality disorders assessed. Following the interview, a psychiatrist 
resolved the best-estimate final diagnosis for each subject using information from the 
SCID interview and all available family and medical records. Individuals who were 
experiencing an acute manic episode were interviewed once they were stable. No 
1 Diagnostic and Statistical Manual of Mental Disorders - 4th edition. 

2 Patient Edition (February 1996 FINAL.) SCID-I/P (Version 2.0) Modified for the Norvatis Bipolar 

Disorder Genetic Study Version: January 7.1998. First, M.B. Spitzer, R.L. Gibbon M and Williams, 

J.B.W. 
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children under the age of 16 were interviewed unless they had already been diagnosed 
with BPD by a psychiatrist. 
2.2 RESULTS 
To date, biological material and clinical information from 131 (two and three generation) 
families, which comprise of 809 individuals, have been archived. The diagnostic 
categories prevalent in the cohort of 809 individuals included mood, substance use and 
anxiety disorders (Table 2.2). Table 2.3 illustrates the distribution of these diagnostic 
categories according to ethnicity and gender; with a greater percentage of females than 
males recruited for both Caucasian and Mixed ancestry population groups. 
Of the total cohort (809), the majority of individuals (n=472) were diagnosed with a 
mood disorder (Table 2.4). 51.1 % of these affected individuals were diagnosed with BPI 
(age range of 17-87 years) and BPII (age range from 15-88 years), the core phenotypes 
of this study. 
Table 2.2: Diagnostic categories of subjects in BPD archive 

Diagnostic category 
 Number of individuals 

Mood disorders 
 472 (58.3%) 

Substance use disorders 
 36 (4.5%) , 
Anxiety disorders 27 (3.3%) 

Psychotic disorders 
 15(1.9%) 
Other disorders 1 16 (2%) 
240 (29.6%) 
Interviews not completed2 
I No diagnosis 
3 (0.4%) 
Total (%) 809 (100%) 
Utner a Isoraers. Incluolng AttentiOn OeTlClt olsorc er, tsoroerllne personality Olsoroer, ueluslona disorder, Dementia, Migraine 
Interviews not completed due to i) interviewee mental state. ii) refused prolonged participation in study iii) lack of collateral 
information to complete diagnostic process. 
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Table 2.3: Ethnic and gender distribution of diagnostic categories 
Diagnostic category Mixed Ancestry Caucasian 
M F M F 
Mood disorders 69 141 111 151 
Substance use disorders 19 2 13 2 
. Anxiety disorders 3 7 6 11 
Psychotic disorders 6 5 1 3 
Other disorders 2 3 6 5 
No diagnosis 41 78 54 67 
Interviews not completed - - 3 -
TOTAL 140 236 194 239 
Table 2.4: Summary of mood disorder diagnoses 
Diagnosis Total 
Bipolar I 200 (42%) 
Bipolar II 43 (9.1%) 
Cyclothymia 4 (09%) 
Bipolar NOS 5(1.1%) 
MOE ­ recurrent 113 (24%) 
MOE - single episode 92 (%) 
Dysthymia 8 (1.7%) 
DNOS 7 (1.5%) 
TOTAL (%) 472 (100%) 
Table 2.5 illustrates the distribution of these mood disorders according to ethnicity and 
gender. BPD showed a higher degree of co-occurrence with other Axis I psychiatric 
disorders (Table 2.6), including anxiety, substance use and psychotic disorders. In 
some cases, participants (8%) presented with more than two Axis I diagnoses. The Axis 
II, borderline and anti-social PDs were diagnosed in 1 % of participants. Furthermore, 
with the exception of substance use disorder, women diagnosed with a mood disorder 
showed greater co-morbidity with all the different psychiatric diagnoses than men. 
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Table 2.5: Ethnic and gender distribution of mood disorders 
Diagnosis IMixed ancestry Caucasian 
M F M F 
Bipolar I 42 65 48 45 
Bipolar II 5 8 13 17 
Cyclothymia 1 - 2 1 
Bipolar NOS 1 2 2 -
MOE ­ recurrent 10 34 23 46 
MOE - single episode 7 25 18 41 
Dysthymia 2 3 2 1 
DNOS 1 4 2 -
Total 69 141 111 
1 
151 
Table 2.6: Comorbid disorders (n=472) 
. Clinical 
phenotype 
Diagnostic category * TOTAL 
1 2 3 4 5 6 7 
Bipolar I 132 19 23 - 5 5 15 199 
Bipolar II 21 3 8 - 2 - 9 43 
Cyclothymia 3 - 1 - - - - 4 
Bipolar NOS 4 - - - 1 - - 5 
MDE-R 74 15 9 1 3 1 10 113 
MDE-S 67 10 8 1 1 1 3 91 
Dysthymia 5 1 2 - - - - 8 
Depression 
NOS 
5 - 1 - 1 - - 7 
TOTAL (%) 311 
(66%) 
48 
(10%) 
52 
(11%) 
2 
(0.4%) 
13 
(3%) 
7 
(1%) 
37 
(8%) 
470 
(100%) 
! 
Ula nostic cate 09 9 ry 
1. Primary f Only diagnosis. 2. Co-morbid with Anxiety disorders. 3. Co-morbid with Substance Use disorders, 
4. Co-morbid with Psychotic disorders, 5. Co-morbid with Other disorders including Attention deficit disorder. Borderline personality 
disorder. Delusional disorder. Dementia and Migraine, 6: Co-morbid with Axis' " diagnosis specifically borderline + anti-social 
personality disorders, 7. Co-morbid with >2 Axis I diagnosis 
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The most prevalent mood disorders in the Mixed ancestry and Caucasian populations 
were BPD (BPI and BPI!) and MOE (recurrent and single) (Table 2.7). More individuals 
of Mixed Ancestry descent were diagnosed with BPD (n=120), whereas mOre 
individuals of Caucasian descent were diagnosed with MOE (n=129). 
Table 2.7: Diagnostic distribution of BPD and MOE according to ethnicity 
ETHNICITY 
DIAGNOSIS Mixed ancestry Caucasian TOTAL 
BPI and II 120 123 243 
MDE recurrent and single 76 129 205 
TOTAL 196 259 448 
A subset of 73 (9%) individuals, comprising of 48 families (1 - 8 members per family), 
had a tlistory of suicide attempts (Table 2.8). Of these individuals, 53% were diagnosed 
as BPI, 13% as BPII, 23% as MOE recurrent and 9% as MOE single depressive 
episode. Suicide attempts peaked between the ages 31 - 50 years (56%) with the age­
group 21 - 30 years having a higher attempt rate (19%) than the 51 - 60 age-groups 
(11%). 
Table 2.8: Number of individuals who 
groups and diagnostic category. 
attempted suicide according to age 
AGE BPI BPII MDE-R MDE-S Alcohol TOTAL 
0-20i 0 0 0 1 0 1 (1%) 
21 -30 6 1 4 3 0 14 (19%) 
31 -40 
i 
12 3 6 0 1 22 (30%) 
41 -50 12 4 3 0 0 19 (26%) 
51 -60 6 0 1 1 0 8(11%) 
61 - 70i 2 1 3 0 1 7 (10%) 
71 -80 1 0 0 1 0 2 (3%) 
39 (53%) 9 (12%) 17 (23%) 6 (8%) 2 (3%) 73 
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2.3 DISCUSSION 

In any attempt to identify genes underlying disease it is important to have a well­
characterised large sample population for linkage analysis (or whatever mode of 
analysis will be used) and more specifically to aid the identification of multiple genes 
that exert varying magnitudes of effect on overall susceptibility. In order to locate such 
susceptibility genes that confer risk to BPD, a sizeable collection of families with 
subjects diagnosed as having BPD has been assembled in the Division of Human 
Genetics (UCT) in South Africa. Knowledge at hand indicates that this was the first 
neuropsychiatric genetics research project undertaken by a Human Genetics laboratory 
in South Africa. By the year 2000, around 131 families with 809 individuals had been 
ascertained, with diagnostic information captured in a well-maintained database and 
biological material archive in the molecular genetics laboratory. The biological 
resource consists of DNA material, but does not include transformed cell lines. It is 
possible that the existing resource of 809 relatives might be profitably utilised for 
parallel statistical and genetic analyses to investigate properties of diagnostic 
heterogeneity and familial patterns of inheritance, effects of birth cohort, and other such 
variables. 
It is reasonable to keep families and population groups separate when attempting to 
identify genetic elements in heterogeneous disorders. The Indigenous Black SA 
population was not recruited because of the unavailability of appropriately translated 
diagnostic resources. Of the two population groups in this study, a great number was 
observed in the proportion of subjects affected with BPD (BPI and BPI!) in the Mixed 
Ancestry population compared to the proportion of individuals affected with BPD in the 
Caucasian population (P = 0.009). Furthermore, there was a lower proportion of 
subjects affected with MOE (recurrent and single) in the Mixed Ancestry population 
compared to the proportion of individuals affected with MOE in the Caucasian 
population (P = 0.009). Therefore it is possible that different susceptibility alleles are 
present in these two population groups, and supports the separate analysis of the two 
population groups in subsequent genetic investigations. 
Affected family members were diagnosed with BPI, BPII and MDE-R, the so-called BPD 
spectrum of phenotypes. The most common co-occurring illnesses among individuals 
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with BPD are anxiety and substance use disorders. More females than males were 
recruited, which could be attributed to one of two reasons, (1) more females were 
willing to participate in the study or (2) there is an association between females and 
bipolar disorder (P = 0.001). 
At the time of the interview 9% of the recruited individuals admitted to having attempted 
suicide at least once in their lifetime. Eight years later, this figure is not an accurate 
representation of the incidence of attempted suicide in the study sample. Furthermore, 
the diagnoses of individuals could have changed. Therefore the implementation of 
systematic .screening methods is required to update changes in psychiatric status 
(course of illness) on perhaps a yearly basis for all pedigrees. 
In the design of the present study, three data sets (Table 2.9) of the archived families 
were selected, based on their informativity for genetic analysis and the diagnoses of the 
subjects (described in subsequent chapters). The research plan involved (ii) the 
identification of areas of interest, (ii) typing either flanking markers or markers within 
those areas and (iii) the modelling of two locus interactions. 
Table 2.9: Data sets selected for Ph.D investigation 
Data set Sample Description 
of sample 
I BPO genetic linkage study 22 Caucasian pedigrees Chapter 3 
Genetics of Suicide attempts: case-
control study 
46 cases, 160 controls Chapter 4 
Genetics of Suicide attempts: linkage 
analysis of extended families 
9 extended pedigrees Chapter 4 
These data sets were chosen for genotyping a subset of chromosomal regions, 
containing several loci for which there have been reports of suggestive evidence for 
linkage to BPD and association with suicide attempts. In this report, analytic techniques 
including non-parametric (model-free) linkage and case-control analyses were 
performed and are reported separately. 
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CHAPTER 3 

GENETICS OF BIPOLAR DISORDER IN 

SOUTH AFRICAN FAMILIES 

The term affective disorders, encompasses several clinical conditions characterised by 
disturbance of mood (DSM-IV). Estimated to disrupt the lives of up to 15% of the 
population, affective disorders are perhaps the most destructive group of 
neuropsychiatric disease in terms of prevalence, mortality, economic cost, and impact 
on families. Of the affective disorders, the sub-group of BPD can be diagnosed with the 
most certainty and for which convincing evidence for familial disposition is available. 
Owing to huge medical, interpersonal, societal and economic costs (Evans and 
Charney, 2003) current BPD research is underway at an unprecedented rate. This 
surge of research is aimed at understanding the aetiology of the illness to inform 
treatment and prevention. In addition to extensive BPD research involving post-mortem 
(including expression studies), neuro-imaging and biochemical studies (as discussed in 
Chapter 1), there is great and increasing emphasis on genetics. Genetics is seen as a 
potentially powerful tool to identify shared genetic elements between individuals bearing 
similar phenotypic traits. Such shared material is likely to code for biological elements 
related to the pathophysiology of disease. 
During the past 20 years, several genomic regions have been implicated as candidates 
by parametric and non-parametric linkage analyses (see Risch and Botstein, 1996). 
Regions on chromosomes 1, 3, 4, 5, 6, 12, 15, 18, 22 and X have all been implicated at 
one time or another. Occasionally a single gene may have a major effect in some 
families, however, generally the development of BPD is considered to involve multiple 
genes and environmental factors (Craddock and Jones, 1999). Due to this 
multifactorial nature, genetic analysis of BPD is complicated. The possible involvement 
of multiple genes, which are likely to be heterogeneous and of small individual effect 
sizes, together with their epistatic interactions add to the complexity of the disorder 
(Craddock and Jones, 1999). Novel statistical methods that permit the joint analysis of 
multiple chromosomal regions have successfully been applied to diabetes (Cox et aI., 
1999; Cordell et aI., 2000) and BPD (Mcinnis et aI., 2003a; Schulze et aI., 2004). In 
addition to improved statistical genetic analyses, genomics has emerged as a promising 
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strategy/approach. Genomics not only focuses on a single gene/locus, but aims to 
interpret whole genomic information and its impact on biological systems (Guttmacher 
and Collins, 2002). The incredible advance in the science of genomics resulted in (i) an 
increase in the amount of data at the molecular and medical levels deposited in public 
databases; (ii) an increased need to develop tools to mine the data, organise it and 
create hypothesis-driven laboratory research (Debes and Urrutia. 2004). The advent of 
bioinformatics (as discussed in Chapter 1) provided researchers with essential tools to 
help make sense of biological data stored in databases. Moreover, bioinformatics 
represents a unique way to enhance our understanding of diseases, correlate 
genotypes to phenotypes, clarify multifactorial inheritance, and identify novel 
therapeutic targets. 
The application of genetic mapping strategies and bioinformatics form the subject of the 
present investigation, i.e. (i) the application of linkage analysis strategies to candidate 
regions on chromosomes 1q32, 2q33.3, 4p16.1, 7q11.23, 10q23.31, 12q24, 13q32, 
15q12, 16p13.3, and 22q12.1, that have been implicated in bipolar disorder (see Table 
3.1), and (ii) the development and application of bioinformatics tools to identify and 
prioritise potential candidate genes in linked and other regions (Table 1.2). 
Table 3.1: Candidate regions under investigation 
Candidate region Reference 
1q31-32 Turecki et aI., 1995; Detera-Wadleigh et aI., 1999 
2q33.3 Zubenko et aI., 2002; Kelsoe et aI., 2001 
4p16.1 Blackwood et aI., 1994; Als et aI., 2004 
7q Detera-Wadleigh et aI., 1994; 1997 
10q Cichon et aI., 2001 b 
12q23-q24 Dawson et aI., 1995; Morisette et a/., 1999 
13q32 Detera-Wadleigh et aI., 1999; Liu et aI., 2001 
15q12 Ginns et aI., 1996; Craddock and Lendon, 1999 
16p13 Ewald et al.,1995; Edenberg et aI., 1997 
22q11-q13 Lachman et aI., 1997; Kelsoe et aI., 2001 
A brief summary and annotation of these candidate regions (Table 3.1) and the 
microsatellite markers used for linkage analysis is provided. 
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i. Chromosome 1q31-32 
Interest in this region stems from a cytogenetic study reporting an association between 
BPI and a fragile site at 1q32 (Turecki et aI., 1995). In a genome-wide scan of 22 U8 
pedigrees, suggestive linkage of BPO to 1q31-q32 was reported (Oetera-Wadleigh et 
aI., 1999). Using affected sib pair analysis, a multipoint non-parametric lod score of 
2.64 at 0181660-0181678 (P=0.00022), under a narrow disease definition (including 
individuals diagnosed with BPI and BPII), was obtained. This finding was supported by 
parametric linkage analysis, with a lod score of 2.37 at marker GATA124F08, assuming 
a dominant mode of transmission. 
p 
q 
D1S1660-194 069 719bp 
31.1 3929436bp31.3 
32.1 
32.2 0132655 - 197 999 155bp 
41 
936825bp 
D1S1678-198935980 
Figure 3.1: Ideogram of chromosome 1q31-q32 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected 
for linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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ii. Chromosome 2q33.3 
Zubenko et al. (2002) reported linkage of unipolar mood disorders to a 451 kb region of 
2q33-34, with maximum non-parametric lod scores of 6.331 and 6.866 at 02S2321 and 
02S2208, respectively. Linkage of mood disorders to this region, which contains the 
CREB1 gene, was detected only among affected female relative pairs. 
p 
q 
D252321- 206998 434bp 
451014bp 
32.3 
33.3 
34 
::::::11("'---_ D252208 ­ 207449 448bp 
36.1 
Figure 3.2: Ideogram of chromosome 2q33.3 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected 
for linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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iii. Chromosome 4p16.1 
Under a dominant model of inheritance, Blackwood et al. (1994) observed linkage in a 
large 8cottish pedigree, where the marker 048394 generated a two-point parametric 
lod score of 4.1. Multipoint analyses with neighbouring markers gave a maximum 
parametric lod score of 4.8, under a narrow disease phenotype (including BPI, BPII and 
cases of recurrent and single episode unipolar depression) and a dominant model of 
transmission. Oetera-Wadleigh et al. (1999) reported support for linkage to this region, 
with a multipoint non-parametric lod score of 1.77, under a broad disease phenotype 
(including individuals diagnosed with BPI, BPII and MOE). Recently, Als et al. (2004) 
reported evidence for association between BPO and a two-marker segment of 048394­
0482983 (P=0.0162) at 4p16.1. 
Wolframin gene - 6 389 648bp p 16.3 
16.1 691498bp 
D4S394 7081 146bp 
785785bp 
D4S2983 - 7866931 bp 
2784911bpq D4S1582 -10651 842bp 
Figure 3.3: Ideogram of chromosome 4p16.1 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected 
for linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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iv. Chromosome 7q 
In their analysis of 20 pedigrees, under a dominant model, Oetera-Wadleigh et at 
(1994) obtained a lod score >3 at 07S78. In the bipolar series of the National Institute 
of Mental Health (NIMH) Genetics Initiative, chromosome 7q displayed elevated allele 
sharing (Oetera-Wadleigh et al.. 1997). Coincident with this location. Oetera-Wadleigh 
et aJ. (1999) reported evidence for linkage to an area between 07S1799 and 07S501 
(Iod score of 2.08, P=0.00099), under the broad disease phenotype, in 22 US 
pedigrees. 
p 
D7S613 72984476bp 

310 567bp 

q 11.23 
 D7S2472 73295 043bp 
243602bp21.1 ~ D7S1870 73538 645bp 
22 30216792bp 
___ ~ D7S1799 - 103755 437bp 
31.1 ~ 2278880bp 
D7S501-106 034 317bp 31.3 

32 

36 
Figure 3.4: Ideogram of chromosome 7q and the distances between markers. 
Key: Italics - Markers implicated in literature; Grey - Markers selected 
for linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (i.e. distance in bp) is from telomere (pter) to centromere. 
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v. Chromosome 10q 
In their analysis of 75 German pedigrees, Cichon et al. (2001 b) obtained a parametric 
lod score of 2.86 at 010S217 on 10q25-26, under a dominant model and a broad 
disease definition (including all cases with a diagnosis of BPI, BPII, schizoaffective, 
bipolar type, recurrent unipolar and unipolar single episode). Kelsoe et al. (2001) 
reported suggestive linkage of BPO to chromosome 10q with marker 010S1223 
(parametric lod score 2.27), under a dominant model of inheritance. 
p 
q 11.22 01OS1753 ­ 91634 580bp 
21.1 186757bp 
010S564 ­ 91 821 337bp 
94546bp 
23.31 010S1171 - 91 915 883bp 
3681935Dbp 
Figure 3.5: Ideogram of chromosome 10q and the distances between markers. 
Key: Italics - Markers implicated in literature; Grey - Markers selected for 
linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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vi. Chromosome 12q23-q24 
Morisette et al. (1999) reported a non-parametric lod score of 3.92 at D12S82 in a large 
Canadian family, under a broad disease definition (where a diagnosis of BPI, BPII, 
schizoaffective, bipolar type, and recurrent major depression are considered as 
affected). Using non-parametric analyses Dawson et al. (1995) and Detera-Wadleigh et 
al. (1999) observed modest support for linkage to this region, 12q23-q24, in 44 
European families and 22 US pedigrees, respectively. A recent genome-wide scan. 
pointed to a susceptibility locus for BPD on 12q23-q24 with a parametric lod score of 
3.35 at D12S378 (Shink et aI., 2004). 
D12$82 ­ 89 239 142bp 
q 26342110bp 
012S79 -115581 252bp 
3097749bp 
D12S86 -118 679 001bp 
21.3 4337088bp 
23 D12$378-123 016 089bp 
1639272bp 
24.2 
24.31 
24.32 
D1281612 -124 655 361bp 
24.33 
p 
Figure 3.6: Ideogram of chromosome 12q23 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected for 
linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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vii. Chromosome 13q32 
In their affected sib pair analysis of 22 U5 pedigrees, Oetera-Wadleigh et a!. (1999) 
obtained the strongest evidence for linkage at chromosome 13q32 that yielded a 
parametric lod score of 3.5 (P=0.000028) at the 01351252-01351271 interval, under a 
broad disease definition (including individuals diagnosed with BPI, BPI! and MOE). By 
typing nine additional markers in this region, in the same pedigree set, Liu et al. (2001) 
proved the validity of these findings and suggested a finer localisation of the 
susceptibility gene(s) on chromosome 13q32. 
p 
q 
D13S1298 - 93 412 898bp 

842533bp 

D13S1271- 94255 431bp 

32 

33 
 20998bp 
D13S1284 - 94 276 429bp 
Figure 3.7: Ideogram of chromosome 13q32 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected for 
linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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viii. Chromosome 15q12 
Ginns et al. (1996) reported linkage of BPO with excess allele sharing at 015845 
(P=O.0003), under the BPI diagnostic category. Oetera-Wadleigh and co-workers 
(1998) found evidence of linkage to 0158695 (P=0.017) on 15q21.1. In the linkage 
data report on the Workshop on Chromosome 15 at the sixth World Congress of 
Psychiatric Genetics, in Bonn, Germany, the region on chromosome 15q13-q15 was 
most promising for functional psychoses (Craddock and Lendon, 1999). This region 
contains the alpha 7 nicotinic receptor and the gamma-aminobutyric acid receptor, 
alpha-5 (GABRAS) genes. Recently, chromosome 15q was identified in a genome-wide 
scan for regions influencing the age at onset of mania in BPO (Faraone et aI., 2004). 
p 
0158122 - 18397 081bp 
q 
12 
2319999bp 
13 01581002 - 20717 080bp 
21.1 1 908258bp 
01581048 - 22625 338bp 
21464593bp 
015S659-44 089 931bp 
___~ 
Figure 3.8: Ideogram of chromosome 15q12 and the distances between 
markers. Key: Italics - Markers implicated in literature: Grey - Markers selected for 
linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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ix. Chromosome 16p13 
Ewald et al. (1995) reported possible evidence for linkage between BPO and 016S510 
(parametric lod score 2.52), under a recessive model, in Oanish families. In the 97 
bipolar pedigrees of the NIMH Genetics Initiative, Edenberg et al. (1997) reported 
increased IBO sharing at 016S2619 (IBO=0.54, P=0.006) on chromosome 16p13. 
p 13.3 
13.2 
13.1 
q 
D16S3024 - 1 681 284bp 
2403194bp 
01683027 - 4 084 478bp 
1 657 707bp 
D16S510 - 5742 185bp 
1 505257bp 
01683088 - 7 247 442bp 
6461444bp 
D16S2619 - 13708 886bp 
Figure 3.9: Ideogram of chromosome 16p13 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected for 
linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (i.e. distance in bp) is from telomere (pter) to centromere. 
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x. Chromosome 22q 11-13 
In a study of 17 US BPD families, Lachman et al. (1997), using non-parametric 
multipoint analyses, reported suggestive evidence for linkage to chromosome 22q11 
(P=O.017), near the Velo-Cardio-Facial syndrome region. This finding was supported 
by Detera-Wadleigh et al. (1999), who obtained a non-parametric multipoint lod score of 
2.1 (P = 0.00094), under a broad disease definition (including individuals diagnosed 
with BPI, BPII and MDE) in 22 US pedigrees. The 'right' extension/branch of the Old 
Order Amish pedigree 110 was selected as the 22nd pedigree, because it seemed to 
contain a single known ancestor with bipolar disorder (Berrettini et aI., 1994). Kelsoe et 
al. (2001) observed a parametriC lod score of 3.84 in the same general region, under a 
dominant model, in 20 families from the general North American population. 
022S419 - 22639 313bp 
p 

8930bp 

022S421 - 22648 243bp 

q 

63696bp11.2 
12.1 
12.3 022S315 - 22711 939bp 
13.1 
13.2 106864bp
13.3 
022S1164-22 818 803bp 
Figure 3.10: Ideogram of chromosome 22q11-q13 and the distances between 
markers. Key: Italics - Markers implicated in literature; Grey - Markers selected for 
linkage analyses, based on proximity and heterozygosity (>0.60). The 
orientation (Le. distance in bp) is from telomere (pter) to centromere. 
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3.1 EXPERIMENTAL APPROACH 
3.1.1 Subjects 
From the large collection of families (n=131), 22 multiply affected pedigrees of 
Caucasian decent were selected as an initial candidate region screening panel. These 
families, with 4 to 33 members per family, typically had members diagnosed with BPI, 
BPII and MDE, with some unaffected relatives to allow inference of identity by descent 
(IBD) where possible (Table 3.2). A copy of the consent form completed by patients is 
included as Appendix A. The sample includes 168 individuals with; 31 BPI, 18 BPII, 24 
single MDE and 46 recurrent MDE.ln order to maximise the utility of the sample for 
genetic analyses and owing to the uncertainty about the spectrum of disease that is 
inherited, linkage analysis was carried out using two hierarchical models (Affection 
status models I and II) of the affected bipolar phenotype. For affection status model I 
(ASM I), a narrow disease definition was used to describe the affected phenotype, 
consisting of BPI and BPII. For the second model, ASM II, the affected phenotype was 
broadened to include those individuals with single and recurrent episodes of major 
depression. 
3.1.2 DNA extraction 
Peripheral blood (20ml) was col/ected from subjects into 10ml EDTA-containing plastic 
tubes. These tubes were labelled with the patient's name, surname and date of birth. 
Together with the cornpleted consent form, the blood specimens were received by the 
molecular genetics laboratory of the Division of Human Genetics, UCT, where all the 
information was captured in a Microsoft Access database. Subsequent storage of 
blood specimens was at -20°C. The Genomix™ extraction kit (Talent, Italy) was used 
to extract genomic DNA (gDNA) from frozen lymphocytes (Appendix B, section B.1). 
gDNA samples were quantitatively assessed by spectrophotometry and working 
dilutions of 200ng/ul were made of the stock concentrations. 
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1Table 3.2: Summary of diagnoses of 22 Caucasian pedigrees 
FAMILY BPI MDE·R MDE-S AA Psychosis Other No diagnosis TOTAL 
1 1 1 1 - - - - 2 4 
2 
- - - 5 - - - - 5 
3 3 - 2 2 - - - 1 8 
4 2 1 4 
- 2 1 - 3 13 
5 1 1 3 - - - 1 3 9 
6 2 2 1 1 - - - 3 9 
7 1 1 - 2 1 - - - 5 
8 2 - 3 1 1 - 2 4 13 
.9 3 - 5 - - 1 - 2 11 
10 - - 4 2 - - - 2 8 
11 2 1 - - - - - 2 5 
12 3 5 4 1 - - 1 - 14 
I 
13 1 1 1 3 - - - - 6 
14 1 1 1 - - - - 1 4 
15 1 1 7 1 - - - 3 13 
16 2 - 2 - - - - I - 4 
17 2 1 1 1 1 - - - 6 
18 1 1 - 2 - - - 4 8 
19 1 1 - 1 - - - 1 4 
, 20 
! 
1 - 4 - - - - 1 6 
21 2 1 - - - - 1 2 6 
1122 1 - 1 1 1 - - - 4 
* Large pedigree was split into pedigrees 9 and 10 for linkage analysis 
3.1.3 DNA analysis 
The microsatellite markers used for genotyping (Table 3.3) consisted of tandem 
repeated dinucleotides and tetranucleotides. Markers were chosen from the literature 
and the following databases: the Foundation Jean Dausset - Centre d'Etude du 
Polymophisme Humain (CEPH) (www.cephb.fr). the National Centre for Biotechnology 
Information (NCBI) (www.ncbLnlm.nih.gov/) and the Human Genome Browser 
(www.genome.ucsc.edu/). Marker heterozygosity ranged from 0.60 to 0.96 and averaged 
0.85. The average inter-marker spacing across the candidate locus, in 262 affected 
relative pairs (ARP), was -3cM, based on sex-average distances between them 
(Cooperative Human Linkage Center, CHLC). With few exceptions, multiplex PCR 
amplification was carried out in 1Oul volumes in 96-well plates, containing 
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Table 3.3: List of primer sequences for markers genotyped in candidate regions 

Chromosome 
 Markers Forward Primer (5'-3') Reverse primer (5'-3') 

1q32 
 01S1660 tgctatcctctcaccagtga gtctgaagttcatgggaacg 
01S2655 agggtccccaaagagccttc atggcagcacatcctgcttc 
01S1678 actttctcacatgaccacagg cagcgagactctgtcaaaaa 

2q33.3 
 02S2321 ccatgtggtgtttggcag gagcagaattgcagggc 
02S2208 ctatttgtaaacatgcggga agctaagtacctgctcaggaaa 

4p16.1 
 04S394 cccttgagcatcctgacttc gagtgagcccctgtactcca 
04S2983 tgtccagttggcaggg ggtcgcattcattcgc 
04S1582 atcagggttctccacacaaa ttggttgaaacttgtggatataaa 

7q11.23 
 07S613 cag cct ggg taa caa aag c cctccctccctaatccatg 
07S2472 tct aaa gtc tgc cag gct ac gcagcgagactccatc 
07S1870 ttc act cag gaa gtg gc tggtgatgtgctttactacg 

10q23.31 
 010S1753 ctgctgccaccaacctaa caagtggagactcgatgaca 
010S564 tgggaatgtgtctttatcca gctctaacatagaggccagat 
010S1171 gggttgaataaacatgcatg gaatggggatgcagctaaa 

12q24 
 012S79 ttggactgaactgagatgcc tatgtgcacccagactacca 
012S86 ctatcccctgatgatctccc 
012S1612 
agctagtctggcatgagcag 
tcagcccctgtctcac gcatccttgatgtccc 

13q32 
 gattgttttatattctctgcttttc cctaccagtgggactttc 
013S1271 
013S1298 
gcggtttttgccattaaag 
013S1284 
ccgagattgcaccactg 
tgtggctgcaaatgac 
15q12 
gaggtgtccatcaatgc 
gataatcatgcccccca cccagtatctggcacgtag 
015S1002 
015S122 
ctcttgctagagacagcagg 
015S1048 
gtatcccaaggccataccct 
tgcagccactgtggaa 
16p13.3 
agccgtctttgtgcca 
agctgccagtatatggagga 
016S3027 
acatgctgtgccacct016S3024 
ccagcatgagttgcttt 
016S3088 
atatttggcatctgggg 
ctctgaatagggtggggatg aaggaaatctggggtgtacg 
22q12.1 ctgctgcccctaacatatcac ggccaggagtgtctgaatttta 
022S315 
022S421 
gcattatgattcatttctcacaga 
022S1164 
tgcctattaaactctccactcctta 
cattcagaagccatttgcatccagacactgcctctc 
200ng gDNA, 10pmol of each fluorescent primer (labelled with either HEX or FAM, 
purchased from the Synthetic DNA laboratory, UCT, South Africa). reaction buffer 
containing 10mM Tris-HCI (pH8.3) and 50 mM KCI, 1.0 or 1.5 mM MgCI2, 200uM 
dATP,dGTP,dCTP, dTrp (Invitrogen, UK) and 0.5 units of BiotaqTM (Bioline, UK) or Taq 
DNA polymerase (Invitrogen, USA). 
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All amplifications were carried out on a Perkin Elmer DNA Thermal Cycler. In general, 
cycling conditions included an initial denaturation step at 95°C for 3 minutes followed by 
10 cycles of denaturation at 94°C for 15 seconds, annealing at 55°C (ranging from 60°C 
to 50°C) for 15 seconds, extension at 72°C for 30 seconds. The remaining 20 cycles 
included denaturation at 89°C for 15 seconds, annealing at 55°C (dependent on the 
primer pair in use) for 15 seconds, extension at 72°C for 30 seconds, followed by an 
extension step at 72°C for 5 minutes. 
PCR products were genotyped using the Applied Biosystems (ABI) 377 and 3100 
sequencers (Perkin Elmer) (Appendix B section B.3). Allele sizes were called using the 
Genescan® version 3.1/Genotyper® version 2.1 and GenemapperTM version 3.0 
programs, on the ABI 377 and ABI 3100 sequencers respectively. In order to 
standardise markers run on different sequencing machines, allele sizes generated from 
two control DNA samples were used. Genotypic data was transferred to 
Genopedigree™ version 1.0.1 (Perkin Elmer), along with the phenotypic data and stored 
in Genbase ™ version 2.0.1. Mendelian inconsistencies were checked manually with 
Genotyper® version 2.1 software and resolved before linkage analysis. All data for 
statistical analysis were exported from Genbase TM. 
3.1.4 Statistical analysis 
Because the pattern of inheritance of any genes influencing the relative risk for bipolar 
disorder is unknown (Craddock and McGuffin, 1993), model-free/non-parametric 
analyses were relied on to assess evidence for linkage due to a single locus and two 
locus interactions. Model-free methods, based on allele-sharing at marker locations, 
are not dependent on a specific model proposed for the disease as in the case of 
parametric LCD score methods. Affected relative pair (ARP) methods were used, as 
they are more robust than affected sib pair (ASP) methods, to conditions of genetic 
heterogeneity and multifactorial inheritance (Risch, 1990a-c). 
3.1.4.1 Single (major)-Iocus analysis 
Linkage, i.e. the identification of chromosomal positions showing an excess of alleles 
shared IBO among the affected relative pairs, was assessed under the affected 
phenotype groupings of ASM I and ASM II. Linkage analyses were performed by using 
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MERLIN version 1.10.2 (Abecasis et aI., 2002; MERLIN website) in conjunction with 
SimWalk2 version 2.89 (Sobel and Lange, 1996; Sobel et aI., 2001; Sobel et aI., 2002). 
To estimate more accurately the relative location of the BPO susceptibility gene and 
marker loci, multipoint linkage analyses (at three steps/increments equidistant between 
markers) were carried out, using sex-averaged maps, i.e. the test statistic was 
evaluated at positions between marker loci (as well as at the marker loci themselves), 
using allele-sharing information from the markers and their specified locations. The 
probability of the observed sharing is calculated by using the non-parametric linkage 
(NPL), Z. score approach (Kruglyak et aI., 1996). Pedigrees were analysed using the 
ALL scoring function of Merlin, which examines all individuals simultaneously and 
assigns a higher score when more of them share the same allele by decent. Kruglyak 
and colleagues (1996) have demonstrated that the NPLALL statistic results in a more 
powerful test than the NPLpAIRs statistic. However. the ALL scoring function can have 
skewed distribution in large pedigrees and therefore which statistic is more powerful 
depends on the true mode of transmission. MERLIN calculates exact non-parametric Z 
scores to assess the extent of allele-sharing (IBO) among the affected sibling and other 
relative pairs. One pedigree in the data set was too large to be analysed by MERLIN, 
and was evaluated by SimWalk2. This software performs Markov Chain Monte Carlo 
(MCMC) methods to estimate results for the combined sample of relative pairs and 
larger pedigrees, which could not be analysed by MERLIN. The NPL_ALL statistic of 
SimWalk2, was used and it is a measure of whether a few founder-alleles are 
represented in excess in the affecteds. MERLIN analysis was also done after splitting 
the large pedigree into smaller pedigrees (9 and 10). to compare the results. Mega2 
(Manipulation Engine for Genetic Analysis) version 2.5 R3 (Mukhopadhyay et aI., 1999) 
was used to generate from data stored in linkage-format files all the input files required 
for the MELRIN/SIMWALK2 analysis option. 
3.1.4.2 Multi-locus analysis 
Next the joint effects of two loci in BPO were considered. Again model-free methods 
are most convenient for combining this information into a test for linkage and/or 
interaction with a second disease locus, as they are not dependent on the specification 
of a two-locus disease susceptibility model. Two such two-locus analyses, restricted to 
(locations) which had previously shown evidence of linkage in single-locus analyses, 
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were carried out. In both analyses, the increased ISD sharing at any given position is 
considered as an estimation of disease location. 
The first two-locus analysis method allows multipoint allele-sharing analysis at a 
postulated second locus, by weighting families according to their evidence for linkage at 
the first locus (Cox et aI., 1999). Three weighting schemes were used to model positive 
interactions (such as epistasis) (weighto1 and weightnpl) and heterogeneity (weight10). 
Weighto1 assigns weight 0 to families with 0 or negative linkage scores and weight 1 to 
families with positive linkage scores; Weightnpl assigns weight 0 to families with 0 or 
negative linkage scores and families with positive linkage scores are assigned the 
specific linkage score as a weight; Weight1Q assigns weight 1 to families with 0 or 
negative linkage scores and weight 0 to families with positive linkage scores. Weightnpl 
is similar to weight1Q, except that more weight is assigned to families with positive 
linkage scores. 
The program Allegro version 1.2c (Gudbjartsson et aI., 2000) was used to carry out four 
allele-sharing model analyses incorporating the specific scoring function (Spairs or Sail) 
and family weighting scheme. Gudbjartsson and co-workers (2000) promote the use of 
the exponential allele-sharing model of Kong and Cox (1997) and cite McPeek (1999) in 
promoting the Whittemore and Halpern (1994) Spairs scoring function as a concession 
choice for a scoring function that behaves well over all disease models (see Allegro 
report which accompanies the Allegro manual). The following allele-sharing models 
were specified: 
1. 	 MODEL rnpt exp pairs equal exppairseq.mpt ; this model causes multipoint ('mpt') 
allele-sharing analysis to be performed using the exponential ('exp') model and the 
Spairs scoring function with all families weighted equally ('equal'). Using the equal 
weights scheme, a standard unweighted linkage analysis was performed creating 
the output file exppairseq.mpt. 
2. 	 MODEL mpt exp pairs weights:weighto1 exppairs01.mpt ; this model causes 
multipoint ('mpt') allele-sharing analysis to be performed using the exponential 
('exp') model and the Spairs scoring function with all families weighted according to 
scheme weightD1. 
3. 	 MODEL mpt exp pairs weights:weight1o exppairs10.mpt ; this model causes 
multipoint ('mpt') allele-sharing analysis to be performed using the exponential 
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('exp') model and the Spairs scoring function with all families weighted according to 
scheme weight1 o. 
4. 	 MODEL mpt exp pairs weights:weightnpl exppairsnpl.mpt; this model causes 
multipoint ('mpt') allele-sharing analysis to be performed using the exponential 
('exp') model and the Spairs scoring function with all families weighted according to 
scheme weightnpl. 
Models 2 - 4 test linkage at the second locus, weighted by the evidence of linkage at 
the first locus. Zir statistics are reported for each model at each marker and at three 
points equidistant between each marker, rather than NPL scores as these tend to be 
too conservative when inheritance data are incomplete. Under the null hypothesis of no 
linkage, Zir has a standard normal distribution, with mean 1 and variance O. 
The difference in Zir statistics between the equal weights (baseline) model and each of 
the three weighted models (diff01, diff10 and diffnpl ) were calculated. The significance 
associated with these differences in Zlr, when evidence for linkage at a particular 
location is taken into account using family specific weights, was determined by writing a 
script to perform permutations in the statistical analysis package R. That is, to see how 
often performing a weighted analysis gave a result as significant as the result (diffo1, 
diff10 and diffnpl ) we observed by chance, 1000 permutations were performed using 
actual data and the R (R Development Core Team, 2004) script reoms shown in 
Appendix D, section D.1 . In order to correct for using three weighting schemes, the 
maximum difference (maxdiff) of all three weighting schemes were also calculated. 
In the second two-locus method a likelihood-ratio analysis, based on the two-locus ISD 
sharing probabilities of affected relative pairs (Cordell et aI., 1995; Farrall, 1997; Cordell 
et aI., 2000) is performed. This method is a generalisation and extension of the 
maximum lod score (MLS) method (for a single locus) introduced by Risch (1990c) to 
the problem of detecting the effects and modelling the action of several disease loci, 
using all affected relative pairs. The single-locus MLS test statistic, tests for departure 
from 0.25, 0.5 and 0.25 ISD sharing probabilities: MLS=log10 L(~)/L(0.25, 0.5, 0.25), 
where ~ =(zo, Z1, Z2), the values of (zo, Z1, Z2) that maximise the likelihood (probability) of 
the data. The program lWOLOCARP (Cordell et aI., 1995; Farrall, 1997; Cordell et aI., 
2000) was used to calculate two-locus MLS statistics, which model the 3 by 3 matrix of 
0, 1, and 2 ISD sharing probabilities at both locus 1 and locus 2, under the null 
hypothesis that locus 2 is not involved in disease. Prior and posterior probabilities, that 
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each affected relative pair shares i alleles IBO at particular locations on locus 1 and 
locus 2, were required. The Fortran utility maketwo.f (Appendix 0 section 0.2) was 
used to convert the prior and posterior IBO output files generated by Allegro for each 
locus into input files, twoprior and twoposterior, required by TWOLOCARP. Various 
two-locus models are generated, including a multiplicative (MUL), an additive (ADD) 
and a general (GEN) model. The MUL model, is an epistatic model (Risch, 1990a), 
where the two-locus MLS for two unlinked loci is equal to the sum of the individual 
single-locus MLSs at the two loci; the ADD model, is a good approximation of a 
heterogeneity (HET) model (Risch, 1990a), where the two loci are considered to be 
independent causes of the disease; both the MUT and ADD models are embedded in 
the GEN model, i.e. may be considered as special cases of the GEN model. The 
significance associated with the increased MLS value, when evidence for linkage at a 
particular location is taken into account, was determined by simulation in MERLIN, 
using the R script goodscript (Appendix 0, section 0.3). Simulation was carried out by 
allowing MERLIN to perform gene-dropping, under the assumption of no linkage to 
disease, at the second (test) locus. 
3.1.5 Bioinformatics 
Literature on the molecular genetics of BPO was reviewed (Table 1.2) and used to 
compile a list of candidate regions implicated in the aetiology of the disease. Using the 
genetic markers reported in the literature, the boundaries of these candidate regions 
were refined using: 
i) Genome Database (GOB, www.gdb.org) to find the corresponding 0 segment number 
for the reported flanking markers in cases where the marker names were reported in 
radiation hybrid format, in order to standardise nomenclature. 
ii) National Centre Biotechnology Information (NCBI, www.ncbLnih.gov), to find the 
nucleotide sequence of the identified flanking markers and their physical distances on 
the genome. 
iii) University of California Santa Cruz (UCSC) BLAT server (http://genome.ucsc.edu) to 
identify and extract the genes reported in the corresponding intervals in the 
pu blications. 
In cases where more than one marker was reported in the candidate region of interest 
(by different investigators), markers were ordered according to base pair positions 
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along the chromosome and the smallest and largest base pair positions were used to 

define the boundaries of the interval. In instances where only one marker was reported 

in the candidate region of the publications, an artificial boundary was established 5cM 

outward on either side of the reported marker. The resulting long list of genes, 

extracted from the candidate regions, was processed to remove hypothetical genes as 

well as repeated genes, henceforth referred to as master list (LIST_MASTER). The 

processing was executed on a Pentium IV personal computer running on a REDHAT 

L1NUX VB using a purpose written PERL script c1ean_tbl.pl. 

Three additional short lists were created. The parameters and criteria used to create 

these additional lists are explained below: 

i) L1ST_MICROARRAY: This list comprises of genes implicated in Bipolar Disorder 

(BPD) based on reported micro-array expression studies (Table 3.4). 

Tabe 3.4: Sources of microarray expression studies in BPD 
Literature 
1. Detera_Wadleigh, 2001 
2. Niculescu and Kelsoe, 2001 
3. Kakiuchi et aI., 2003 
4. Tkachev et aI., 2003 
5. Iwamoto et aI., 2004 
ii.) LIST _CNS: This list comprises of genes involved in different neurotransmitter 
pathways in the Central Nervous System (CNS). The data for this list was obtained from 
various sources (Table 3.5). 
Table 3.5: Sources of CNS data 
Books 
Fundamental Neuroscience, 1999, Academic Press 
Essential Psychopharmacology, 2nd Edition, 2000, Cambridge University Press 
World wide web 
htt~://www.biocarta.com/l2athfiles/l1eurotranslTlittersPathway.as12 
htt~://www.biocarta.com/l2athfiles/h crebPathway.asl2 
htt~://www.genome.ad·iQ/kegg/ 
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iii) LIST_SAGE: The genes in this list were obtained from Serial Analysis of Gene 
Expression (SAGE) data, located at http://www.ncbi.nlm.nih.gov/sage and 
ftp:/lncbi.nlm.nih.gov/pub/sage (Lash et aI., 2000). Using the PERL script 
get_brain_exp_pl., genes were extracted from the human brain SAGE library. 
A preliminary tool was designed, using the PERL script get_matches_pl., to match the 
genes in the individual lists to those in the master list, called LIST_MATCHES, in order 
to identify (short-list) candidate genes in the reported intervals, implicated in BPO. 
Next, the genes 'flagged' in the region(s) implicated in the linkage analysis, were 
investigated by Gene Ontology (Hammond and Birney, 2004) (www.geneontology.org), 
a resource for molecular function, biological process and cellular component ontologies, 
for a given gene(s), i.e. to find genes that are related by ontologies. 
3.2 RESULTS 
A total of 32 polymorphic microsatellite markers covering 11 candidate regions (Table 
3.1), with an average spacing of -3 cM between markers, were genotyped in 22 
multiplex families. Two affection status models, narrow (ASM I) and broad (ASM II), 
were deliberately chosen prior to linkage analysis. Non-parametric linkage calculations 
identified candidate regions with excess IBO sharing. 
3.2.1 Single-locus analysis 
The results of the NPLALL score analysis, before splitting the larger pedigrees, are 
depicted in Table 3.6. The table lists all markers and their respective empirical P values 
associated with the NPLALL statistic of SimWalk2. Under ASM II, the strongest evidence 
for linkage was produced by chromosome 1 q32, generating a P value of 0.0526 
(NPL=1.2786) at marker 01S1678. After splitting the large pedigree into two smaller 
pedigrees, analysis in MERLIN, detected greater evidence for linkage to 1 q32 under 
ASM II, yielding a non-parametric P value of 0.011 (Zmean=2.28) at marker 01 S1678 
(Table 3.7). Table 3.7 depicts all markers with the results of the multipoint MERLIN 
analysis, performed at three increments equidistant between marker loci. Under ASM I, 
chromosome 12q23-q24 yielded the next strongest support for linkage to BPO, 
generating a P value of 0.0327 (NPL=1.4850) at marker 012S1612. There was no 
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significant change in the P value before and after splitting the large pedigree. 
Furthermore, none of the other regions showed any evidence of linkage to BPD. 
Table 3.6: Linkage data derived through MERLlN/SimWalk2 analysis before 
splitting the large pedigree 
A5MI A5M II 
Chromosomes Markers NPLAll P value NPLAll P value 
1q32 0151660 0.1112 I 0.01030 
0152655 0.0839 0.0753 
0151678 0.0821 0.0526 II 
2q33.2 I 0252321 0.7276 0.5937 II 
0252208 0.8555 0.7693 
4p16.1 045394 0.6887 6 
0452983 0.6551 0.9759 
0451582 0.3779 0.4494 
7q11.23 075613 0.1643 0.2831 
0752472 0.3905 0.1992 
0751870 0.6073 0.3704 
10q23.31 01051753 0.7216 0.3524 
0105564 0.8002 0.4348 
01051171 0.4432 0.1154 
12q24 012579 0.3032 0.1370 
012586 0.1127 0.0950 
01251612 0.0327 0.0721 
13q32 01351298 0.2336 0.5740 
01351271 0.1745 0.3693 
01351284 0.1841 0.2340 
15q12 0155122 0.3760 0.2014 
01551002 0.3024 0.2368 
01551048 0.2161 0.2191 
16p13.3 01653024 0.1248 0.4460 
01653027 0.2172 0.2439 
01653088 0.6519 0.4538 
22q12.1 0225421 0.5751 0.6933 
0225315 0.5754 0.9749 
02251164 0.2826 0.9161 
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Table 3.7: Multipoint linkage data derived through MERLIN analysis after 
splitting large pedigrees 
ASMI ASM II 
Chromosome Markers Oistance a P(NPLALd P(LOO)" P(NPLALd P(LOO)° 
1 01S1660 0 0.08 0.04 0.04 0.03 
1.095 0.08 0.03 0.04 0.03 
2.19 0.08 0.03 0.04 0.02 
3.285 10.08 0.04 0.03 0.02 
01S2655 4.38 0.08 0.05 0.03 0.02 
I 4.79 0.07 0.04 0.02 0.014 
5.2 0.07 0.04 0.02 0.011 
5.61 0.06 0.04 0.02 0.008 
01S1678 6.02 0.06 0.05 0.011 0.006 
2 02S2321 0 0.8 0.7 0.7 0.7 
0.003 0.8 0.7 0.7 0.7 
0.005 0.8 0.7 0.7 0.7 
0.008 0.8 0.7 0.8 0.7 
02S2208 0.01 0.8 0.7 0.8 0.7 
4 04S394 0 0.7 0.7 0.7 0.6 
0.37 0.7 0.7 0.8 0.7 
0.74 0.7 0.7 0.9 0.7 
1.11 0.7 0.7 0.9 0.8 
04S2983 1.48 0.7 0.6 1.0 0.8 
3.047 0.6 0.6 0.9 0.7 
4.615 0.5 0.5 0.8 0.7 
6.183 0.5 0.5 0.7 0.7 
04S1582 7.75 0.4 0.4 0.5 0.6 
7 07S613 0 0.4 0.4 0.3 0.4 
0.333 0.4 0.4 0.3 0.3 
0.665 0.5 0.5 0.2 0.2 
0.998 0.5 0.5 0.13 0.2 
07S2472 1.330 0.5 0.5 0.08 0.12 
1.530 0.5 0.5 0.11 0.14 
1.730 0.6 0.6 0.14 0.2 
1.930 0.6 0.6 0.2 0.2 
07S1870 2.130 0.7 0.7 0.2 0.3 
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Table 3.7 : Continued 
ASMI ASM II 
Chromosomes Markers Oistance a P(NPLALL) P(LOO)" P(NPLALd P(LOO)° 
10 010S1753 0 0.7 0.7 0.4 0.3 
0.003 0.7 0.7 0.4 0.4 
0.005 0.7 0.7 0.4 0.4 
0.008 0.8 0.7 0.4 0.4 
010S564 0.01 0.8 0.7 0.4 0.4 
1.218 0.8 0.7 0.3 0.3 
2.425 0.7 0.7 0.3 0.2 
3.632 0.6 0.6 0.2 0.13 
010S1171 4.84 0.5 0.5 0.12 0.1 
12 012S79 0 0.4 0.4 0.13 0.13 
2.308 0.3 0.3 0.13 0.11 
4.615 0.3 0.3 0.12 0.09 
6.923 0.2 0.2 0.11 0.09 
012S86 9.23 0.2 0.2 0.10 0.09 
10.638 0.11 0.11 0.10 0.08 
12.045 0.07 0.06 0.10 0.08 
13.453 0.04 0.04 0.09 0.09 
012S1612 14.86 0.03 0.03 0.09 0.1 
13 013S1298 0 0.3 0.3 0.5 0.5 
0.003 0.3 0.3 0.5 0.5 
0.005 0.3 0.3 0.4 0.4 
0.008 0.2 0.3 0.4 0.4 
i 
013S1271 0.01 0.2 0.3 0.3 0.3 
0.Q13 0.2 0.3 0.3 0.3 
0.015 0.2 0.3 0.3 0.2 
0.018 0.2 0.3 0.3 0.2 
013S1284 0.02 0.2 0.3 0.2 0.2 
15 015S122 0 004 004 0.2 0.14 
2.118 004 004 0.2 0.11 
4.235 004 0.3 0.2 0.1 
6.353 0.3 0.3 0.2 0.12 
015S1002 8047 0.3 0.3 0.2 0.2 
9.605 0.2 0.2 0.2 0.2 
10.74 0.2 0.2 0.2 0.2 
11.875 0.2 0.2 0.3 0.2 
015S1048 13.01 0.2 0.2 0.3 0.3 
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Table 3.7 : Continued 
ASMI ASM II 
Chromosomes Markers Distance a P(NPLALd P(LODt P(NPLALL) P(LOD) ° 
,16 01683024 0 0.07 0.02 0.4 0.4 
0.415 0.07 0.013 0.4 0.4 
0.83 0.08 0.02 0.3 0.3 
1.245 0.11 0.03 0.3 0.3 
01683027 1.66 0.2 0.09 0.3 0.3 
2.763 0.2 0.14 0.4 0.3 
3.865 0.3 0.3 0.4 0.4 
4.968 0.5 0.5 0.5 0.5 
01683088 6.07 0.7 0.6 0.6 0.6 
22 0225421 0 0.7 0.7 0.7 0.6 
0.003 0.7 0.7 0.8 0.7 
0.005 0.7 0.7 0.9 0.7 
0.008 0.7 0.7 0.9 0.8 
0228315 0.01 0.7 0.7 1 0.8 
0.013 0.6 0.6 1 0.8 
0.015 0.5 0.5 1 0.8 
0.018 0.4 0.4 0.9 0.8 
02281164 0.02 0.3 0.3 0.9 0.8 
Distance In cM, calculated from our data 
b P value for the Kong and Cox allele-sharing lad score (Zlr statistic) 
3.2.2 Multi-locus analysis 
Evidence for linkage was assessed at a second region, 2q33.3, 4p16.1, 7q11.23, 
10q23.31, 12q24, 13q32, 15q12, 16p13.3 or 22q12.1, conditioned on the evidence for 
linkage at 1 q32, under ASM II, using 2 two-locus methods. The first method involves 
weighting a family's contribution to the Zir statistic at locus 1 q32, through the program 
Allegro, using three weighting schemes (Cox et aI., 1999), weighto1, weight10 and 
weightnpl' Table 3.8, illustrates the baseline Zir values observed at the second locus 
and those weighted by the contribution of 1q32, under ASM II. The most significant 
difference between baseline and 1 q32 weighted Zir statistics, was observed at region 
10, with a difference of 1.0147 (weightnpl minus baseline). 
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Table 3.8: Zir statistics of Allegro analysis of two locus interactions, under 
ASM 1/, showing positions with increased Zlr scores 
Region Position Baseline Zir 1 q32 weighted Zir 
2q33.3 - - -
4p16.1 7.750 0.2629 1.2256 (weighto1 ) 
7q11.23! 1.930 0.9598 1.3738 (weightnpl ) 
10q23.31 4.840 1.7863 2.8010 (weightnpl) 
12q24 14.860 1.2718 1.8485 (weight1O) 
13q32 0.020 0.7637 1.6133 (weightnpl) 
15q12 8.470 1.2212 1.3528 (weightnpl) 
16p13.3 1.660 0.8685 2.1287(weight10) 
22q12.1 
- - -
-: Negative contributions to Zlr, no significant increase in 1q32 weighted Zir 
To assess the significance of this difference, 1000 permutations, using the actual data, 
were performed. Nineteen out of 1000 permutations gave a result greater than 1.0147, 
with an associated P value of 0.019. Next, the permutation test was used to correct for 
the use of the 3 weighting schemes (by looking at the maximum difference of the three 
results) and produced a marginally significant result P value of 0.05. The second most 
significant difference, of 1.2606 (weighto1 minus baseline) was detected at region 16. 31 
out of 1000 permutations gave a re ult greater than 1.0147, with an associated P value 
of 0.031. As with 10q23.31, a similar corrected P value of 0.055 was produced on 
chromosome 16, when amending for the use of multiple weights. 
The second two-locus method involves calculating the MLS statistic, based on the two­
locus ISO sharing probabilities of affected relative pairs, using the program 
TWOLOCARP (Cordell et aI., 1995; Farrall, 1997; Cordell et aI., 2000). Table 3.9 lists 
the MLS statistics for the MUT, AOO/HET and GEN models. For all locus pairs, the 
MLS scores for the MUL model were equal to the MLS results for the single loci (results 
not shown). Therefore, the multiplicative model does not explain any underlying 
interaction model that might be present. Overall, the individual GEN model fits better Le. 
gave greater MLS scores than the single locus (MUL model) for all locus pairs. To 
estimate the significance of the difference between single locus (MUL model) MLS 
scores and GEN model MLS scores, 1000 simulations were carried out using the 
90 

Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Table 3.9: MLS statistics of TWOLOCARP analysis under· 
ASM II showing regions with highest MLS scores for each 
locus pair under the GEN model 
Locus pair Position* MLS 
MUL HET GEN 
• 1 q32 - 2q33.3 2.0000 0.2841 0.3434 0.3434 
1 q32 - 4p16.1 9.0000 0.0313 0 0.8997 
1q32-7q11.23 1.0000 3.0686 3.0977 3.1086 
1 q32 -10q23.31 9.0000 0.4805 0.3713 1.3997 
1q32 - 12q24 2.0000 4.0063 4.7598 4.7598 
1q32 - 13q32 5.0000 0.2556 0.2150 0.3737 
1q32-15q12 1.0000 1.5617 2.2958 2.2958 
1q32 -16p13.3 5.0000 1.2728 13898 1.3979 
i1q32 - 22q12.1 4.0000 0.1496 0.0837 0.3238 
,...oslIIon (at three steps equidistant between 3 marKerS) where the hlgnest ML::i score was observed for each locus pair 
SIMULATE option in MERLIN. Where the primary focus is the detection of a second 
disease locus (GEN model), out of 1000 simulations none of the MLS statistics proved 
to be significant. However when evaluating the significance of the statistic GEN-MUL 
(0.9192) for locus pair 1q32-10q23.31, Le. to measure whether conditioning on 1q32 
improved linkage to 10q23.31, 23 out of 1000 simulations (P value 0.023) gave a result 
greater than 0.9192. This test for interaction is most similar to the weighted analysis 
performed in Allegro. 
Under ASM I, chromosome 12q24 showed weak evidence for linkage to BPD, P value 
of 0.0327. It was decided to carry out the same two-locus methods to assess the 
evidence for linkage and/or interaction at 1q32, 2q33.3, 4p16.1, 7q11.23, 10q23.31, 
13q32, 15q12, 16p13.3 or 22q12.1, conditioned on the evidence for linkage at 12q24, 
under ASM I. As before, three weighting schemes (Cox et aI., 1999) were created for 
analysis in Allegro, using the individual family contribution to the Zir statistic at locus 
12q24. No significant results were obtained (Zlr<1.96) for any of the locus pairs (Table 
3.10). 
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Table 3.10: Zir statistics of Allegro analysis of two locus 
interactions, under ASM I, showing regions with increased Zir 
scores 
Region Position Baseline Zir 12q24 weighted 
1q32 5.200 1.6627 1.8884 (weighto1) 
7q11.23 0.665 0.8198 1.6683 (weightnpl) 
10q23.31 4.840 0.0386 1.1853 (weightnpl) 
13q32 0.002 0.5470 1.7154 (weightnpl) 
10.740 1.5361 (weightnpl)0.8453• 15q12 
2q33.3 0.007 -1.0639 0.1782 (weightnpl ) 
4p16.1 7.750 0.2629 1.2256 (weighto1 ) 
16p13.3 0.415 1.9503 -
0.020 0.5809 0.8820 (weightnpl)II 22q12.1 
-: No Increase In any one otthe three 12(q :4 wellhted Llr9 
TWOLOCARP (Cordell et aI., 1995; Farrall, 1997; Cordell et aI., 2000) analyses of locus 
pairs, under ASM I (Table 3.11), yielded the highest MLS score, 1.5294 (under the GEN 
model), for locus pair 12q24 and 1 q32. As before 1000 simulations were carried out 
using the SIMULATE option in MERLIN and no significant linkages were detected at the 
second disease locus, based on the evidence for linkage to the first locus, i.e. 12q24. 
Furthermore, no evidence for interaction was detected between 12q24 and a second 
disease locus. 
3.2.3 Bioinformalics 
The number of genes extracted from the list of candidate regions (Table 1.2) implicated 
in the aetiology of BPD, i.e. the master list, totalled 4713. Three additional short lists 
were created, LIST _MICROARRAY (with 19 genes), LIST_SAGE (with 487 genes) and 
LIST _CNS (with 604 genes). The PERL utility get_matches_pl., which matches 
LlST_MICROARRAY, LIST_SAGE and LlST_CNS with genes in the master list 
(LIST_MASTER), yielded a short list, LIST_MATCHES, of 'flagged' genes (n=231), Le. 
genes present, in UST_MICROARRAY, LlST_CNS and/or LIST_SAGE; and therefore 
potential candidate genes involved in BPD. Table 3.12 shows the Gene Ontology 
information on the candidate genes 'flagged' on chromosomes 1 q32 and 10q23.31. 
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The file containing the various lists and utilities may be downloaded at 
ftp.proto.hmg.uct.ac.za/CC/LISTS using anonymous login. 
Table 3.11: MLS statistics of TWOLOCARP analysis under 
ASM I showing regions with highest MLS scores for each 
locus pair under the GEN model 
Locus pair 
12q24 - 1q32 
12q24 - 2q33.3 
12q24 - 4p16.1 
12q24 - 7q11.23 
12q24 - 10q23.31 
12q24 - 13q32 
12q24 - 15q12 
12q24 -16p13.3 
Irzq24 - 22q 12.1 
Position* 
MUL 
7.0000 1.0825 
1.0000 0.0253 
9.0000 0.0021 
1.0000 1.4061 
1.0000 0 
1.0000 1.1906 
5.0000 0.5706 
·3.0000 0.5601 
9.0000 0.3174 
t-'osltlon (at tnree steps eqUiOIstant oetween ;j marKerS) wnere 
MLS 

HET 

0.3364 

0.2064 

0 

1.6746 

0.0305 

1.3009 

0.3210 

0.2932 

0.0055 

GEN 

1.5294 

0.2064 

0.1180 I 
1.7193 

0.0305 

1.3278 

0.6434 

0.7109 

0.7380 

."'. ML~ score was ooserved for each locus pair 
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Table 3.12: Gene ontology data on 'flagged' genes in linked regions 1q32 and 10q23.31 
Gene Molecular Function Biological Process Cellular component 
ADORA 1, adenosine 
receptor A 1, 1 q32 
A 1 adenosine receptor activity, 
rhodopsin-like receptor activity 
Signal transduction, neurogenesis, 
phagocytosis, inflammatory response, 
Integral to plasma 
membrane 
NAV1, Neuron 
navigator-1, 1 q32 
ATP binding, nucleotide 
binding 
No available information No available information 
----­ .­
Integral to plasma 
membrane 
HTR7, serotonin 
receptor 7, 10q23.31 
Serotonin receptor activity, 
melanocortin receptor activity 
Synaptic transmission, circadian rhythm 
PLCE1, 
phospholipase C 
epsilon 1, 10q23.31 
---_.........._. _ ........... _._--
Phosphoinositide 
phospholipase C activity, 
receptor Signalling protein 
activity 
Activation of MAPK, cell proliferation, 
inositol phosphate-mediated signalling 
Plasma membrane, 
cytosol 
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3.3 DISCUSSION 
The aim of this study was the investigation of the molecular basis of BPO in South 
African families affected with the condition. The genetics of BPO is complex and is 
thus likely to be caused by multiple interacting susceptibility genes; therefore non­
parametric linkage methods were applied in the identification of those regions that 
may confer susceptibility to this psychiatric condition. Genotype analyses were 
conducted on 22 Caucasian families with BPO, using 32 marker loci covering 
candidate regions on chromosomes 1q32, 2q33.3, 4p16.1, 7q11.23, 10q23.31, 
12q24, 13q32, 15q12, 16p13.3, 18p11.2 and 22q12.1. Oifferent analytical methods 
were employed using the programs MERLIN, Simwalk2, Allegro and TWOLOCARP. 
Single-locus analyses we(e carried out in (i) MERLIN, in conjunction with Simwalk2 
(MERLIN/Simwalk2) for large pedigrees and (ii) MERLIN, after splitting the one large 
pedigree. Splitting the large pedigree, gave greater evidence for linkage to 1q32 (P 
value, 0.006, at marker 01S1678), under AMS II, compared to keeping the pedigree 
together (P value, 0.0526, at marker 0131678). One possible explanation is that 
more distant relatives provide less information when a susceptibility allele is common 
(Badner et aI., 1998), thus subsequent analyses were performed using split 
pedigrees. 
Although primary single locus analysis has implicated chromosome 1q32, with 
marginal evidence for linkage to BPO, under ASIVI II, it is not considered significant 
for linkage on the basis of Lander and Kruglyak's (1995) proposed guidelines for a 
genomic scan. However, previously implicated candidate regions were investigated 
in the current study. The findings may therefore be considered meaningful on the 
basis of prior probability. Furthermore, nearly half of the families (41 %) contribute 
positive scores to the total score on 1 q32, suggesting that the linkage signal is not 
driven by a few large families. Under ASM I, chromosome 12q24 also showed 
marginal evidence for linkage to BPO, but to a lesser extent than the region on 1 q32. 
Broadening of the classification of affected phenotypes to include major depression, 
may therefore have had a significant effect on the NPL score. None of the other 
candidate regions, 2q33.3, 4p16.1, 7q11.23, 10q23.31, 13q32, 15q12, 16p13.3 and 
22q12.1, showed any evidence of linkage to BPO. However, given the multifactorial 
nature and expected heterogeneity of BPO, it is likely that contributions by these loci 
are of such small effect, that linkage is not detected, when examined individually. So, 
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to increase power to detect linkage to these loci, two-locus analyses were performed. 
Using model-free methods, the linkage information at 1q32, under ASM II, was 
incorporated into a test for linkage and/or interaction with a second disease locus, 
2q33.3, 4p16.1, 7q11.23, 1Oq23.31, 12q24, 13q32, 15q12. 16p13.3 or 22q12.1, 
thereby avoiding indiscriminate application of two-locus analysis. In the first two-locus 
analysis method of Cox et al. (1999) families were weighted based on their 
contribution to the Zir statistic at 1 q32, using three weighting schemes. The most 
promising result was observed at 10q23.31 with weightnpl. generating a corrected P 
value of 0.05, suggesting an interaction between susceptibility loci on 1q32 and 
10q23.31. When modelling interaction between 1 q32 and 16p13. using weighto1, a 
corrected P value of 0.055 was obtained. Based on the TWOLOCARP analysis, the 
true genetic model is not multiplicative, as the IVIUL model MLS score was equal to 
the single locus MLS score. Furthermore, as expected, the individual GEN model 
better fits the two-locus sharing probabilities than the embedded MUL and HET 
models, thus indicating that these embedded models do not sufficiently explain the 
data. In the interest of unbiased reporting, two-locus analyses were also performed 
on 1q32, 2q33.3, 4p16.1, 7q11.23, 10q23.31, 13q32, 15q12, 16p13.3, and 22q12.1, 
based on the linkage result obtained at 12q24. Allegro and TWOLOCARP analyses, 
showed no evidence for linkage to and/or interaction with 1q32, 2q33.3, 4p16.1, 
7q11.23, 10q23.31, 13q32, 15q12, 16p13.3, and 22q12.1. These results are all very 
marginal and could become significant by performing genetic analysis on additional 
affected family members and by typing the remaining families in our BPD research 
archive. 
Owing to the application of statistical testing on two affection status models, ASM I 
and ASM II, a cautious interpretation of these findings is warranted. The two models 
have extensive overlap, and the tests are therefore not entirely independent. 
Furthermore, the same data are explored using various analytic methods which 
interrogate possible interactions between two loci, and with no transparent procedure 
of correcting for these effects (which are common to several linkage analyses in 
human genetics), false positive results are more likely to occur. The genetic 
mechanisms of anticipation, genetic imprinting and mitochondrial mutations that are 
known to generate complex patterns of inheritance have not been focussed on. 
Therefore, the findings of tentative linkage and interaction should only be regarded 
as the first steps in understanding the biologic properties of illness and its 
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significance in South African subpopulations. Nonetheless, the decision to continue 
with studying these regions might be better based on biological relevance in order to 
improve power for linkage analysis. 
Traditionally, molecular biology research was carried out exclusively at the 
experimental laboratory bench, but the considerable increase in the amount of data 
being generated by the genome projects has necessitated the need to integrate 
computers into this research process. In the present investigation, the development 
and implementation of bioinformatics tools have been initiated in an effort to narrow 
down and prioritise the candidate genes, contained in the regions implicated in BPD 
(Table 1.2), into a short list that may be screened for mutations in affected 
individuals. With such a short list of candidate genes, hypothesis driven genotype 
analysis can be performed in the research laboratory. Furthermore, such tools will 
make it possible; (i) to pinpoint the underlying biochemical pathways most likely to be 
involved in disease pathology; (ii) to look for possible gene-gene interactions that 
may explain the phenotype and (iii) to ultimately assign biological meaning to 
genomic data. The following lists (1-4) were created: 
1. 	 a list of genes (LIST_MASTER, n=4672) using standardised HUGO gene 
symbols (www.gene.ucl.ac.uklnomenclature) given the input of flanking 
markers or chromosome bands implicated in BPD (Table 1.2). 
2. 	 a list of genes according to the expression profile of human brain 
(LIST_SAGE, n=487) 
3. 	 a list of genes according to micro array expression data on BPD, published in 
the literature (LlST_MICROARRAY, n=19) 
4. 	 a list of genes based on biochemical pathway data (LlST_CNS, n=546) 
obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways 
A preliminary 'matching' tool was developed that allows the comparison of these lists 
(2-4) to the list of genes created with regions implicated in BPD (1). Consequently, a 
ranked list of candidates, flagged according to hits of genes in lists 2, 3 and/or 4 
(n=177), was created. This list, called LIST_MATCHES, and all the other lists can be 
downloaded at ftp.proto.hmg.uct.ac.za/CC/LiSTS. Further investigations involve: 
i. 	 the interrogation of the Gene Ontology information 
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(http://www.geneontology.org), which aims to formalise our knowledge about 
biological processes, molecular functions and cellular components, and return 
a list of genes related by ontologies 
ii. 	 examining and interrogating available tools such as eVoke, the human 
expression vocabulary at the South African National Bioinformatics Institute 
(SANBI), creating a list of genes related byeVOC 
(http://www.sanbi.ac.za/evoc) ontologies, 
iii. 	 creating a list of published candidate genes and lists from any other sources 
that may become available. 
Recent developments at Ensembl (http://www.ensembl.org), a comprehensive 
genome information resource, provide access to a variety of links to external 
databases, such as protein databases (SWISSPROT and trEMBL), ontology and 
expression databases (www.geneontology.org and eVoc at SANBI), making data 
retrieval and data mining sufficiently fast to accommodate a wide range of possible 
queries. Ensembl provides interactive interfaces such as BlastView, for sequence 
homology searches and MartView, which permits the user to formulate a query and 
select the output format, including genes, markers, SNPs, proteins, ontologies. and 
orthologues. While it is now possible to execute queries on live data and therefore 
generate more comprehensive lists compared to our original outputs, the comparison 
of these will still need to be carried out locally. 
In 2004, Ogden and co-workers described the use of a convergent functional 
genomics approach in the identification of genes in BPD. The approach involves the 
integration of; (i) brain gene expression data from a pharmacogenomic mouse model 
(involving treatments with methamphetamine and valproate), Oi) human linkage data 
and (iii) variations in post-mortem brains from patients with bipolar disorder. Similar 
to our study, the authors came up with a short list of candidate genes for individual 
analysis in a prioritised manner. DARPP-32 (dopamine- and cAMP-regulated 
phosphoprotein of 32kDa) on 17q12. PENK (preproenkephalin) on 8q12.1 and TAC1 
(tachykinin 1. SUbstance P) on 7q21 topped their list of candidate genes. More 
recently and much like the strategy adopted in this study, Hattori et al. (2005), 
describes a "systems genetics" approach, requiring an intensive literature review and 
mining of electronic databases for entire pathways, in the compilation of candidate 
genes. 
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Individually, the chromosomal regions 1q32 and 10q have been implicated in BPD 
(Detera-Wadleigh et aI., 1999, Cichon et al.. 2001 b). Based on the evidence of 
interaction observed between loci on chromosomes 1q32 and 10q23.31, the 
matching tool described in section 3.1.5, was used to 'flag' candidate genes in these 
two regions. Located on chromosome 1q32.1, Neuron navigator-1 (NAV1), is 
expressed in the developing brain (Maes et al.. 2002). The exact function of this 
gene is not known in humans, although the Caenorhabditis e/egans homolog. unc­
53, is involved· in axon guidance. Abnormal neuronal development has been 
implicated in BPD (Manji et al.. 2000). The gene that encodes the adenosine A 1 
receptor is another interesting gene in this region. ADORA 1 regulates the release of 
neurotransmitters and, in rodents, antidepressant treatments such as 
electroconvulsive therapy (Newman et aI., 1984). sleep deprivation (Yanik and 
Radulovacki, 1987) and carbamazepine (Daval et al.,1989) have been shown to 
increase ADORA 1 density. Increased expression of ADORA 1 may. therefore. be one 
of the mechanisms mediating antidepressant effects at the molecular level. 
Located on chromosome 10q23.31. the serotonin receptor 7 (HTR7) is one of seven 
classes of receptors that mediate the effects of serotonin in the central nervous 
system (Barnes and Sharp, 1999). Abnormal functioning of the serotonergic system, 
including HTR7, has been implicated in BPD (Lin et aI., 2003). A second candidate 
gene on 10q23.31, phospholipase C epsilon 1 (PLCE1) belongs to the phospholipase 
family that catalyses the hydrolysis of phosphoinositide 4, 5-biphosphate (PIP2) to 
diacylglycerol (DAG) and inositol-1, 4, 5-triphosphate (IP3) (Gould and Manji, 2002). 
Production of second messengers involved in phosphatidylinositol signalling system, 
i.e. DAG and IP3, depends on a continued source of free myo-inositol for the re­
synthesis of precursor phospholipids. Free myo-inositol in turn, is generated by the 
dephosphorylation of myo-inositol monophosphate by the enzyme myo-inositol 
monophosphatase (IMPase) (Sjoholt et aI., 2004). Known as the inositol depletion 
hypothesis, inhibition of IMPase enzyme, has been a reputed target of lithium 
treatment (Berridge et aI., 1989). 
In order to find biological evidence in support of possible interactions between NA V1 
or ADORA 1 on 1 q32 and HTR7 or PLCE1 on 10q23.31 the genes were examined by 
Gene Ontology. Not much is known about the NAV1 gene (Maes et aI., 2002). None 
of the genes appear to have the same molecular function, although ADORA 1, HTR7 
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and PLCE1 all have receptor activity. Furthermore, the genes are involved in 
different biological processes although one could argue that not enough is known 
about these protein products and cannot be ruled out as ontologically candidates. 
Interestingly, ADORA 1, HTR7 and PLCE1 are all integral to the plasma membrane; 
however, further investigation into interactions is required. 
In summary, the results suggest that chromosomal regions, 1q32 and 10q23.31 not 
only contain susceptibility genes, but that their joint effects may playa role in the 
aetiology of BPD in at least a subset of populations. Further pedigree linkage studies 
of these regions are needed in delineating genetic vulnerability to BPD. In addition, 
with the application of bioinformatics, candidate genes on chromosomes 1 q32 and 
10q23.31 were identified, for genetic analysis in order to understand the underlying 
pathophysiology of BPD. With the use of bioinformatics, researchers are able to 
mine the wealth of biological information concealed in the mass of sequence data 
and to obtain a better understanding of the fundamental biology underlying complex 
disease and to channel this information to enhance the standard of health care. 
The recruitment of extended families and "endogamous" populations, together with 
thoroughly investigated phenotypes need to be strongly encouraged. The present 
results should be followed up in the populations, in order to "mine" specific genetic 
aspects of BPD as a homogeneous entity. 
As mentioned in Chapter 1 many patients diagnosed with BPD have one time or 
another in their lifetime attempted suicide, making suicide a serious complication for 
these individuals. Importantly, identification of these high risk patients is important, in 
order to prescribe effective treatment, and so reduce morbidity and mortality in 
patients with BPD. A subset of the patients in our BPD archive has attempted suicide 
(as described in Chapter 2) and in the next chapter the same methodological 
approaches, used in this chapter, are applied to try and uncover the underlying 
genetic susceptibility loci in this "sub-phenotype" of BPD. 
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CHAPTER 4 

GENETICS OF SUICIDE ATTEMPTS 

Suicidal behaviour is frequently encountered in the course of BPD (see Chapter 1 
section 1.3.1). According to Tondo and Baldessarini (2000) suicide attempts in BPD 
are inclined to be of high lethality, with one completed suicide per three attempts, in 
contrast with one completed suicide in 18 attempts in the general population. 
In 2001, in South Africa the National Injury Mortality Surveillance System (NIMSS, 
http://www.sahealthinfo.org/violence/nimssannuaI2001.htm) found that suicide 
accounted for 46.5% of all non-natural deaths in the 20-34 age ranges across all 
population groups. In addition, these data show that suicide rates peaked in the 
Asian population group in the 20-24 year age group with the bulk of cases occurring 
between years 15-34 (54.4%), while among Caucasians suicide peaked in the 30-34 
and 45-49 year age groups (49.7%). Suicide-related deaths peaked in the 25-29 
year age group among the Black (-22.4%) and Mixed Ancestry populations (17%). 
The NIMSS, and the South African National Burden of Disease study (Bradshaw et 
aI., 2003), did not provide information on the influence of neuropsychiatric illness on 
suicide. However, if one considers suicide to emerge from this group of conditions, it 
contributes substantially to the health-related socio-economic burden in this country. 
The study by Lourens (1998) on suicide rates in Cape Town, South Africa, showed 
that 69% of individuals (N=44) who committed suicide, suffered from a psychiatric 
condition and, particularly, affective disorders (80%). Because of its size, this pilot 
study may not be an accurate reflection of the incidence of psychiatric disorders 
amongst individuals who commit suicide in South Africa, but it may indicate the 
general trend. 
It is apparent that certain vulnerabilities predispose some individuals to suicidal 
behaviours more than others (Jamieson, 2000). In an effort to explain the occurrence 
of suicidal behaviour, i.e. the relationship between the underlying biological 
predisposition to suicide and the precipitants/stressors that trigger it, Mann (1999) 
developed the stress-diathesis model. This model states the risk for suicidal acts is 
determined by a stressor (including psychiatric illness and adverse life events) and a 
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diathesis (predisposition/vulnerability). Suicide attempters compared to non­
attempters, with the same psychiatric condition and a similar number of adverse life 
events, experience more subjective depression and hopelessness and report fewer 
reasons for living (Mann et aI., 1999; 2002). The overwhelming sense of 
hopelessness and greater number of suicidal ideations can be explained by the 
presence of vulnerability for such feelings in the face of disease. It is possible that 
the pressure of greater lifetime aggressivity and impulsivity presents a second 
vulnerability component in suicidal persons. Examination of the literature highlights a 
point of contention, with regards to the importance of psychotic symptoms in suicidal 
behaviour in persons with mood disorders; where some studies found no support for 
increased suicidality in relation to psychosis and affective disorder, whilst other 
studies support the association of psychotic features (such as the symptom of 
delusional thinking) in major depression and suicide (see Sher et aI., 2001 for 
review). Recently, Warman and co-workers (2004) reported increased suicide 
ideation in a heterogeneous sample. In addition to the well-known risk factors ­
depression, hopelessness, substance abuse, and poor problem-solving - this 
increase in suicide ideation was associated with psychosis. Furthermore, in a 
comparison of multiple versus single suicide attempts, Forman and co-workers 
(2004) reported greater severity of psycopathology (including psychosis), suicidality 
(including ideation, intent and lethality) and interpersonal deficits in the group of 
multiple suicide attempters compared to the single suicide atternpters. The 
interaction between these various risk factors, diverse as they are in nature and their 
extent of complexity, still remains to be elucidated. 
It has been reported that the family environment and genetic factors inHuence the 
threshold for suicidal behaviour in affective disorders (Linkowski et aI., 1985; Brent et 
aI., 1996; Sher et aI., 2001). The high rates of attempted suicide in individuals 
diagnosed with affective disorders (Jamison, 2000; Oquendo et aI., 2000; 
Grunebaum, 2001) stress the importance of identifying clinical and genetic 
characteristics that might aid in the recognition of those patients at high risk of 
suicidal behaviour. Because of their role in complex behaviour, initial genetic studies 
have regarded genes of the serotonergic and dopaminergic systems as primary 
candidates for investigation in suicidal behaviour (see Roy, 2001 for review). Table 
4.1 lists a few of the genetic studies on suicidal behaviour. 
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Dysfunction of the serotonergic neurotransmitter system has been implicated in a 
variety of traits and behaviours such as mood, anxiety, impulsive aggression, sleep 
and appetite (Mendes de Oliveira et aI., 1998; Serretti et al.. 2001). Moreover, 
alterations in serotonergic neurons may play a role in the pathophysiology of 
depression (Owens and Nemerhoff, 1994). Many molecular genetic studies have 
implicated the serotonin transporter (5-HTT) and the serotonin receptor 2A (5-HT2A) 
in affective disorders and in suicidal behaviour (see Anguelova et aI., 2003a; 2003b 
for systematic review). Tryptophan hydroxylase (TPH1). the rate-limiting enzyme in 
the biosynthesis of serotonin is a major candidate in the pathogenesis of BPD 
(Sellivier et al.. 1998) and suicidality (Nielsen et aI., 1994; Nielsen et aI., 1998). 
In the central nervous system (CNS), dopamine affects brain processes that control 
movement, cognition. emotion and neuro-endocrine secretion (Grandy et aI., 1992; 
Emilien et aI., 1999). Several studies implicate dopaminergic neurotransmission in 
SPD, because of the ability of; (i) amphetamine, a dopamine agonist, to precipitate 
mania (Silverstone and Romans-Clarkson, 1989) and, (ii) dopaminergic drugs to 
enhance the antidepressant activity in patients with treatment-resistant depressive 
disorders (Nierenberg et aI., 1998). 
Not many studies have investigated the dopaminergic system in suicidal behaviour. 
Even though decreased binding to D1 and D2 receptors in the PFC has been 
reported, studies have not determined whether there are alterations in dopamine or 
its major metabolite, homovanillic acid (HVA). in either the PFC or brainstem (Mann, 
1998). Reasons for further evaluation of the dopaminergic system in suicidal 
behaviour include: (i) the observation of reduced cerebrospinal fluid HVA in suicide 
attempters in the context of major depression (Traskman et aI., 1981). and (ii) 
findings connecting diminished dopaminergic function in major depression (Kapur 
and Mann, 1992). Genes of the dopaminergic system, including those coding for the 
dopamine transporter (DA T) and the dopamine receptors, as well as the COMT 
enzyme. which catalyses the methylation and hence degradation of catecholamines, 
are plausible candidates for suicidal behaviour. 
In an attempt to further elucidate the pathophysiology of bipolar disorder, 
investigators have increasingly focussed on intracellular second messenger systems, 
in particular, the cAMP pathway (Duman et aI., 1997). The postsynaptic response to 
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dopamine is mediated by cAMP (Crocker, 1994) and one of the downstream targets 
of the cAMP pathway, brain-derived neurotrophic factor (BDNF), has been suggested 
as a candidate molecule in the pathophysiology of psychiatric disorders. Duman et 
al. (1997) described the association of decreased levels of BDNF with major 
depressive disorder. Increased expression of BDNF was detected in hippocampal 
regions in subjects treated with antidepressant medications at the time of death, 
compared with untreated subjects (Chen et aI., 2001). Furthermore, by typing SNPs 
in the gene, two independent research groups reported an association between the 
BDNF gene and BPD (Neves-Pereire et aI., 2002; Sklar et aI., 2002). More recently, 
Dwivedi and co-workers (2003) showed reduced gene expression of brain-derived 
neurotrophic factor (BDNF) in postmortem brain of suicide subjects. 
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Table 4.1: Genetic studies on suicidal behaviour 
Study Type of study Sample {origin} Gene {polymorphism} Findings 
Nielsen et aL, Association study 56 impulsive and 14 non­ TPH1 (A799C) Association of TPH1 with a history of 
1994 impulsive, alcoholic, violent suicide attempts 
offenders and 20 healthy controls 
(Finland) 
New et aL, 2001 Association study 145 personality disorder (PO) HTR1B (G816C) Association between the G-allele and a 
subjects (USA) history of suicide attempts in Caucasian 
subjects with POs 
-----------
OuetaL, 1999 Association study 24 depressed suicide victims and 5-HTT (5-HTTLPR), HTR2A The 5-HTTLPR long-allele may be 
31 controls (Hungary) (T102C and His452Tyr) associated with suicide in depressed 
subjects 
Ou et aI., 2000 Association study 120 cases with major depression HTR2A (T102C) 102C allele associated with suicidal 
and 131 controls (Canada) ideation in major depressive disorder 
Preuss et aI., Association study 163 patients with alcohol 5...HTT (5-HTTLPR) Association between the 5-HTTLPR short­
2001 dependence and 117 healthy allele and suicide attempts in alcohol-
controls (South Germany) dependent subjects 
Zubenko et aI., Linkage study 81 families with recurrent, early­ Genome-wide scan Evidence of suicide risk loci on 2p, 6q, 8p 
2004 onset, major depression (USA) and Xq 
Jernej et aI., 2004 Association study 192 suicide victims and 377 TPH1 (218AC) and 5-HTT Combined 5-HTT and TPH1 genotypes 
controls without a history of (VNTR-2) were associated with increased risk for 
neuropsychiatric disorders suicidal behaviour 
(Croatia) 
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The present investigation uses the candidate gene approach, focussing on genes 
with reported functional relevance for suicide. Brief summaries and annotations of 
these candidate genes, with their respective markers examined in association and 
linkage studies, are given below. 
i. Tryptophan hydroxylase (TPH1) 
Tryptophan hydroxylase (TPH1), the rate-limiting enzyme in the biosynthesis of 
serotonin is a major candidate in the pathogenesis of bipolar disorder (Bellivier et al., 
1998) and suicidality (Nielsen et aI., 1994; Nielsen et aI., 1998). The human TPH1 
gene has been localised to chromosome 11 p14-p15.3. A significant association has 
been reported between the A218C polymorphism (A-allele) in intron 7 and bipolar 
disorder (Bellivier et aL, 1998). The A218C polymorphism is in tight linkage 
disequilibrium with the polymorphism A779C in intron 7, which showed evidence of 
assoCiation to suicidality (Nielsen et aI., 1998). 
D1181888 -17734 484bp 
162021bp 
D1181310-17 896 505bp 
102609bp 
TPH (A218C) - 17 999 114bp 
Figure 4.1: Ideogram of chromosome 11 with A218C polymorphism in TPH1; 
Key: Grey - microsatellite markers used for linkage analysis and the 
physical distances between markers. The orientation (i.e. distance in bp) is 
from telomere (pter) to centromere. 
p 
q 
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ii. D4 dopamine receptor (DRD4) 
The DRD4 gene, mapped to chromosome 11p15.5, contains a hypervariable region 
in the third cytoplasmic loop, comprised of 2-10 imperfect 48 base-pair variable 
number tandem repeats (VNTRs) (Van Tol et aI., 1992). In an investigation of suicide 
attempters and normal controls, Persson and co-workers (1999) found no association 
between the 48bp VNTR of DRD4 and suicide attempts. Interestingly, however, is 
the reported association between this polymorphism and novelty seeking and risk­
taking behaviours (Benjamin et aI., 1995). 
DRD4 (48bp VNTR) - 627 305bp 
934210bp 
p 
15.3­
15.1­
0118922 - 1 561 515bp 
722252bp 
D1181318-2 283 767bp 
q 
Figure 4.2: Ideogram of chromosome 11 with 48bp-VNTR in DRD4; 
Key: Grey - the microsatellite markers used for linkage analysis and the 
distances between markers. The orientation (Le. distance in bp) is from 
telomere (pter) to centromere. 
15.5- ·r·,.,.;::;~-----
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iii. BDNF 
The gene encoding BDNF maps to chromosome 11p13-14 (Hanson et aI., 1992). 
It contains a missense SNP at nucleotide 196 (G/A) (Proschel et aI., 1992) producing 
an amino acid substitution, val66met (dbSNP reference number rs6265). The 
val66met (V66M) polymorphism of BDNF has been associated with bipolar disorder 
(Neves-Pereira et aI., 2002). 
p D11 84152 - 27 573 630bp 
59390bp
14.3 
14.1 BDNF (V66M) - 27 633 020bp 15.1 
61 402bp 
q 
01184115 - 27 694 422bp 
Figure 4.3: Ideogram of chromosome 11 with V66M polymorphism in BDNF; 
Key: Grey - the microsatellite markers used for linkage analysis and the 
distances between markers. The orientation (i.e. distance in bp) is from 
telomere (pter) to centromere. 
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iv. Serotonin type 2A receptor (5-HT2A) 
The human 5-HT2A gene codes for a post-synaptic receptor and is located on 
chromosome 13q14-q21. A silent mutation at position 102 (102 TIC) has been 
reported to be associated with bipolar affective disorder (Vincent et aI., 1999). Du et 
al. (2000) and Arias et al. (2001) described an association between 5-HT2A -C allele 
and suicidality in major depression. 
p 
D138 126 - 46 208 236bp 
13 97277bp 
14.2 
___ 
14.3 -==::r-!"E::-----­ HTR2A (T102C) - 46 305 513bp 
403814bp 
0138168 46709 327bp 
Figure 4.4: Ideogram of chromosome 13 with T102C polymorphism in HTR2A; 
Key: Grey - the microsatellite markers used for linkage analysis and the 
distances between markers. The orientation (Le. distance in bp) is from 
telomere (pter) to centromer . 
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V. Serotonin transporter (5-HTT) 
The human 5-HTT gene was mapped to chromosome 17q11.1-q12. A 44 base pair 
deletion/insertion (44bp ins/del) polymorphism in the promoter region results in two 
allelic variants, a long (I) variant and a short (s) variant with different transcriptional 
activities (Lesch et aI., 1997). Hauser et al. (2003) described an association between 
the lower activity (s) allele and bipolar disorder. Du and co-workers (1999) reported 
an association between this 5-HTT polymorphism and depressed suicide victims. 
p 
D 178841 - 24 566 579bp 
982453bp 
q 1\~ -----, l~------ 5-HTT (44bp ins/del) - 25 549 032bp 
2488887bp 
D1 680 - 28037 919bp 
Figure 4.5: Ideogram of chromosome 17 with 44bp ins/del in 5-HTT; 
Key: Grey - the microsatellite markers used for linkage analysis and the 
distances between markers. The orientation (i.e. distance in bp) is from 
telomere (pter) to centromere. 
The Current Study 
From the initial cohort of recruited individuals (n=809, described in Chapter 2), a 
subset of subjects, diagnosed with an affective disorder and/or substance abuse, had 
a history of suicide attempts. This subset comprised of 73 individuals (between 1 
and 8 members from a family), who admitted to attempting suicide at least once in 
their lifetime (ranging from 1 - 30 attempts). The present investigation was carried 
out in two stages; (i) an association study, comparing the frequency of the individual 
candidate gene polymorphisms in 46 unrelated cases (patients), diagnosed with an 
affective disorder and who have attempted suicide, and in healthy controls, and (ii) a 
non-parametric linkage study using microsatellite polymorphic markers, where 
extended families were available. As depicted in Table 4.1, large sample sets are 
advocated in the genetic dissection of suicidal behaviour. However, the relatively 
small dataset of the current study is meant to reflect its pilot nature, in order to 
ascertain the possibility of future large scale investigations. 
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4.1 EXPERIMENTAL APPROACH 
4.1.1 Subjects 
4.1.1.1 Cases vs controls 
Of the 73 individuals who admitted to attempting suicide, a total of 46 unrelated 
individuals from the Mixed Ancestry and Caucasian ethnic groups were included in a 
case-control (association) study. The cases comprised of patients suffering from 
BPI, BPll and MOE (single and recurrent) (Table 4.2). 
Table 4.2: Summarised diagnostic data of subjects with a history 
of suicide attempts who were included in this study 
Clinical diagnosis Caucasian Mixed Ancestry 
BPI 19 12 
BPII 3 2 
MDE-S 2 0 
MDE-R 3 5 
TOTAL 27 19 
Control samples from the South African subject matched background population (100 
Caucasian and 60 Mixed Ancestry) were incorporated into the study. The control 
subjects were collected from amongst individuals referred to the human genetics 
laboratory for genetic research unrelated to psychiatric illness. Only research 
subjects who have formally consented to their DNA samples being used outside of 
their specific "research project" were utilised. Table 4.3 describes the gender, age, 
and ethnic characteristics of the cases and the control subjects. 
4.1.1.2 Extended families 
Of the 46 individuals who attempted suicide, 12 (3 of Mixed Ancestry and 9 of 
Caucasian origin) had one or more relatives who also attempted suicide, i.e. a family 
history of suicide attempts. Because of the observed association between some 
markers and suicidality, genotypes were generated only in those families. Table 4.4 
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summarises the diagnoses of these nine families, where suicide attempts occurred 
within the context of an affective disorder. 
Table 4.3: Age and gender distribution of cases and control samples 
A. Caucasian data-set 
I Variable Cases (n =27) 
, 
Controls (n =100) 
Mean SEM Mean SEM 
Gender 78 % F 69 % Fa 
Age 46.11 2.62 
(23 - 70) 
51.16 b 
(9 - 95) 
1.68 
B. Mixed Ancestry data-set 
Data on gender and age was available for only 96 Caucasian control samples. 
Data on gender and age was available for onl  55 c and 40 d Mixed Ancestry control samples. 
IVariable Cases (n =19) Controls (n =60) 
Mean SEM Mean SEM 
Gender 79% F 71 % Fe 
Age 33.32 1.65 48.10 a 2.84 
• (23 - 45) (13 - 77) 
a and 97 
Table 4.4: Summary of the diagnoses in subjects from nine extended families 
(suicide attempters are shown under the respective diagnoses and in bold) 
FAMILY BPI BPII MDE-R MDE-S AA Psychosis Other No diagnosis TOTAL 
1 2 1 4 - 1 - - 2 10 
2 1+1 2 1 1 - - - 4 10 
3 - - 6+2 2 - 1 - 4 15 
4 1 
-
1+1 - - - - 1 4 
5 3 2+3 11+3 1 - - 1 - 14 
6 1 1 1 - - - 3 13 
7 2 1 1 1 1 - - - 6 
8 1 
- - -
1 - - 1 3 
9 1 - 1 1 1 - - - 4 
Linkage analysis was performed for the mood disorder phenotype with and without 
the inclusion of suicide attempts, using three affection status models (ASMs). In an 
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attempt to assess whether suicide attempts made a significant contribution to the 
linkage statistic, ASM I consisted of those affected relatives who have attempted 
suicide, and ASM " included all affected relatives diagnosed with a mood disorder 
(excluding those who have attempted suicide). ASM III is ASM I and ASM II. 
combined, in order to determine whether suicide attempts influenced the linkage 
information at the candidate genes. 
4.1.2 DNA extraction 

As described in Appendix B, section B.1. 

4.1.3 Genotyping 
4.1.3.1 Association study 
PCR was performed on genomic DNA for each of the five p lymorph isms, shown in 
Table 4.5, using standard protocols (except for incorporation of 7-deaza dGTP for 
DRD4) and the primers indicated in Table 4.5. Where appropriate. the PCR products 
were digested with restriction enzymes, following the manufacturers' suggested 
protocol (Table 4.5). TPH and 5-HTT DNA fragments were electrophoresed on 2.5% 
agarose gels and visualised by ethidium bromide staining. Digested PCR products 
were separated on 6% polyacrylamide gels (Appendix C, section CA) at 220 V for 
30min using the flat bed discontinuous buffer system, Multiphor /I Electrophoresis 
Unit. Digested products were visualised by silver staining the gels after 
electrophoresis. In order to confirm the sequence of the restriction enzyme site, 
samples which exhibited homozygous and heterozygous alleles upon restriction 
enzyme digestion were selected for sequence analysis. The PCR products were first 
resolved on a 2% (w/v) agarose gel after which the DNA fragments were excised with 
a clean, sharp scalpel. DNA fragments were purified from the agarose gel slices 
using the QIAquick Gel extraction protocol (Qiagen. UK) (Appendix B, section 8.5). 
Cleaned fragments were sequenced in both directions. using the reverse and forward 
primers of the original PCR reaction. Sequencing reactions were performed using 
the BigDye terminator cycle sequencing kit (Applied Biosystems. USA). Sequence 
products were purified with Sephadex G-50 fine columns (Princeton separations. 
USA) (Appendix B, section B.5) and separated by automated gel electrophoresis 
using an ABI PRISM 377 DNA sequencer (Applied Biosystems, USA). These 
samples were used as reference samples on subsequent gels. 
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4.1.3.2 Linkage study 
In addition to the genetic markers (Table 4.5) for each polymorphism, microsatellite 
markers (Table 4.6) were chosen from Ensembl (www.ensembl,org) and the Human 
Genome Browser (www.genome.ucsc.edu/) databases, for genotype analysis of the 
nine extended families. These microsatellite markers, chosen because of their close 
proximity to the candidate genes, consisted of tandem repeated dinucleotides and 
tetranucleotides. For three of the five candidate genes, BDNF, HTR2A and 5-HTT, 
one marker on either side of the candidate gene was selected for genotype analysis. 
Appropriate flanking markers at a reasonable distance for the remaining two 
candidate genes, TPH1 and DRD4, did not exist, necessitating the use of markers on 
only one side of these genes. Marker heterozygosity ranged from 0.65 to 0.88 
(average 0.740). The genomic region across the candidate locus of interest ranged 
from 0.12 - 3.5cM. Target sequences were amplified in 177 affected relative pairs 
(ARP), in a 10ul multiplex reaction solution, in 96-well plates, containing 200ng 
gDNA, 10pmol of each fluorescent primer labelled with either HEX or FAM (Synthetic 
DNA Laboratory, University of Cape Town, South Africa), reaction buffer containing 
10mM Tris-HCI (pH8.3) and 50 mM KCI, 1.0 or 1.5 mM MgCb, 200uM dATP, dGTP, 
dCTP, dTTP (Invitrogen, UK) and 0.1 units of GoTaq DNA polymerase. 
After an initial denaturation of the DNA templates for 3 min, 10 cycles were 
performed, each consisting of 94°C for 15 seconds, 55°C for 15 seconds and 72°C 
for 30 seconds. The remaining 20 cycles consisted of 89°C for 15 seconds, 50°C for 
15 seconds and 72°C for 30 seconds. A final extension step involved incubating 
72°C for 5 minutes. PCR products were typed and processed on the Applied 
Biosystems (ABI) 3100 sequencer (Perkin Elmer) (Appendix B, section B.3.2). 
After an initial denaturation of the DNA templates for 3 min, 10 cycles were 
performed, each consisting of 94°C for 15 seconds, 55°C for 15 seconds and 72°C 
for 30 seconds. The remaining 20 cycles consisted of 89°C for 15 seconds, 50°C for 
15 seconds and 72°C for 30 seconds. A final extension step involved incubating 
72°C for 5 minutes. PCR products were typed and processed on the Applied 
Biosystems (ABI) 3100 sequencer (Perkin Elmer) (Appendix B section 8.3.2). 
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Table 4.5: The candidate genes and the specific polymorphisms genotyped in this study 
Chromosome 
11 p15.3-15.5 
Gene 
Symbol 
TPH1 
11p15.5 
11p13 
DRD4 
BDNF 
13q14-q21 5HT2A 
17q11.1-q12 5-HTT 
Polymorphism 
A218C 
48 bpVNTR 
Val66met 
T34C 
44 bp insldel 
Position 
intron 7 
exon 3 
Codon66 
exon 1 
5' regulatory 
region 
Restriction 
enzyme 
Bfa! 
N/A 
BbrP I 
Mspl 
N/A 
Forward primer (5'-3') I Reverse primer (5'-3') I Reference II 
ttcagatcccttctataccccagag caccactcgatgcaacatttg Nielsen et aL, 1992 
Ebstein et aL, 1996 
db8NP reference 
number rs6265 
Warren et aI., 1993 
gcgactacgtggtctactcg 
caagaggcttgacatcattggctg 
tctgctacaagttctggctt 
ggtctgcggtggagtctg 
ccgacatgtccactgcagtctttt 
ctgcagctttttctctaggg 
ggcgttgccgctctgaatg c gagggactgagctggacaaccac Matsushita et aL, 2001 
Table 4.6: List of primer sequences for microsatellite markers genotyped around candidate genes 
Chromosome (candidate gene) 

11 p15.3-15.5 (TPH1) 

11 p15.5 (DRD4) 

11 p13 (BDNF) 

13q14-q21 (HTR2A) 

r--;-------­
17q11.1-q12 (5-HTT) 
Markers 
01181888 
01181310 
0118922 
01181318 
01184115 
01184152 
0138126 
0138168 
017S841 
01781880 
Forward Primer (5'-3') 
ccccagtaccctgtataggc 
taagaaaaagcacctccaag 
ggggcatctttggcta 
cccgtatggcaacagg 
tggcatgtaaatntaagagactcac 
ccttagcagtagagaataacacaca 
tcaccagtaaaatgctattgg 
gcctagcccagtggtg 
tggactttcttacatggcag 
agggattgcttgagcc 
Reverse Primer (5'-3') 
cacttgtgtgtttgtatcgagtca 
ctctgaacttccagtaggt 
tccggtttggttcagg 
tgtgcatgtncatgagtg 
ctgctacctcagaagtatctcaa 
tcagccagccagattg 
gtgattttcaaatttgctctg 
tgcttgtgcctatgttcttg 
aggttagtagtctatgtcacagcg 
tgacagaatttgaacactttg 
115 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
4~1.4 Statistical analysis 
4.2.4.1 Case-control study 
Comparisons of genotype and allele frequencies, of the respective gene 
polymorph isms, between the cases and controls were carried out using Pearson's 
chi-square (x2 ) analysis with two-tailed P value. All statistical calculations were 
performed using the computer software program Epi-Info, version 6 (Centers for 
Disease Control [CDC], Atlanta, USA). 
4.2.4.2 Family-based study 
Model-free single-locus and two-locus linkage analyses are detailed in Chapter 3, 
section 3.1.4. Briefly, single-locus analyses were carried out under ASM I, II and III, 
at three increments equidistant between markers (multipoint analysis). using the 
program MERLIN version 1.10.2 (Abecasis et aI., 2002). The ALL scoring function of 
MERLIN was used to analyse nine families, each of which were adequately sized to 
be analysed by the software. Any locus showing evidence of linkage, i.e. an excess 
of lBO-allele sharing among ARPs at a single location, was used to perform two­
locus analyses, Le. modelling the joint effects of two loci. The two-locus analysis 
methods described in section 3.1.4.2, Le. the weighted analysis of Cox et al. (1999) 
using Allegro version 1.2c (Gudbjartsson et aI., 2000) and the likelihood-ratio analysis 
of Cordell et al. (1995, 2000) and Farrall et al. (1997) using TWOLOCARPARP, were 
performed on the present data set. In the case of the weighted analysis, where the 
Zir statistic of the baseline model was improved by the weighted models, 1000 
permutations were carried out in the statistical analysis package R, to determine the 
significance of this improvement. Alternatively, in the case of the likelihood-ratio 
analysis, where the MLS statistic of the GEN (two-locus) model has improved that of 
the single locus model, 1000 simulations were carried out in MERLIN (as described 
previously in Chapter 3 section 3.1.4.2), to determine the significance of conditioning 
on another locus. 
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4.2 RESULTS 
4.2.1 Association analysis 
In the total sample of unrelated cases, diagnosed with an affective disorder and with 
a history of suicide attempts (n=46), 59% were of Caucasian descent and 41 % were 
of Mixed Ancestry. Table 4.2 lists the clinical characteristics of the cases under 
investigation, with BPI as the most common diagnosis in both population groups. 
The mean age of the Caucasian cases was 46 years, compared to 33 years in the 
Mixed Ancestry cases (Table 4.3). The majority of cases and controls were females, 
in both the Caucasian and Mixed Ancestry population groups. Table 4.7 shows the 
genotype and allele frequencies of the five polymorphisms under investigation, in 
cases and controls. The genotype distributions in all the groups were in Hardy­
Weinberg equilibrium. 
Significant differences were observed in the genotypic distributions of the DRD4 
locus between the Caucasian and the Mixed Ancestry cases (x2 = 6.20, df = 2, P = 
0.045), thereby verifying the need for separate analysis of the two population groups. 
Significant differences were observed in the genotypic and allelic distribution of the 
DRD4 48 bp VNTR polymorphism between Caucasian cases and control subjects 
(genotype, x2 = 5.976, df = 2, P = 0.05; allele frequency, x2 = 8.16, df = 1, P = 0.004; 
odds ratio, 2.42). Following correction for multiple testing (Bonferroni correction, 
p<0.01), the allele distribution was marginally significant in the Caucasian cases. 
The 4/4-repeat genotype and the 4-repeat allele were significantly less frequently 
observed in individuals, with affective disorders who had attempted suicide, than in 
the background controls. A similar effect in this gene was not observed for the Mixed 
Ancestry group. No significant differences were observed between cases and 
controls (in either the genotype distribution or the allele frequencies) for the 
remaining polymorph isms, in both population groups. 
4.2.2 Family-based study (allele-sharing) 
A total of 15 genetic markers, covering 5 candidate genes, were genotyped in 9 
multiplex families, under three affection status models (ASM I, II and III). Non­
parametric linkage methods were used to identify excess IBD allele-sharing among 
affected relative pairs. 
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Table 4.7: Genotype and allele distributions for the candidate gene loci. 
-----------­
Gene Ethnic group Disease Genotype frequency Allele frequency 
status 
DRD4 4/4 (%) 4/7 (%) 4/other (%) other (%) 4 (%) 7 (%) other (%) 
Caucasian Cases 12 (44) 0 10 (37) 5 (.19) 34(63) 0 20 (37) 
Controls 68 (68) 0 25 (25) 7 (7) 161(81) 0 39 (19) 
Mixed Ancestry Cases 14 (78) 1 (5) 2 (12) 1 (5) 31 (86) 1 (3) 4 (11) 
Controls 46 (77) 0 8 (13) 6 (10) 100(83) 1 (1) 19 (16) 
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Table 4.7: Continued 
Gene Ethnic Group Disease status Genotype frequency Allele frequency 
TPH1 AlA (%) AlC (%) CIC (%) A (%) 
22 (41) 
C(%) 
32 (59) Caucasian Cases 3 (11) 16 (59) 8 (30) 
Controls 17 (17) 52 (52) 31 (31) 86 (43) 
. 
9 (24) 
114 (57) 
29 (76) Mixed 
Ancestry 
Cases 0 9 (47) 10 (53) 
Controls 5 (9) 30 (48) 25 (43) 40 (33) 
G (%) 
80 (67) 
A (%) BDNF GIG (%) GIA (%) AlA (%) 
Caucasian Cases 17 (63) 7 (26) 3 (11) 41 (76) 13 (24) 
Controls 62 (62) 31 (31) 7 (7) 155 (77) 45 (23) 
Mixed 
Ancestry 
Cases 14 (74) 4 (21) 1 (5) 32 (84) 6 (16) 
Controls 32 (53) 26 (43) 2 (4) 90 (75) 30 (25) 
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Table 4.7: Continued 
Gene Ethnic Group Disease status Genotype frequency Allele frequency 
5HT2A TIT (%) TIC (%) C/C (%) T (%) C (%) 
Caucasian Cases 6 (22) 9 (33) 12 (45) 21(39} 33 (61) 
Controls 19 (19) 45 (45) 36 (36) 83(42) 117(58) 
Mixed Cases 4 (21) 8 (42) 7 (37) 16(42) 22 (58) 
Ancestry 
Controls 7 (12) 34 (57) 19 (31) 48(40} 72 (60) 
c--~~ ~~--~~ 
5-HTT UL(%) US(%) SIS (%) L (%) S (%) 
Caucasian Cases 10 (37) 12 (44) 5 (19) 32 (59) 22 (41) 
Controls 30 (30) 51 (51) 19(19} 111 (56) 89 (44) 
Mixed Cases 9 (47) 9 (47) 1 (6) 27 (71) 11 (29) 
Ancestry 
Controls 27 (47) 24 (42) 6 (11) 78(68) ~ 36 (32) 
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4.2.2.1 Single-locus analysis 
In single locus analyses the best evidence of linkage was found for TPH1 and BDNF, 
under all three ASMs. Table 4.8 lists the results of the multipoint MERLIN analysis, 
carried out at three steps equidistant between marker loci. In an effort to correct for 
testing linkage at five loci, we considered P values less than 0.01 as significant. 
BDNF yielded significant evidence of linkage under ASM I (at V66M, Lod=1.32, P 
value 0.007) and ASM II (at 011 S4152, Lod=1.25, P value 0.008). Adding the 
suicide attempters (ASM I) to individuals with mood disorders (ASM II), similar 
evidence of linkage was detected to BDNF, under ASM III (at 011S4152, Lod=1.26, 
P value 0.007). TPH1 showed evidence of linkage under ASM II (at 011S1888, 
Lod=1.33, P value 0.007) and not under ASM I. Adding the suicide attempters -(ASM 
I) with individuals with mood disorders (ASM II), did not make a significant 
contribution to linkage at TPH1 (ASM III, Lod=1.21, P value 0.009). Subsequent two­
locus interactions were carried out under both ASM I and II. 
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Table 4.8: Multipoint linkage data derived through MERLIN analysis (P < 0.01) 
Chromosome ASMI ASM II ASM III 
(Gene) Markers Distance a P(NPLALL) P(LOD)b P(NPLALL) P(LOD)b P(NPLALL) P(LOD)D 
11 (TPH1) D11S1888 0.000 1.41 0.03 0.0004 0.007 1.97 0.009 
0.041 1.33 0.03 0.0004 0.007 1.92 0.010 
0.81 1.26 0.04 0.0004 0.007 1.88 0.011 
0.122 1.18 0.04 0.0004 0.007 1.84 0.012 
D11S1310 0.162 1.10 0.06 0.0004 0.007 1.80 0.013 
0.188 1.10 0.06 0.0007 0.008 1.70 0.02 
0.213 1.10 0.06 0.0012 0.009 1.60 0.02 
0.238 1.10 0.06 0.002 0.010 1.50 0.02 
A218C 0.264 1.10 0.06 0.003 0.012 1.40 0.02 
11 (DRD4) 48bp VNTR 0.000 -0.61 0.7 0.5 0.4 -0.61 0.7 
0.233 -0.74 0.8 0.5 0.5 -0.74 0.8 
0.466 -0.75 0.8 0.5 0.4 -0.75 0.8 
0.698 -0.64 0.7 0.4 0.3 -0.64 0.7 
D11S922 0.931 -0.41 0.7 0.3 0.2 -0.41 0.7 
1.111 -0.45 0.7 0.3 0.2 -0.45 0.7 
1.292 -0.53 0.7 0.3 0.3 -0.53 0.7 
1.472 -0.66 0.8 0.4 0.3 -0.66 0.8 
D11S1318 1.653 -0.82 0.8 0.4 0.4 -0.88 0.8 
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Table 4.8: Continued 
-----------­
Chromosome ASMI ASM II ASM III 
(Gene) Markers Distance a P(NPLALL) P(LOD)b P(NPLALL) P(LOD)b p(NPLALL) P(LOD)b 
11 (BDNF) 011S4115 0.000 2.29 0.014 0.0002 0.008 2.09 0.007 
0.015 2.41 0.011 0.0003 0.012 2.03 0.009 
0.030 2.53 0.009 0.0005 0.02 1.97 0.010 
0.044 2.65 0.008 0.0010 0.03 1.91 0.012 
V66M 0.059 2.77 0.007 0.002 0.05 1.85 0.014 
0.064 2.78 0.006 0.0012 0.04 1.88 0.013 
0.068 2.79 0.006 0.0009 0.03 1.90 0.012 
0.072 2.80 0.006 0.0009 0.02 1.91 0.011 
011S4152 0.077 2.81 0.006 0.0007 0.02 1.93 0.011 
13 (HTR2A) 013S126 0.000 -0.65 0.7 0.5 0.4 -0.53 0.6 
0.025 -0.65 0.7 0.5 0.4 -0.52 0.6 
0.049 -0.65 0.7 0.5 0.4 -0.52 0.6 
0.073 -0.65 0.7 0.4 0.4 -0.51 0.6 
T102C 0.098 -0.66 0.7 0.4 0.3 -0.50 0.6 
0.198 -0.58 0.7 0.4 0.2 -0.41 0.6 
0.298 -0.40 0.7 0.4 0.2 -0.25 0.6 
-
0.390 -0.13 0.6 0.3 0.12 -0.02 0.5 
013S168 0.498 0.24 0.4 0.3 0.12 0.28 0.4 
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0 ~istance in cM, calculated from our data 

b P value for the Kong and Cox allele-sharing lad score (Zlr statistic) 

--
~--
----
Table 4.8: Continued 
Chromosome ASM I .ASM II ASM III 
(Gene) Markers Distance a P(NPLALL) P(LOD)D p(NPLALd P(LOD)D P(NPLALL) P(LOD)D 
17 (5-HT1) 0178841 0.000 0.18 0.4 0.2 0.3 1.37 0.10 
0.246 0.10 0.5 0.3 0.3 1.22 0.11 
0.491 0.01 0.5 0.4 0.4 1.08 0.14 
0.737 -0.08 0.5 0.5 0.5 0.94 0.2 
44bp insldel 0.982 -0.16 0.6 0.6 0.7 0.80 0.2 
1.593 -0.19 0.6 0.4 0.4 0.94 0.2 
2.204 -0.21 0.6 0.3 0.2 1.07 0.13 
2.816 -0.23 0.6 0.14 0.2 1.20 0.11 
01781880 3.427 -0.26 0.6 0.06 0.11 1.32 0.09 
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4.2.2.2 Two-locus analysis 
TPH1 (under ASM II) and BDNF (under botH ASM I and II) were used as the conditioning 
loci in assessing evidence for linkage at a second candidate gene (the test locus), Le. in 
the first round of two-locus interactions, DRD4, BDNF, HTR2A and 5-HTT were 
conditioned on TPH1 and in the second TPH1, DRD4, HTR2A and 5-HTT were 
conditioned on BDNF. 
The first method involved modelling positive interactions (using weighto1 and weightnPI) and 
heterogeneity (using weighto1) (Cox et aI., 1999), through the program Allegro, based on 
the family contributions to the Zir statistic at TPH1 (Table 4.9) and BDNF (Table 4.10). 
Table 4.9 shows the baseline Zir values detected at the second/test locus and those 
weighted by the contribution of TPH1, under ASM " (mood disorders only). TPH1 was not 
used as a conditioning locus in two-locus interactions under ASM I (suicide attempters 
only), as it was not significant in single-locus analyses. The significance associated with 
the increased Zlr, was determined by performing 1000 permutations. None of the 
differences between baseline and TPH1 weighted Zir statistics at any of the test loci were 
significant. Table 4.10 shows the baseline Zir values detected at the second/test locus 
and those weighted by the contribution of BDNF, under ASM I (Table 4.1 OA) and II (Table 
4.10B). The significance of the differences between baseline and BDNF weighted Zir 
scores, i.e. the increased Zlr, was assessed by permutation. Based on the evidence of 
linkage at BDNF, using family-specific weights, we found no evidence of linkage and/or 
interaction between BDNF and any of the test loci under both ASM I and II. 
Table 4.9: TPH1 weighted Zir statistics of two locus interactions, 
, under ASM II (showing positions with increased Zir scores) 
Gene (test locus) Position Baseline Zir TPH1 weighted Zir 
DRD4 0.940 0.9295 1.9648 (weightnpl) 
BDNF 0.000 2.4429 2.5482 (weightnpl) 
HTR2A - - -
5-HTT 3.520 1.3808 1.5313 (weightnpl) 
-: NO Increase In tl-'Hl welgr eo ,m 
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Table 4.10: BDNF weighted Zir statistics of two locus 
interactions (showing positions with increased Zir scores). 
under ASM I and ASM II 
A. ASM I 

I Gene Position I Baseline Zir BDNF weighted Zir 
TPH1 0.000 1.5862 1.7498 (weighto1 ) 
DRD4 .0.940 I -0.4852 0.1142 (weighto1) 
HTR2A 0.500 0.1279 0.7058 (weightnpl) 
5-HTT 0.000 0.3523 1.0068 (weight10) 
B. ASM II 

IGene 
ITPH1 
Position 
0.000 
Baseline Zir 
-
• BDNF weighted Zir 
-
• 
I DRD4 
I HTR2A 
! 0.940 
0.500 
0.9295 
1.9965 
1.3480 (weighfnpl) 
1 .3056 (weightnpl) 
I 
1 
5
-
HTT 0.000 1.4810 
-: NO Increase In I t-'t11 welgntea Llr 
1.8367 (weightnpl) I 
The second two-locus method assesses two-locus IBD sharing probabilities of affected 
relative pairs. by calculating MLS scores with the program TWOLOCARP (Cordell et al.. 
1995; Farrall. 1997; Cordell at al.. 2000). Table 4.11 shows the MLS scores for the 
MUL. HET and GEN models for TPH1 locus pairs (under ASM II) and BDNF locus pairs 
(under ASM I and II). For all locus pairs. the MLS scores for the MUL model (defined as 
the sum of the two single-locus MLSs) were equal to the MLS results for the single loci 
(results not shown). Therefore. the multiplicative model does not explain any underlying 
interaction model that might be present. 
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Table 4.11: MLS statistics of two locus interactions, 
showing regions with highest MLS scores for each locus 
pair, under the GEN model 
A. ASM I 
~ ... 
I IVILS 
Two-Locus pair Position* MUL HET GEN 
BDNF-TPH1 1.0000 10.8088 1.5512 I 1.9081 
i 
BDNF-DRD4 9.0000 0.0226 0 0.2107 
. BDNF-HTR2A 9.0000 0.227 0 0.1295 
BDNF-5-HTT I 1.0000 0.4826 1.6884 1.6890 
B.ASM II 
I 
.. 
I 
I 
Two-Locus pair Position* 
MLS 
MUL HET GEN 
i 
TPH1-DRD4 5.0000 0.8806 0.0 1.9344 
I 
TPH1-BDNF 1.0000 2.1558 0.4922 3.6565 
TPH1-HTR2A 9.0000 0.8510 0.0287 2.4541 
TPH1-5-HTT 9.0000 1.4335 0.3812 3.0840 
BDNF-TPH1 5.0000 3.2462 1.5827 4.7470 
BDNF-DRD4 5.0000 0.8806 0.1885 1.8920 
BDNF-HTR2A 9.0000 0.8510 0.2955 1.3519 
BDNF-5-HTT 9.0000 1.4335 0.7645 1.8993 
t-'osltlon (at tnree sleps equlllislam oelween;j marKers) wnere me nlgnesllVlL.;j score was 
observed for each locus pair 
The GEN model gave a greater MLS score than the single locus (MUL model) for all the 
TPH1 locus pairs (under ASM II, Table 4.11 B). In order to assess whether this 
conditioning on TPH1 (under the GEN model) is significantly better than the single locus, 
1000 simulations were carried out, using the SIMULATE option in MERLIN. The only 
significant MLS score under the single locus model, was obtained at BDNF (P value of 
0.043), which is consistent with the MERLIN single-locus analysis. Under the GEN 
model, locus pairs TPH1-BDNF (P value of 0.028) and TPH1·5-HTT (P value of 0.043) 
provided significant evidence of interaction. Furthermore, conditioning on TPH1 
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improved linkage at HTR2A (P value of 0.033). There was no evidence of linkage 
and/or interaction to DRD4. 
Similar to the TPH1 locus pairs, greater MLS scores were observed under the GEN 
model, compared to the single locus (MUL) model for all BDNF locus pairs (under both 
ASM I and /I). In order to assess whether conditioning on BDNF (under the GEN model) 
significantly improves linkage to the single locus, simulations were carried out in 
MERLIN and, as before, no evidence of interaction was detected under ASM I. Under 
ASM II. TPH1 gave the only significant single-locus MLS score (P value of 0.016), which 
is consistent with the MERLIN single-locus analysis. Conditioning on BDNF provided 
evidence of interaction between BDNF and TPH1 (P value of 0.014, under the GEN 
model). None of the other locus pairs proved significant for linkage or interaction. 
4.3 DISCUSSION 
Bipolar disorder includes a component of impulsivity that determines an individual's risk 
for impulsive acts (Swann et aI., 2003). It is widely accepted that suicide attempts 
(associated with violent and impulsive traits), broadly defined as self-destructive 
behaviour with the purpose of ending one's life, are more prevalent in mood disorders 
than in the general population (Guze and Robins, 1970; Oquendo et aI., 2000; Jamison, 
2000; Sher et aI., 2001). Suicidal behaviour is dependent on inherent genetic 
susceptibility, which is influenced by environmental factors. 
Upon closer examination of the diagnostic classifications of the 809 individuals archived 
in our research laboratory, a subset of 73 individuals diagnosed with an affective 
disorder also presented with a history of suicide attempts. At the time of the interview, 
the question of suicide attempts was not of primary concern. It is likely that further 
directed interrogation of this "phenotype" could have shown a greater incidence of 
suicide attempts amongst the subjects. It was decided to carry out a pilot study on the 
genetics of suicide attempts, on 46 of the 73 cases (I.e. unrelated cases suffering from 
an affective mood disorder) and controls in a test for association between suicide 
attempts and selected polymorph isms in five candidate genes. The genotypic and allelic 
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distributions were compared between cases and controls, gathered from the Caucasian 
(n=100) and Mixed Ancestry (n=60) population groups. In order to eliminate the 
possible confounding effect of population non-stratification, the Caucasian and Mixed 
Ancestry population groups were analysed separately. 
The greater number of female cases, in both the Caucasian and the Mixed Ancestry 
population groups can be attributed to one or a combination of three possible reasons, 
(i) females are more likely to acknowledge attempting suicide, (ii) more females were 
willing to participate in the study, and (iii) females are at a higher risk than males for 
suicide attempts (Chen and Dilsaver, 1996; Wunderlich et aI., 2001). 
An interesting finding of this study was a significant difference in the frequency of the 
4/4-repeat genotype in the DRD4 gene, between Caucasian cases and control subjects 
(44% vs. 68%). Furthermore, the 4-repeat allele is significantly less frequent in the 
cases than controls (63% vs. 81 %). This allele may therefore confer a possible 
'protection' against susceptibility to development of an affective mood disorder and/or 
attempted suicide. DRD4 receptors are abundant in the frontal brain, a region 
recognized to play a vital role in human personality, in particular irritability and 
impulsivity (Benjamin et aI., 1996; Ebstein et aI., 1996). Several reports indicated an 
association between the length of DRD4 alleles and risk-taking behaviours (for review, 
see Kluger et aI., 2002). Suicide and suicidal behaviour might be considered as an 
extension of novelty-seeking behaviour with aggression, violence and depreSSion being 
perhaps significant in the act of suicide (Apter et aI., 1995). However, there is limited 
data on the association of suicidal behaviour and BPD with the DRD4 exon III 
polymorphism. The possibility that functional differences in the affinity and intracellular 
signalling system of the DRD4, exon III protein variants may playa role in the aetiology 
of suicide attempts in affective mood disorders is as yet unclear and warrants further 
investigation. 
In a world-wide population sample (including individuals of African origin) the DRD4 4­
repeat and 7-repeat alleles were the most common, occurring in 65.1% and 19.2% of 
the population, respectively (Ding et aI., 2002). Interestingly, the 7-repeat allele appears 
to be very rare in the South African Caucasian and Mixed Ancestry populations included 
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in the present study. The OR04 association was not observed in the Mixed Ancestry 
subject group and may possibly be due to the small sample size andlor an extensive 
history of admixture in this ethnic group. The results show no association between 
suicide attempts and the remaining alleles under investigation. 
In an attempt to understand the genetic diathesis (predisposition) component that 
underlies suicidal behaviour, we used a family-based design and performed a linkage 
study on the extended family members of some of the cases. Only nine Caucasian 
cases had additional family members who have also attempted suicide. Additional 
microsatellite markers (two per candidate gene) were typed in these families and 
analysed using model-free methods. Analyses were carried out under three affection 
status models (ASMs). Primary single-locus analyses, in MERLIN, provided the best 
evidence for linkage to TPH1 and BDNF, under all three ASMs. The linkage evidence 
does not comply with the Lander and Kruglyak (1995) proposed guidelines for significant 
linkage. Their guidelines, however, are for genomic scans and not for candidate 
genes/regions. Based on prior probability implicating candidate regions in suicidal 
behaviour, the findings of the current study may therefore prove to be significant. 
Excess ISD allele-sharing (NPL score) atBDNF was significant under ASM I and ASM 
II. The group of mood disorders and combined suicide attempts (ASM III) gave the 
same significant result for BDNF as for ASM I and II, suggesting that whatever the 
change is involved in BDNF, it has the same predisposing effect to suicide attempts and 
mood disorders. We detected evidence of linkage to TPH1 in persons with mood 
disorders (ASM II), but not in suicide attempters (ASM I). It therefore appears that TPH1 
predisposes to mood disorders, but somehow confers protection against suicide 
attempts. 
In order to increase the power to detect linkage to DRD4, HTR2A and 5-HTT, two-locus 
interactions were carried out under ASM I and II. In the first instance linkage information 
at TPH1 was incorporated into a test for linkage and lor interaction with DRD4, BDNF, 
HTR2A and 5-HTT, followed by incorporation of linkage information at BDNF into a test 
for linkage and lor interaction with TPH1, DRD4, HTR2A and 5-HTT. Using family 
weights (Cox et aI., 1999), none of the loci showed any evidence of interaction with 
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either TPH1 or BDNF, which could be ascribed to the choice of weights, i.e. none of the 
weights specified in our analyses were appropriate in explaining the underlying genetic 
model. However, two-locus modelling in TWOLOCARP (Cordell et aI., 1995; Farra II, 
1997, Cordell et al.. 2000) allows more general interaction terms between the test locus 
and the conditioning locus. Modest evidence was observed in support of linkage to 
HTR2A conditioned on TPH1 and 5-HTT conditioned on TPH1, in persons diagnosed 
with a mood disorder. However the most promising result from TWOLOCARP analyses 
was the improvement of the single-locus result for TPH1, by conditioning on BDNF 
(GEN model) and vice versa. The GEN model better explained the underlying genetic 
model. than the embedded MUL and HET models. 
Sklar and co-workers (2002) identified BDNF as a potential risk locus in bipolar disorder 
in a large family based association study of 76 candidate genes. However. their study 
did not investigate the combined effects of loci. In the face of genetic heterogeneity, few 
studies have investigated the joint effects of candidate loci in suicidal behaviour and 
mood disorders. Jernej and co-workers (2004) reported an association between the 
combined intronic variants of TPH1 and 5-HTT and suicidal behaviour. In an 
independent study, Serretti and co-workers (2004) reported evidence of interaction 
between 5-HTT and TPH1 variants in response to selective serotonin re-uptake 
inhibitors in persons with mood disorders. 
The statistical evidence obtained from linkage and two-locus interactions in the current 
study is upheld by biological relevance. In 1976, Asberg and colleagues provided the 
first indication that the serotonin neurotransmission system has a function in the 
pathogenesis of suicidal behaviour. It is the function and growth of serotonin neurons in 
the brain. i.e. serotonin system development that is promoted by BDNF (Mamounas et 
aI., 1995). Interacting with trk B receptor tyrosine kinase (trk B). BDNF (one of the most 
important neurotrophins) is involved in cell survival and synaptic plasticity (Thoenen. 
1995). Stress is reported to induce depression and decrease the expression of BDNF in 
the hippocampus (Smith et al.. 1995). whereas antidepressants enhance BDNF mRNA 
levels in the brain via HTR2A and r.3-adrenoceptor subtypes, inhibiting stress -induced 
decreases in BDNF mRNA levels (Alleva and Santucci, 2001). Recently. Dwivedi and 
co-workers (2003) detected reduced expression of BDNF and trk B in post-mortem brain 
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in suicide subjects, thereby linking BDNF and trk B to the underlying pathophysiology of 
suicidal behaviour. Furthermore, infusion of BDNF in the adult rat brain has been shown 
to augment serotonin synthesis by directly enhancing TPH1 mRNA levels (Siuciak et aI., 
1998). TPH1 is the rate-limiting enzyme in the biosynthesis of serotonin (Jernej et aI., 
2004), which in turn binds to postsynaptic receptors, such as HTR2A which activates the 
downstream effector, phospholipase C (see Serretti and Artioli, 2004 for review). 
Following the release of serotonin into the synapse, levels of available serotonin and 
serotonin turnover are regulated by the serotonin transporter (5-HTT), which transports 
serotonin back to the serotonergic neurons (Du et aI., 2001). 
Based on the biological evidence, the findings of the present study suggest alterations in 
BDNF expression in both mood disorders and suicide attempts. In mood disorders the 
changes in BDNF expression leads to the attenuation of TPH1 expression. It is possible 
that this attenuation decreases serotonin synthesis and therefore impacts on the binding 
activity of HTR2A and the re-uptake of serotonin by the serotonin transporter. The exact 
mechanism underpinning the biological interactions between these candidate genes in 
mood disorders and suicidal behaviour is unclear. The recent discovery of TPH2, a new 
brain-specific TPH isoform is worthy of mention at this stage (Walther et aI., 2003). 
TPH2, located on chromosome 12q21, may playa much more important role in 
serotonin synthesis in the brain than TPH1. This might explain why TPH1 has no effect 
on risk for suicide, but perhaps TPH2 does. 
Future work includes replication of these findings in large data sets, in conjunction with 
mutation analyses of BDNF, TPH1 and TPH2, HTR2A and 5-HTT in affected families to 
ascertain their impact on suicidal behaviour in affective mood disorders, and ultimately 
on public health. Of great interest are the upstream components of BDNF, which might 
influence altered expression of BDNF in mood disorders and suicidal behaviour. 
Antidepressant treatment activates intracellular signal transduction cascades, one of 
which is the cAMP-CREB cascade (reviewed by Duman et aI., 2000). Chronic 
administration of antidepressants augments Gs-protein coupling to adenylate cyclase, 
particularly increasing levels of cAMP-dependent protein kinase A and CREB. 
Phosphorylation of CREB involves Ca2';'-dependent protein kinases, which in turn can be 
activated by the phosphatidylinositol pathway or by glutamate ionotropic receptors. 
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CREB, a transcription factor, induces BDNF, one gene target of the cAMP-CREB 
cascade and antidepressant treatment. Anyone of the components of the cAMP-CREB 
cascade, preceding BDNF is a potential candidate gene in mood disorders and suicidal 
behaviour. 
Study Limitations 
Association Study. It is difficult to predict the sample size needed to illustrate a genetic 
_ 	 association, as it relies on the degree of association, linkage disequilibrium, the 
accuracy of phenotypic data and heterogeneity of allele frequencies. Nevertheless, the 
limited number of cases analysed suggests that caution should be exercised with regard 
to interpreting our findings. 
It remains possible that the 4-repeat allele may be in linkage disequilibrium with another 
functional variant that contributes to the phenotype, and therefore it is suggested that 
three or more polymorph isms, covering the gene, should be analysed instead of only 
one. The diagnostic heterogeneity of the patient group and the use of non-accurately 
matched controls are further limitations of the study. 
Our investigation of the genetics of BPD and suicide attempts is ongoing, i.e. the search 
for and genotype analysis of more SI\lPs covering the genes of interest continues. In 
addition the extension of the size of the patient group requires a follow-up interview with 
previously recruited individuals to assess any change in their diagnOSis including 
suicidal behaviour. This is currently underway as part of a study feedback and data 
updating process. 
Linkage study. The small number of families included in linkage analysis warrants a 
cautious interpretation of the present findings. It is difficult to correct for testing under 
three affection status models, and using various analytical methods. Furthermore, we 
did not assess the temperamental variables of impulsivity and aggression among 
ind ividuals with mood disorders, as these are also associated with suicidal acts. 
In summary, the preliminary findings provided evidence for an association between 
DRD4 of the dopaminergic pathway and suicide attempts in subjects diagnosed with an 
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affective mood disorders. This association was not supported by linkage analysis in 
nine extended families, suggesting that the initial result was either a false-positive or 
DRD4 is in linkage disequilibrium with another locus. Linkage analysis provided 
statistical evidence in support of linkage to TPH1 in the group of mood disorders and not 
suicide attempts, suggesting a protective effect against suicidal behaviour. Alterations 
in BDNF appear to confer risk to mood disorders and suicidal behaviour. 
Linkage analysis (family-based studies) has proven to be successful, given that the 
underlying genetic model was such that the assumptions made under the various 
analytical methods improved the power of detecting linkage and interaction. Although 
the sample size was small to begin with, the findings of this study are cause for optimism 
as biological evidence places BDNF, TPH1, HTR2A and 5-HTT in the same biochemical 
pathway, thereby supporting evidence of interaction between them. 
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CHAPTERS 

GENERAL DISCUSSION 
The aim of the present research was to identify susceptibility loci in BPO, by 
incorporating both classical and advanced linkage methodologies. Geneticists working 
on complex disorders need to abandon dogmatic uniformity in ideas, gambling our 
achievement on a single methodological approach. It is clear from what is already 
known in biology that there is considerable interaction between various gene products, 
which is equally true for those protein products of genes that influence complex 
disorders, and specifically BPO. 
The present study derives from an archival resource for genetic studies in BPO, 
comprising of biological material and clinical information from 131 families. This 
resource is comparable to that ·of international large-scale formal BPO studies in the 
USA (Blehar et aI., 1988), Canada (Shink et aI., 2004), Austria (Bailer et aL, 2002), 
United Kingdom-Ireland (Bennett et aI., 2002; Lambert et aI., 2005), Finland (Ekholm et 
aI., 2002), and Germany (Cichon et aI., 2001). However, unlike these huge international 
enterprises, research initiatives (in psychiatry) in South Africa do not enjoy high priority 
status in terms of the country's health care expenditure. Few of the eight academic 
departments of psychiatry in this country have a firm commitment to research, possibly 
due to the clinical service load. This status quo is exacerbated by few, mostly short-term 
and non-sustainable, national research fellowships. In spite of these challenges, 
investigations of the genetics of psychiatric disorders (the present research included) are 
positive developments. More recently, investigations have focussed on schizophrenia 
(Abecasis et aI., 2004), obsessive-compulsive disorders (Niehaus et aI., 2001) and 
Alzheimer's disease (Heckmann et aI., 2004). In addition, there is a recent surge of 
cross disciplinary interest in developing sustainable research along specific "signature 
themes" here at the University of Cape Town. In this regard, the invitation by the 
research directorate to develop the theme of "Brains and Behaviour" bodes well for the 
BP 0 research. This project has been recognised as a cornerstone of the Brains and 
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Behaviour signature theme, highlighting the value of pathology and genetics as 
instruments in the neurosciences. 
As illustrated in Chapter 2 of this thesis, genealogical studies of BPD reveal the 
phenotypic spectrum, which hinges on the classically characterised BPI or BPII 
syndromes. This heterogeneity introduces the layered complexity, ranging from the 
need to define clear phenotypes (and the difficulty of assigning affected/unaffected 
status to subjects), to the challenge of genetic mapping against the wide range of 
candidate loci already discussed. 
Several genomic regions have been implicated in the aetiology of BPD. However, owing 
to issues of study desjgn and methods of analysis, many studies have been marked by 
the limited success of reproducible findings. In an attempt to address these issues, the 
present study relied on a combination of statistical, computational and bioinformatics 
methods to improve the chances of identifying susceptibility loci in BPD, in a subset of 
22 multiplex South African families. These families were chosen because of the level of 
. confidence in phenotypic designation and the availability of the most number of affected 
individuals per pedigree. Non-parametric linkage analysis found a modest linkage signal 
for a susceptibility locus on chromosome 1q32. In light of the multifactorial nature of 
BPD, the analysis was extended to two-locus models, which implied interaction between 
regions at 1q32 and 10q23.32. It is important, however, to interpret these findings with 
caution until there is definitive biological proof of genetic variants influencing the 
phenotype. 
Attempting to locate plausible candidate genes in the regions identified, bioinformatics 
revealed the candidate genes NAVand ADORA1 in region 1q32, and HTR7 and PLCE1 
in region 10q23.31. The only information on possible interactions assembled from Gene 
Ontology was that ADORA 1, HTR7 and PLCE 1 all have receptor activity and are integral 
to the plasma membrane. Mutation analysis of these candidate genes and their 
association with illness are suggested as the next phase of research. Individually, the 
chromosomal regions 1q32 and 10q have been implicated in BPD (Detera-Wadleigh et 
aI., 1999; Cichon et aI., 2001b), however, no other study has reported evidence for 
statistical interaction (or oth erwise) between susceptibility loci on 1q32 and 10q. The 
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strategy adopted in the present study is based on the convergent functional genomics 
approach of Niculescu and co-workers (2000). Their approach, integrating gene 
expression data from a mouse model with human linkage data, cross validates findings, 
thereby prioritising candidate genes for individual analysis. In 2004, Ogden and co­
workers presented an expanded convergent functional genomics approach, integrating 
many more independent converging lines of evidence, as a way of dissecting the 
genetic code of bipolar mood disorders. More recently and much like the strategy 
adopted in this study, Hattori et al. (2005), describes a "systems genetics" approach, 
requiring an intensive literature review and mining of electronic databases for entire 
pathways, in the compilation of candidate genes. Mutation analysis of the candidate 
genes identified by Niculescu, Ogden, and Hattori, and the modelling of gene-gene 
interactions between the same candidate genes, might forge optimal strategies for the 
mapping and identification of susceptibility genes in BPO (as well as other complex 
disorders). 
An intrinsic limitation in the genetic analysis of BPO is the variable phenotype, which all 
form part of a spectrum of disorders, with variable genetic involvement. In order to 
address this limitation, we used the parameter of suicide attempts in an effort to enrich 
for what might be classified as a "sub-phenotype" of BPO, thereby enriching for a 
smaller subset of candidate genes. Findings from the "pilot" association study (46 cases 
vs 160 controls) showed d creased frequencies in suicide attempters (from the 
Caucasian subpopulation) of the 4-repeat allele, of DRD4, suggesting that the 4-repeat 
allele may confer a possible 'protection' against susceptibility to development of an 
affective disorder and/or attempted suicide. Because nine of the 46 cases were 
members of families, these were included in linkage analysis. The outcome of single­
locus analyses was in support of linkage between suicide attempts (ASM I) and BONF, 
and therefore it seems that BDNF might be a susceptibility locus in suicide attempts. 
Two-locus modelling showed no evidence of interaction between BONF and other loci 
under ASM L It is worth noting that under ASM II, which includes individuals with mood 
disorders, two-locus models showed evidence of statistical interaction between BDNF 
and TPH1, HTR2A and TPH1, and 5-HTT and TPH1, in the broader spectrum of mood 
disorders. The data suggest that BDNF predisposes vulnerable individuals to both 
mood disorders and suicide attempts, whereas TPH1 predisposes to mood disorders but 
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not to the risk of suicide. Perhaps this suggests a protective role for TPH1 against 
suicidal behaviour in this group of mood disorder patients. The positive linkage findings 
of BDNF (Owivedi et aI., 2003), TPH1 (Siuciak et aI., 1998), HTR2A (reviewed in Serretti 
and Artioli, 2004) and 5-HTT (Ou et aI., 2001), individually, have been implicated in the 
pathophysiology of suicidal behaviour, by other authors. However, no two-locus 
interactions have been reported before. Importantly, biological context places each of 
these candidates in the same biochemical pathway, lending credence to possible 
interactions between these candidate genes. 
In each of the studies carried out, the multiple-testing cost of modelling gene-gene 
interactions is a major issue. To limit this cost, loci that achieved at least marginal 
significance in the single locus analyses were used, in all subsequent two-locus models. 
In addition, permutations and simulations were used to estimate empirical significance of 
individual (pair-wise) results. Of the genetic mechanisms commonly known to contribute 
to the complex patterns of inheritance, attention was focussed on epistatic effects only, 
anticipation, genetic imprinting and mitochondrial mutations were not considered. As far 
as addressing variability of phenotype is concerned, a refined sub-phenotype of suicide 
attempts were investigated, however, endophenotypes, which may have improved the 
chances of detecting linkage and association, were not examined. While the need for 
accuracy of demographic and phenotypic data is recognised in sample size and study 
design in the type of research reported here, one should not understate the value of 
classical genetic analysis, taking into account IBO information reflecting shared genomic 
regions, at least within pedigrees. 
At present the study of geographically and genetically isolated populations provides the 
best chance of mapping susceptibility loci in complex disorders. Examples of such 
communities that have grown from a restricted gene pool with fewer segregating genes 
that predispose to BPO, include the North American Old Order Amish (Ginns et aI., 
1996), isolated populations of the Faroe Islands (Als et aI., 2004), and the Saguenay­
Lac-St-Jean area of Quebec in Canada (Morissette et aI., 1999). The anthropological 
history of South Africa provides researchers with valuable 'genetiC isolates', such as the 
European-derived Afrikaner and indigenous African Xhosa populations. These relatively 
homogeneous gene pools have been investigated in psychiatric genetics, for example 
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Afrikaners with schizophrenia (Abecasis et a!., 2004); Afrikaners with obsessive­
compulsive disorder (Hemmings et aI., 2004), and a large Xhosa pedigree with early­
onset Alzheimer's disease (Heckman et aI., 2004). Given the integrative approach and 
the evidence of statistical interactions of this current study, the next suggested step in 
contributing to our understanding is to extend genealogies in stratified populations, for 
example the Afrikaner and the Nguni-speaking indigenous African populations. 
Importantly, the genetic research presented here has already created a heightened 
awareness of the role of genetics in psychiatric disorders and emphasizes the need to 
maintain and grow large scale research enterprises in BPO, in South Africa. There is 
also greater understanding of the need to probe genealogical information on bipolar­
associated disorders. Although the research in South Africa lags behind the major 
international centres with established BPO programmes, the attempts to engage with 
psychiatrists to develop awareness of genetics and biological heterogeneity in 
psychiatry is gaining favour. The expanding research programme will create the very 
necessary link between international (and even local) research findings and translation 
for local clinical consumption 
Future work suggested in this study includes the validation of the findings of the 
association and linkage studies reported here, such as genetic testing on a larger scale, 
in an increased number of families and candidate gene screening for mutations. 
Furthermore, systematic screening methods need to be put in place, in order to update 
changes in psychiatric status (on a yearly basis) for families already in the BPO archive. 
There is no question that the vast international efforts aimed at the genetic dissection of 
BPO has already benefited psychiatry, even though the inventory of predisposing genes 
have not been formed. The demand for phenotypically "homogeneous" samples has led 
to a sobering of the approach to collect vast amounts of biological material, and the 
current project will be extended in this regard. 
In conclusion, we set out to connect the dots between interacting genes using a multi­
faceted approach, bringing together an exploration of a phenotypic spectrum (including 
suicidality) with statistical analyses, bioinformatics, and data on the relevant biochemical 
and neurophysiological systems. Strategies such as this, building on past and 
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incorporating present methodologies, are expected to improve diagnosis, prevention, 
and treatment of BPD, and indeed can be adopted for other complex disorders. 
140 

Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
REFERENCES AND APPENDICES 

Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
REFERENCES 

Abecasis GR, Burt RA, Hall D, Bochum S, Doheny KF, Lundy SL, Torrington M, Roos JL, Gogos JA, 
Karayiorgou M (2004) Genomewide scan in families with schizophrenia from the founder 
population of Afrikaners reveals evidence for linkage and uniparental disomy on chromosome 1. 
Am J Hum Genet 74:403-417 
Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin--rapid analysis of dense genetic maps 
using sparse gene flow trees. Nat Genet 30:97-101 
Adams 	LJ, Mitchell PB, Fielder SL, Rosso A, Donald JA, Schofield PR (1998) A susceptibility locus for 
bipolar affective disorder on chromosome 4q35; Am J Hum Genet 62:1084-1091 
Adolphs R, Tranel D, Damasio H, Damasio A (1994) Impaired recognition of emotion in facial expressions 
following bilateral damage to the human amygdala. Nature 372:669-672 
Aita VM, Liu J, Knowles JA, Terwilliger JD, Baltazar R, Grunn A, Loth JE, Kanyas K, Lerer B, Endicott J, 
Wang Z, Penchaszadeh G, Gilliam TC, Baron M (1999) A comprehensive linkage analysis of 
chromosome 21 q22 supports prior evidence for a putative bipolar affective disorder locus. Am J 
Hum Genet 64:210-217 
Akiskal 	HS (2003) Validating 'hard' and 'soft' phenotypes within the bipolar spectrum: continuity or 
discontinuity? J Affect Disord 73:1-5 
Akiskal HS, Benazzi F (2003) Family history validation of the bipolar nature of depressive mixed states. J 
Affect Disord 73:113-122 
. Alleva E, Santucci D (2001) Psychosocial vs. "physical" stress situations in rodents and humans: role of 
neurotrophins. Physiol Behav 73:313-320 
Almasy L, Blangero J (1998) Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum 
Genet 62:1198-1211 
Als TD, Dahl HA, Flint TJ,Wang AG, Vang M, Mors 0, Kruse TA, Ewald H (2004) Possible evidence for a 
common risk locus for bipolar affective disorder and schizophrenia on chromosome 4p16 in 
patients from the Faroe Islands. Mol Psychiatry 9:93-98 
Ambelas A (1979) Psychologically stressful events in the precipitation of manic episodes. Br J Psychiatry 
135:15-21 
Ambelas A (1987) Life events and mania. A special relationship? Br J Psychiatry 150:235-240 
Anderson AK, Phelps EA (2001) Lesions of the human amygdala impair enhanced perception of 
emotionally salient events. Nature 411 :305-309 
Angst J, Marneros A (2001) Bipolarity from ancient to modern times: conception, birth and rebirth. J Affect 
Disord 67:3-19 
Angst J. 2002. Historical aspects of the dichotomy between manic-depressive 

disorders and schizophrenia. Schizophrenia Research 1 ;57(1 ):5-13. 

Apter A, Gothelf D, Orbach I, Weizman R, Ratzoni G, Har-Even D, Tyano S (1995) Correlation of suicidal 
and violent behavior in different diagnostic categories in hospitalized adolescent patients. J Am 
Acad Child Adolesc Psychiatry 34:912-918 
141 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C, Smeraldi E (2004) A single 
nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of 
illness in patients affected by bipolar disorder. Neurosci Lett 355:37-40 
Benjamin J, U L, Patterson C, Greenberg BD, Murphy DL, Hamer DH (1996) Population and familial 
association between the 04 dopamine receptor gene and measures of Novelty Seeking. Nat 
Genet 12:81-84 
Bennett P, Segurado R, Jones I, Bort S, McCandless F, Lambert 0, Heron J, Comerford C, Middle F, 
Corvin A, Pelios G, Kirov G, Larsen B, Mulcahy T, Williams N, O'Connell R, O'Mahony Payne 
A, Owen M, Holmans P, Craddock N, Gill M (2002) The Wellcome trust UK-Irish bipolar affective 
disorder sibling-pair genome screen: first stage report. Mol Psychiatry 7:189-200 
Berrettini WH (1999) On the future of genetic research in bipolar and schizophrenic syndromes. 

Neuropsychopharmacology 21: 1-2 

Berrettini WH (2000) Are schizophrenic and bipolar disorders related? A review of family and molecular 
studies. Bioi Psychiatry 48:531-538 
Berrettini WH, Ferraro TN, Goldin LR, Weeks DE, Detera-Wadleigh S, Nurnberger JI, Jr., Gershon ES 
(1994) Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility 
gene. Proc Natl Acad Sci USA 91 :5918-5921 
Berridge MJ, Downes CP, Hanley MR (1989) Neural and developmental actions of lithium: a unifying 
hypothesis. Cell 59:411-419 
Bezchlibnyk Y, Young LT (2002) The neurobiology of bipolar disorder: focus on signal transduction 
pathways and the regulation of gene expression. Can J Psychiatry 47:135-148 
Bidzinska EJ (1984) Stress factors in affective diseases. Br J Psychiatry 144:161-166 
Blackwood DH, Fordyce A, Walker MT, St Clair OM, Porteous OJ, Muir WJ (2001) Schizophrenia and 
affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts 
brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 69:428-433 
Blackwood DH, He L, Morris SW, McLean A, Whitton C, Thomson M, Walker MT, Woodburn K, Sharp 
CM, Wright AF, Shibasaki Y, St Clair OM, Porteous OJ, Muir WJ (1996) A locus for bipolar 
affective disorder on chromosome 4p. Nat Genet 12:427-430 
Blangero J, Williams JT, Almasy L. 2001. Variance component methods for 
detecting complex trait loci. Adv Genet. 2001 ;42: 151-81. Review. 
Blehar MC, Weissman MM, Gershon ES, Hirschfeld RM (1988) Family and genetic studies of affective 
disorders. Arch Gen Psychiatry 45:289-292 
Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G, Thornquist M, et al. (1998) 
Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 20:70-73 
Bobb AJ, Castellanos FX, Addington AM, Rapoport JL (2004) Molecular genetic studies of ADHD: 1991 to 
2004. Am J Med Genet 
Boehnke M (1986) Estimating the power of a proposed linkage study: a practical computer simulation 
approach. Am J Hum Genet 39:513-527 
Bohringer S, Hardt C, Miterski B, Steland A, Epplen JT (2003) Multilocus statistics to uncover epistasis 
and heterogeneity in complex diseases: revisiting a set of multiple sclerosis data. Eur J Hum 
Genet 11 :573-584 
BoseUi F, Seemann R, Bell JM, Zahorchak R. Friedman E, Rapoport SI, Manickam P (2002) Analysis of 
143 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Clark LN, Levy G, Tang MX, Mejia-Santana H, Ciappa A, Tycko B, Cote LJ, Louis ED, Mayeux R, Marder 
K (2003) The Saitohin 'Q7R' polymorphism and tau haplotype in multi-ethnic Alzheimer disease 
and Parkinson's disease cohorts. Neurosci LeU 347:17-20 
Cloninger CR, Bayon C, Svrakic DM (1998) Measurement of temperament and character in mood 
disorders: a model of fundamental states as personality types. J Affect Disord 51 :21-32 
Cloninger CR, Svrakic DM, przybeck TR (1993) A psychobiological model of temperament and character. 
Arch Gen Psychiatry 50:975-990 
Collins FS, Patrinos A, Jordan E, Chakravarti A, Gesteland R, Walters L (1998) New goals for the U.S. 
Human Genome Project: 1998-2003. Science 282:682-689 
Compton MT, Nemeroff CB (2000) The treatment of bipolar depression. J Clin Psychiatry 61 Suppl 9:57­
67 
Concannon P, Gogolin-Ewens KJ, Hinds DA, Wapelhorst B. Morrison VA, Stirling B, Mitra M, Farmer J, 
Williams SR, Cox NJ, Bell GI, Risch N, Spielman RS (1998) A second-generation screen of the 
human genome for susceptibility to insulin-dependent diabetes mellitus. Nat Genet 19:292-296 
Cook EH, Jr., Courchesne RY, Cox NJ, Lord C, Gonen D, Guter SJ, Lincoln A, Nix K, Haas R, Leventhal 
BL, Courchesne E (1998) Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 
markers. Am J Hum Genet 62:1077-1083 
Coon H, Jensen S, Hoff M, Holik J, Plaetke R, Reimherr F, Wender P, Leppert M, Byerley W (1993) A 
genome-wide search for genes predisposing to manic-depr ssion, assuming autosomal dominant 
inheritance. Am J Hum Genet 52:1234-1249 
Cordell HJ, Todd JA, Bennett ST, Kawaguchi Y, Farrall M (1995) Two-locus maximum lod score analysis 
of a multifactorial trait: joint consideration of IDDM2 and IDDM4 with IDDM1 in type 1 diabetes. 
Am J Hum Genet 57:920-934 
Cordell HJ, Wedig GC, Jacobs KB, Elston RC (2000) Multilocus linkage tests based on affected relative 
pairs. Am J Hum Genet 66:1273-1286 
Coryell W, Endicott J, Reich T, Andreasen N, Keller M (1984) A family study of bipolar" disorder. Br J 
Psychiatry 145:49-54 
Cottingham RW, Jr., Idury RM, Schaffer AA (1993) Faster sequential genetic linkage computations. Am J 
Hum Genet 53:252-263 
Couzin J (2002) Genomics. New mapping project splits the community. Science 296:1391-1393 
Cox NJ (2001) Computational issues in mapping variation affecting susceptibility to complex 
disorders: the chicken and the egg. Theor Popul Bioi 60:221-225 
Cox NJ, Frigge M, Nicolae DL. Concannon P, Hanis CL, Bell GI, Kong A (1999) Loci on 
chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican 
Americans. Nat Genet 21 :213-215 
Craddock N, Jones I (1999) Genetics of bipolar disorder. J Med Genet 36:585-594 
Craddock N, Khodel V. Van Eerdewegh P, Reich T (1995) Mathematical limits of multilocus models: the 
genetic transmission of bipolar disorder. Am J Hum Genet 57:690-702 
Craddock N, Lendon C (1999) Chromosome Workshop: chromosomes 11, 14, and 15. Am J Med Genet 
88:244-254 
Craddock N, McGuffin P (1993) Approaches to the genetics of affective disorders. Ann Med 25:317-322 
145 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
American Psychiatric Association., 1994. 
Dick DM, Foroud T, Flury L, Bowman ES, Miller MJ, Rau NL, Moe PR, et al. (2003) Genomewide linkage 
analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental 
Health Genetics Initiative. Am J Hum Genet 73:107~114 
Ding YC, Chi HC, Grady DL, Morishima A, Kidd .IR, Kidd KK, Flodman P, Spence MA, Schuck 
S, Swanson JM, Zhang YP, Moyzis RK (2002) Evidence of positive selection acting at the human 
dopamine receptor D4 gene locus. Proc Nat! Acad Sci USA 99:309-314 
Dong C, Li WD, Li D, Price RA (2005) Interaction between obesity-susceptibility loci in chromosome 

regions 2p25~p24 and 13q13-q21. Eur J Hum Genet 13:102~108 

Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA (2001) 
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Bioi 
Psychiatry 49:81-96 
Drevets WC, Ongur D, Price JL (1998) Neuroimaging abnormalities in the subgenual prefrontal cortex: 
implications for the pathophysiology of familial mood disorders. Mol Psychiatry 3:220~226, 190­
221 
Drevets WC, Price JL, Simpson JR, Jr., Todd RD, Reich T, Vannier M, Raichle ME (1997) Subgenual 
prefrontal cortex abnormalities in mood disorders. Nature 386:824-827 
Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD (2000) Association of polymorphism of serotonin 
2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet 96:56-60 
Du L, Faludi G, Palkovits M, Bakish D, Hrdina PD (2001) Serotonergic genes and suicidality. Crisis 22:54­
60 
Du L, Faludi G, Palkovits M, Demeter E, Bakish D, Lapierre YD, Sotonyi P, Hrdina PD (1999) Frequency 
of long allele in serotonin transporter gene is increased in depressed suicide victims. Bioi 
Psychiatry 46:196-201 . 
Duman 	RS (2002) Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 17 
Suppl 3:306-310 
Duman 	RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen 
Psychiatry 54:597-606 
Duman 	RS, Malberg J, Nakagawa S, D'Sa C (2000) Neuronal plasticity and survival in mood disorders. 
Bioi Psychiatry 48:732-739 
Duman RS, Malberg J, Thome J (1999) Neural plasticity to stress and antidepressant treatment. 
Bioi Psychiatry 46: 1181-1191 
Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2003) Altered gene 
expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem 
brain of suicide subjects. Arch Gen Psychiatry 60:804-815 
Eaves LJ (1994) Effect of genetic architecture on the power of human linkage studies to resolve the 
contribution of quantitative trait loci. Heredity 72 ( Pt 2): 175-192 
Ebstein RP, Novick 0, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, 
Belmaker RH (1996) Dopamine D4 receptor (D4DR) exon III polymorphism associated with the 
human personality trait of Novelty Seeking. Nat Genet 12:78-80 
Edenberg HJ, Foroud T, Conneally PM, Sorbel JJ, Carr K, Crose C, Willig C, Zhao J, Miller M, Bowman E, 
Mayeda A, Rau NL, Smiley C, Rice JP, Goate A, Reich T, Stine OC, McMahon F, DePaulo JR, 
147 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Freis ED (1954) Mental depression in hypertensive patients treated for long periods with large doses of 
reserpine. N Engl J Med 251 :1006-1008 
Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC (1999) Analysis of the 
monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta­
analyses, and sequencing of the promoter. Am J Med Genet 88:398-406 
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, 
Faggart M. Liu-Cordero SN, Rotimi C, Adeyemo A. Cooper R, Ward R, Lander ES. Daly MJ. 
Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296:2225­
2229 
Gershon ES, Badner JA, Detera-Wadleigh SD, Ferraro TN, BerreUini WH (1996) Maternal inheritance and 
chromosome 18 allele sharing in unilineal bipolar illness pedigrees. Am J Med Genet 67:202-207 
Gershon ES, Hamov;t J, Guroff JJ, Dibble E, Leckman JF. Sceery W, Targum SD, Nurnberger JI, Jr., 
Goldin LR, Bunney WE, Jr. (1982) A family study of schizoaffective, bipolar I, bipolar II, unipolar, 
and normal control probands. Arch Gen Psychiatry 39:1157-1167 
Ghaemi SN, Miller CJ. Berv DA, Klugman J, Rosenquist KJ, Pies RW. 2003. 
Sensitivity and specificity of a new bipolar spectrum diagnostic scale. Journal of Affective 
Disorders. In Press, Corrected Proof, Available online 19 September 2003. 
Ghosh S, Collins FS (1996) The geneticist's approach to complex disease. Annu Rev Med 47:333-353 
Ginns EI, Ott J, Egeland JA, Allen CR, Fann CS, Pauls DL, Weissenbachoff J, Carulli JP, Falls KM, Keith 
TP, Paul SM (1996) A genome-wide search for chromosomal loci linked to bipolar affective 
disorder in the Old Order Amish. Nat Genet 12:431-435 
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to 
cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612 
Glassner B, Haldipur CV (1983) Life events and early and late onset of bipolar disorder. Am J 
Psychiatry 140:215-217 
Glatt CE, Freimer NB (2002) Association analysis of candidate genes for neuropsychiatric disease: the 
perpetual campaign. Trends Genet 18:307-312 
Goldberg JF, Garno .IL, Leon AC, Kocsis JH, Portera L (1999) A history of substance abuse complicates 
remission from acute mania in bipolar disorder. J Clin Psychiatry 60:733-740 
Goodwin FK, Murphy DL, Dunner DL, Bunney WE, Jr. (1972) Lithium response in unipolar versus bipolar 
depression. Am J Psychiatry 129:44-47 
Gould TD, Manji HK (2002) Signaling networks in the pathophysiology and treatment of mood disorders. J 
Psychosom Res 53:687-697 
Grandy DK, Allen LJ, Zhang Y, Magenis RE, Civelli 0 (1992) Chromosomal localization of three human 
D5 dopamine receptor genes. Genomics 13:968-973 
Greenwood TA, Alexander M, Keck PE, McElroy S, Sadovnick AD, Remick RA. Kelsoe JR (2001) 
Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder. Am J 
Med Genet 105:145-151 
Greil W, Kleindienst N (2003) Concepts in the treatment of bipolar disorder. Acta Psychiatr Scand 
Suppl:41-46 
Grunebaum MF. 2001. Outcomes of suicidal behaviours. Clinical Neuroscience 
Research 1: 394-404. 
149 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Hill WG, Weir BS (1994) Maximum-likelihood estimation of gene location by linkage disequilibrium. Am J 
Hum Genet 54:705-714 
Hindmarch I (2002) Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur 
Psychiatry 17 Suppl 3:294-299 
Hiroi N, Martin AB, Grande C, Alberti I, Rivera A, Moratalla R (2002) Molecular dissection of dopamine 
receptor signaling. J Chem Neuroanat 23:237-242 
Hirschfeld RM, Williams JB, Spitzer RL, Calabrese .IR, Flynn L, Keck PE, Jr;, Lewis L, McElroy SL, Post 
RM, Rapport DJ, Russell JM. Sachs GS, Zajecka J (2000) Development and validation of a 
screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J 
Psychiatry 157: 1873-1875 
Hodgkinson S. Sherrington R, Gurling H, Marchbanks R. Reeders S. Mallet J, Mcinnis M, Petursson H, 
Brynjolfsson J (1987) Molecular genetic evidence for heterogeneity in manic depression. Nature 
325:805-806 
Hoehe 	MR, Wendel B, Grunewald I, Chiaroni P, Levy N, Morris-Rosendahl D, Macher JP, Sander T, 
Crocq MA (1998) Serotonin transporter (5-HTT) gene polymorph isms are not associated with 
susceptibility to mood disorders. Am J Med Genet 81 :1-3 
Holmans P (1993) Asymptotic properties of affected-sib-pair linkage analysis. Am .I Hum Genet 

52:362-374 

Holmans P, Craddock N (1997) Efficient strategies for genome scanning using maximum-likelihood 
affected-sib-pair analysis. Am J Hum Genet 60:657-666 
Hwu HG, Yeh EK, Chang LY (1989) Prevalence of psychiatric disorders in Taiwan defined by the Chinese 
DiagnostiC Interview Schedule. Acta Psychiatr Scand 79:136-147 
InoueK, Lupski JR (2003) Genetics and genomics of behavioral and psychiatric disorders. Curr Opin 
Genet Dev 13:303-309 
Isometsa E, Henriksson M, Marttunen M, Heikkinen M, Aro H, Kuoppasalmi K, Lonnqvist J (1995) Mental 
disorders in young and middle aged men who commit suicide. Bmj 310:1366-1367 
Isometsa E, Suominen K, Mantere 0, Valtonen H. Leppamaki S, Pippingskold M, Arvilommi P (2003) The 
mood disorder questionnaire improves recognition of bipolar disorder in psychiatric care. BMC 
Psychiatry 3:8 
Itokawa M, Yamada K, Iwayama-Shigeno Y, Ishitsuka Y, Detera-Wadleigh S, Yoshikawa T (2003) Genetic 
analysis of a functional GRIN2A promoter (GT)n repeat in bipolar disorder pedigrees in humans. 
Neurosci Lett 345:53-56 
Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T (2004) Molecular characterization of bipolar disorder by 
comparing gene expression profiles of postmortem brains of major mental disorders. Mol 
Psychiatry 9:406-416 
Jamison KR (2000) Suicide and bipolar disorder. J Clin Psychiatry 61 Suppl 9:47-51 
Jemej B, Stefulj J, Hranilovic D, Balija M, Skavic J, Kubat M (2004) lntronic polymorphism of tryptophan 
hydroxylase and serotonin transporter: indication for combined effect in predisposition to suicide. J 
Neural Transm 111 :733-738 
Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, Ueda H, Cordell HJ, Eaves lA, 
Dudbridge F, Twefls RC, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, 
Tuomilehto J, Gough SC, Clayton DG, Todd JA (2001) Haplotype tagging for the identification of 
common disease genes. Nat Genet 29:233-237 
151 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
H (2001) A genome survey indicates a possible susceptibility locus for bipolar disorder on 
chromosome 22. Proc Natl Acad Sci USA 98:585-590 
Kennedy JL, Basile VS, Macciardi FM (1999) Chromosome 4 Workshop Summary: Sixth World Congress 
on Psychiatric Genetics, Bonn, Germany, October 6-10, 1998. Am J Med Genet 88:224-228 
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC 
(1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1 073-1080 
Kessler RC, McGonagle KA, Swartz M, Blazer DG. Nelson CB (1993) Sex and depression in the National 
Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 29:85-96 
Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl 
Acad Sci USA 93:8455-8459 
Kluger 	AN. Siegfried Z, Ebstein RP (2002) A meta-analysis of the association between DRD4 
polymorphism and novelty seeking. Mol Psychiatry 7:712-717 
Kong A, Cox NJ (1997) Allele-sharing models: LaD scores and accurate linkage tests. Am J Hum Genet 
61 : 1179-1188 
Kruglyak L (1999) Prospects for whole-genome linkage disequilibrium mapping of common disease 
genes. Nat Genet 22: 139-144 
Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996) Parametric and nonparametric linkage analysis: 
a unified multipoint approach. Am J Hum Genet 58:1347-1363 
Kruglyak L, Lander ES (1995) High-resolution genetic mapping of complex traits. Am J Hum Genet 
56:1212-1223 
Kunkel 	LM (1986) Analysis of deletions in DNA from patients with Becker and Duchenne muscular 
dystrophy. Nature 322:73-77 
Lachman HM, Kelsoe JR, Remick RA, Sadovnick AD, Rapaport MH, Lin M, Pazur BA, Roe AM, Saito T, 
Papolos DF (1997) Linkage studies suggest a possible locus for bipolar disorder near the velo­
cardio-facial syndrome region on chromosome 22. Am J Med Genet 74:121-128 
Lambert D, Middle F, Hamshere ML, Segurado R, Raybould R, Corvin A, Green E, O'Mahony E, Nikolov I, 
Mulcahy T, Haque S, Bort S, Bennett P, Norton N, Owen MJ, Kirov G, Lendon C, Jones L, Jones 
I, Holmans P, Gill M, Craddock N (2005) Stage 2 of the Wellcome Trust UK-Irish bipolar affective 
disorder Sibling-pair genome screen: evidence for linkage on chromosomes 6q16-q21, 4q12-q21, 
9p21, 1 Op14-p12 and 18q22. Mol Psychiatry 
Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting 
linkage results. Nat Genet 11 :241-247 
Lander ES, Green P (1987) Construction of multi/ocus genetic linkage maps in humans. Proc Nat! Acad 
Sci USA 84:2363-2367 
Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 265:2037-2048 
Lash AE, Tolstoshev CM, Wagner L, Schuler GD, Strausberg RL, Riggins GJ, Altschul SF (2000) 
SAGEmap: a public gene expression resource. Genome Res 10:1051-1060 
Lathrop GM, Lalouel JM, Julier C, Ott J(1984) Strategies for multilocus linkage analysis in humans. Proc 
Natl Acad Sci USA 81 :3443-3446 
Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ (2004) Reduced spinophil in but not 
microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and 
153 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
MacKinnon OF, Jamison KR, DePaulo JR (1997) Genetics of manic depressive illness. Annu Rev 
Neurosci 20:355-373 
Maes T, Barcelo A, Buesa C (2002) Neuron navigator: a human gene family with homology to unc-53, a 
cell guidance gene from Caenorhabditis elegans. Genomics 80:21-30 
Mamounas LA, Blue ME, Siuciak JA, Altar CA (1995) Brain-derived neurotrophic factor promotes the 
survival and sprouting of serotonergic axons in rat brain. J Neurosci 15:7929-7939 
Manji HK, Bebchuk JM, Moore GJ, Glitz 0, Hasanat KA, Chen G (1999) Modulation of CNS signal 
transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. 
J Clin Psychiatry 60 Suppl 2:27-39; discussion 40-21, 113-116 
Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH (1995) Guanine nucleotide-binding 
proteins in bipolar affective disorder. Effects of long-term lithium treatment. Arch Gen Psychiatry 
52:135-144 
Manji HK, Drevets WC, Charney OS (2001) The cellular neurobiology of depression. Nat Med 7:541-547 
Manji HK, Moore GJ, Rajkowska G, Chen G (2000) Neuroplasticity and cellular resilience in mood 
disorders. Mol Psychiatry 5:578-593 
Mann JJ (1998) The neurobiology of suicide. Nat Med 4:25-30 
Mann JJ (2002) A current perspective of suicide and attempted suicide. Ann Intern Med 136:302-311 
Mann JJ, Waternaux C, Haas GL, Malone KM (1999) Toward a clinical model of suicidal behavior in 
psychiatric patients. Am J Psychiatry 156:181-189 
Maris RW (2002) Suicide. Lancet 360:319-326 
Martin ER, Monks SA, Warren LL, Kaplan NL (2000) A test for linkage and association in general 
pedigrees: the pedigree disequilibrium test. Am J Hum Genet 67:146-154 
Matsushita S, Kimura M, Miyakawa T. Yoshino A. Murayama M. Masaki T. Higuchi S (2004) Association 
study of brain-derived neurotrophic factor gene polymorphism and alcoholism. Alcohol Clin Exp 
Res 28:1609-1612 
Matsushita S, Yoshino A, Murayama M, Kimura M, Muramatsu T, Higuchi S (2001) Association study of 
serotonin transporter gene regulatory region polymorphism and alcoholism. Am J Med Genet 
105:446-450 
Maziade M, Roy MA, Chagnon YC, Cliche 0, Fournier JP, Montgrain N. Dion C, Lavallee JC, Garneau Y, 
Gingras N, Nicole L, Pires A, Ponton AM, Potvin A, Wallot H, Merette C (2004) Shared and 
speCific susceptibility loci for schizophrenia and bipolar disorder: a dense genome scan in Eastern 
Quebec families. Mol Psychiatry 
Maziade M, Roy MA, Rouillard E. Bissonnette L, Fournier JP, Roy A, Garneau Y, Montgrain N, Potvin A, 
Cliche 0, Dion C, Wallot H, Fournier A, Nicole L, Lavallee JC, Merette C (2001) A search for 
specific and common susceptibility loci for schizophrenia and bipolar disorder: a linkage study in 
13 target chromosomes. Mol Psychiatry 6:684-693 
McCarthy A (2001) Pharmacogenetics. Bmj 322:1007-1008 
McDonald C, Bullmore ET, Sham PC, Chitnis X, Wickham H, Bramon E, Murray RM (2004) Association of 
genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural 
endophenotypes. Arch Gen Psychiatry 61 :974-984 
155 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Miklowitz DJ, Goldstein MJ, Nuechterlein KH, Snyder KS, Mintz J (1988) Family factors and the course of 
bipolar affective disorder. Arch Gen Psychiatry 45:225-231 
Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B (2001) Serotonin-
2A-receptor and -transporter polymorphisms: lack of association in patients with major 
depression. Neurosci Lett 303:119-122 
Mitchell P, Mackinnon A, Waters B. 1993. The genetics of bipolar disorder. 

Austr NZ J Psych. 1993 Dec;27(4):560-80. Review. 

Monaco AP, Bertelson CJ, Middlesworth W, Colletti CA, Aldridge J, Fischbeck KH, Bartlett R, Pericak­
Vance MA, Roses AD, Kunkel LM (1985) Detection of deletions spanning the Duchenne muscular 
dystrophy locus using a tightly linked DNA segment. Nature 316:842-845 
Morissette J, Villeneuve A, Bordeleau L, Rochette D, Laberge C, Gagne B, Laprise C, Bouchard G, Plante 
M, Gobeil L, Shink E, Weissenbach J, Barden N (1999) Genome-wide search for linkage of 
bipolar affective disorders in a very large pedigree derived from a homogeneous population in 
quebec points to a locus of major effect on chromosome 12q23-q24. Am J Med Genet 88:567-587 
Morton NE (1955) Sequential tests for the detection of linkage. Am J Hum Genet 7:277-318 
Morton NE (1998) Significance levels in complex inheritance. Am J Hum Genet 62:690-697 
Morton NE, Collins A (1998) Tests and estimates of allelic association in complex inheritance. Proc Natl 
Acad Sci USA 95:11389-11393 
Mukhopadhyay N, Almasy L, Schroeder M, Mulvihill Wp, Weeks DE. 1999. 
Mega2, a data-handling program for facilitating genetic linkage and association analyses. Am J 
Hum Genet 65:A436 
Muller-Oerlinghausen B, Berghofer A, Bauer M (2002) Bipolar disorder. Lancet 359:241-247 
Mundo 	E, Tharmalingham S, Neves-Pereira M, Dalton EJ, Macciardi F, Parikh SV, Bolonna A, Kerwin 
RW, Arranz MJ, Makoff AJ, Kennedy JL (2003) Evidence that the N-methyl-D-aspartate subunit 1 
receptor gene (GRIN 1) confers susceptibility to bipolar disorder. Mol Psychiatry 8:241-245 
Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: Global Burden 
of Disease Study. Lancet 349:1436-1442 
Myrick 	 H, Brady KT (2003) The use of divalproex in the treatment of addictive disorders. 
Psychopharmacol Bull 37 Suppl 2:89-97 
Negash A, Kebede D, Alem A, Melaku Z, Deyessa N, Shibire T, Fekadu A, Fekadu D, 
Jacobsson L, Kullgren G. 2004. Neurological soft signs in bipolar I disorder patients. Journal of 
Affective Disorders 80 (2-3): 221-230 
Nath J, Sagar R (2001) Late-onset bipolar disorder due to hyperthyroidism. Acta Psychiatr Scand 104:72­
73; discussion 74-75 
Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL (2002) The brain-derived 
neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based 
association study. Am J Hum Genet 71:651-655 
New AS, Gelernter J, Goodman M, Mitropoulou V, Koenigsberg H, Silverman J, Siever LJ (2001) Suicide, 
impulsive aggression, and HTR1 B genotype. Bioi Psychiatry 50:62-65 
Newman M, Zohar J, Kalian M, Belmaker RH (1984) The effects of chronic lithium and ECT on A1 and A2 
adenosine receptor systems in rat brain. Brain Res 291:188-192 
157 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Oquendo MA, Waternaux C, Brodsky B. Parsons B. Haas GL. Malone KM. Mann JJ (2000) Suicidal 
behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J 
Affect Disord 59: 107-117 
Ott J (1989) Computer-simulation methods in human linkage analysis. Proc Nat! Acad Sci USA 86:4175­
4178 
Ott J. Hoh J (2000) Statistical approaches to gene mapping. Am J Hum Genet 67:289-294 
Papadimitriou GN, Dikeos DG, Karadima G. Avramopoulos D, Daskalopoulou EG. Vassilopoulos D, 
Stefanis CN (1998) Association between the GABA(A} receptor alpha5 subunit gene locus 
(GABRA5) and bipolar affective disorder. Am J Med Genet 81 :73-80 
Papiol S, Rosa A, Gutierrez B. Martin B, Salgado p. Catalan R, Arias B, Fananas L (2004) Interleukin-1 
cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet 41 :219­
223 
Parsian A, Chakraverty S, Todd RD (1995) Possible association between the dopamine D3 receptor gene 
and bipolar affective disorder. Am J Med Genet 60:234-237 
Parsian A. Todd RD, Devor EJ. O'Malley KL, Suarez BK. Reich T, Cloninger CR (1991) Alcoholism and 
alleles of the human D2 dopamine receptor locus. Studies of association and linkage. Arch Gen 
Psychiatry 48:655-663 
Pauls DL (1993) Behavioural disorders: lessons in linkage. Nat Genet 3:4-5 
Peet NP. Bey P (2001) Pharmacogenomics: challenges and opportunities. Drug Discov Today 6:495-498 
Perez J. Tardito D. Mori S, Racagni G. Smeraldi E. Zanardi R (2000) Altered Rap1 endogenous 
phosphorylation and levels in platelets from patients with bipolar disorder. J Psychiatr Res 34:99­
104 
Perris C (1966) A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. 
Introduction. Acta Psychiatr Scand Suppl 194:9-14 
Persson ML. Geijer T, Wasserman D, Rockah R, Frisch A. Michaelovsky E. Jonsson EG. Apter A. 
Weizman A (1999) Lack of association between suicide attempt and a polymorphism at the 
dopamine receptor D410cus. Psychiatr Genet 9:97-100 
Petty F (1995) GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34:275-281 
Phillips 	ML, Drevets WC, Rauch SL, Lane R (2003) Neurobiology of emotion perception I: The neural 
basis of normal emotion perception. Bioi Psychiatry 54:504-514 
Potash JB, Kane HS, Chiu YF, Simpson SG, MacKinnon DF, Mcinnis MG. McMahon FJ. DePaulo ,IR, Jr. 
(2000) Attempted suicide and alcoholism in bipolar disorder: clinical and familial relationships. Am 
J Psychiatry 157:2048-2050 
Potash JB, Willour VL, Chiu YF, Simpson SG, MacKinnon DF, Pearlson GD, DePaulo JR, Jr., Mcinnis MG 
(2001) The familial aggregation of psychotic symptoms in bipolar disorder pedigrees. Am J 
Psychiatry 158:1258-1264 
Potter WZ, Manji HK (1994) Catecholamines in depression: an update. Clin Chern 40: 279-287 
Prathikanti S. McMahon FJ (2001) Genome scans for susceptibility genes in bipolar affective disorder. 
Ann Med 33:257-262 
Preda A, MacLean RW. Mazure CM, Bowers MB, Jr. (2001) Antidepressant-associated mania and 
psychosis resulting in psychiatric admissions. J Clin Psychiatry 62:30-33 
159 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman 
RM, Charney OS, Krystal JH. 1999. Reduced cortical gamma-amino butyric acid levels in 
depressed patients determined by proton magnetic resonance spectroscopy. Archives of General 
Psychiatry 56(11 ):1 043-7 
Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting 
evidence. Am J Psychiatry 122:509-522 
Schindler KM, Richter MA, Kennedy JL, Pato MT, Pato CN (2000) Association between homozygosity at 
the COMT gene locus and obsessive compulsive disorder. Am J Med Genet 96:721-724 
Schmitz G, Aslanidis C, Lackner KJ (2001) Pharmacogenomics: implications for laboratory medicine. Clin 
Chim Acta 308:43-53 
Schosser A, Fuchs K, Leisch F, Bailer U, Meszaros K, Lenzinger E, Willinger U, Strobl R, Heiden A, 
Gebhardt C, Kasper S, Sieghart W, Hornik K, Aschauer HN (2004) Possible linkage of 
schizophrenia and bipolar affective disorder to chromosome 3q29; a follow-up. J Psychiatr Res 
38:357-364 
Schulze TG, Buervenich S, Badner JA, Steele CJ, Detera-Wadleigh SO, Dick 0, Foroud T, Cox NJ, 
MacKinnon OF, Potash JB, Berrettini WH, Byerley W, Coryell W, DePaulo JR, Jr., Gershon ES, 
Kelsoe JR, Mcinnis MG, Murphy DL, Reich T, Scheftner W, Nurnberger JI, Jr., McMahon FJ 
(2004) Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective 
disorder in the national institute of mental health genetics initiative pedigrees. Bioi Psychiatry 
56:18-23 
Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, OUe AC, Tullius M, Kovalenko S, Bogaert 
AV, Maier W, Rietschel M, Propping P, Nothen MM, Cichon S (2004) Examination of G72 and 0­
amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol 
Psychiatry 9:203-207 
Schurhoff F, Bellivier F, Jouvent R, Mouren-Simeoni MC, Bouvard M, Allilaire JF, Leboyer M (2000) Early 
and late onset bipolar disorders: two different forms of manic-depressive illness? J Affect Disord 
58:215-221 
Schwab SG. Hallmayer J. Albus M. Lerer B, Eckstein GN, Borrmann M, Segman RH, Hanses C, 
Freymann J, Yakir A, Trixler M, Falkai P, Rietschel M, Maier W, Wildenauer DB (2000) A genome­
wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: 
support for loci on chromosome 10p and 6. Mol Psychiatry 5:638-649 
Scott SK, Young AW, Calder AJ, Hellawell OJ, Aggleton JP, Johnson M (1997) Impaired auditory 
recognition of fear and anger following bilateral amygdala lesions. Nature 385:254-257 
Segurado R, Detera-Wadleigh SO, Levinson OF, Lewis CM, Gill M. Nurnberger JI, Jr., Craddock N. et al. 
(2003) Genome scan meta-analysis of schizophrenia and bipolar disorder. part III: Bipolar 
disorder. Am J Hum Genet 73:49-62 
Serretti A, Artioli P (2004) From molecular biology to pharmacogenetics: a review of the 
literature on antidepressant treatment and suggestions of possible candidate genes. 
Psychopharmacology (Berl) 174:490-503 
Serretti A, Cusin C, Rossini 0, Artioli P. Dotoli 0, Zanardi R (2004) Further evidence of a combined effect 
of SERTPR and TPH on SSRls response in mood disorders. Am J Med Genet 129B:36-40 
Serretti A, Lilli R, Mandelli L. Lorenzi C, Smeraldi E (2001a) Serotonin transporter gene associated with 
lithium prophylaxis in mood disorders. Pharmacogenomics J 1 :71-77 
161 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Smith MA, Makino S, Kvetnansky R, Post RM (1995) Stress and glucocorticoids affect the expression of 
brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 
15: 1768-1777 
Sobel E, lange K (1996) Descent graphs in pedigree analysis: applications to haplotyping, location 
scores, and marker-sharing statistics. Am J Hum Genet 58:1323-1337 
Sobel E, Papp JC, lange K (2002) Detection and integration of genotyping errors in statistical genetics. 
Am J Hum Genet 70:496-508 
Sobel E, Sengul H, Weeks DE (2001) Multipoint estimation of identity-by-descent probabilities at arbitrary 
positions among marker loci on general pedigrees. Hum Hered 52:121-131 
Soloff PH, lynch KG, Kelly TM, Malone KM, Mann JJ (2000) Characteristics of suicide attempts of 
patients with major depressive episode and borderline personality disorder: a comparative study. 
Am J Psychiatry 157:601-608 
Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 
7:201-204 
Spedding M, Neau I, Harsing l (2003) Brain plasticity and pathology in psychiatric disease: sites of action 
for potential therapy. Curr Opin Pharmacol 3:33-40 
Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission test for linkage disequilibrium: the insulin 
gene region and insulin-dependent diabetes mellitus (100M). Am J Hum Genet 52:506-516 
Stahl SM, (Eds), 2000. Essential psychopharmacology, second edition. 

Cambridge University press 

Steimer W, Muller B, leucht S, Kissling W (2001) Pharmacogenetics: a new diagnostic tool in the 
management of antidepressive drug therapy. Clin Chim Acta 308:33-41 
Stoll Al, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M (1994) 
Antidepressant-associated mania: a controlled comparison with spontaneous mania. Am J 
Psychiatry 151: 1642-1645 
Stoltenberg SF, Burmeister M (2000) Recent progress in psychiatric genetics-some hope but no hype. 
Hum Mol Genet 9:927-935 
Straub RE, Maclean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Webb BT, Zhang J, Walsh 
0, et al. (1995) A potential vulnerability locus for schizophrenia on chromosome 6p24-22: 
evidence for genetic heterogeneity. Nat Genet 11 :287-293 
Swann 	AC, Bowden Cl, Morris 0, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM (1997) 
Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 
54:37-42 
Swann AC, Pazzaglia P, Nicholls A, Dougherty OM, Moeller FG (2003) Impulsivity and phase of illness in 
bipolar disorder. J Affect Disord 73:105-111 
Thoenen H (1995) Neurotrophins and neuronal plasticity. Science 270:593-598· 
Thome J, Sakai N, Shin K, Steffen C, Zhang Y J, Impey S, Storm 0, Duman RS (2000) cAMP response 
element-mediated gene transcription is upregulated by chronic antidepressant treatment. J 
Neurosci 20:4030-4036 
Tishkoff SA, Verrelli 	BC (2003) Role of evolutionary history on haplotype block structure in the human 
genome: implications for disease mapping. Curr Opin Genet Dev 13:569-575 
163 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, et al. (1998) Large-
scale identification, mapping, and genotyping of single-nucleotide polymorph isms in the human 
genome. Science 280:1077-1082 
Warman OM, Forman EM, Henriques GR, Brown GK, Beck AT (2004) Suicidality and psychosis: beyond 
depression and hopelessness. Suicide Life Threat Behav 34:77-86 
Warren JT, Jr., Peacock ML, Rodriguez LC, Fink JK (1993) An Mspl polymorphism in the hyman serotonin 
receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 2:338 
Washizuka S, Iwamoto K, Kazuno AA, Kakiuchi C, Mori K, Kametani M, Yamada K, Kunugi H, Tajima 0, 
Akiyama T. Nanko S. Yoshikawa T, Kato T (2004) Association of mitochondrial complex I subunit 
gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the National Institute of Mental 
Health pedigrees. Bioi Psychiatry 56:483-489 
Weber WW (2001) The legacy of pharmacogenetics and potential applications. Mutat Res 479:1-18 
Weeks DE, Lange K (1988) The affected-pedigree-member method of linkage analysis. Am J Hum Genet 
42:315-326 
Weeks 	DE, Lange K (1992) A multilocus extension of the affected-pedigree-member method of linkage 
analysis. Am J Hum Genet 50:859-868 
Weeks 	DE, Lathrop GM (1995) Polygenic disease: methods for mapping complex disease traits. Trends 
Genet 11 :513-519 
Wei J, Hemmings GP (2000) Searching for a locus for schizophrenia within chromosome Xp11. Am .1 Med 
Genet 96:4-7 
Weissman MM, Bland R, Joyce PR, Newman S, Wells JE, Wittchen HU (1993) Sex differences in rates of 
depression: cross-national perspectives. J Affect Disord 29:77-84 
Weissman MM, Gershon ES, Kidd KK, Prusoff BA, Leckman JF, Dibble E, Hamovit J, Thompson WD, 
Pauls DL, Guroff JJ (1984) Psychiatric disorders in the relatives of probands with affective 
disorders. The Yale University--National Institute of Mental 'Health Collaborative Study. Arch Gen 
Psychiatry 41 :13-21 
Whittemore AS, Halpern J (1994) A class of tests for linkage using affected pedigree members. Biometrics 
50:118-127 
Wildenauer DB, Schwab SG (1999) Chromosomes 8 and 10 workshop. Am J Med Genet 88:239-243 
Willeit M, Praschak-Rieder N, Zill P, Neumeister A, Ackenheil M, Kasper S, Bondy B (2003) C825T 
polymorphism in the G protein beta3-subunit gene is associated with seasonal affective disorder. 
Bioi Psychiatry 54:682-686 
Williams RS, Cheng L, Mudge AW, Harwood AJ (2002) A common mechanism of action for three mood­
stabilizing drugs. Nature 417:292-295 
Willour VL, Zandi PP, Huo Y, Diggs TL, Chellis JL, MacKinnon OF, Simpson SG, McMahon FJ, Potash 
JB, Gershon ES, Reich T, Foroud T, Nurnberger JI, Jr., DePaulo JR, Jr., Mcinnis MG (2003) 
Genome scan of the fifty-six bipolar pedigrees from the NIMH genetics initiative replication 
sample: chromosomes 4, 7, 9,18,19,20, and 21. Am J Med Genet 1218:21-27 
Wiltshire S, Cardon LR, McCarthy MI (2002) Evaluating the results of genomewide linkage scans of 
complex traits by locus counting. Am J Hum Genet 71 :1175-1182 
Wunderlich U, Bronisch T, Wittchen HU, Carter R (2001) Gender differences in adolescents and young 
adults with suicidal behaviour. Acta Psychiatr Scand 104:332-339 
165 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
APPENDICES 

APPENDIX A: Request form for molecular studies 
APPENDIX B: Techniques 
APPENDIX C: Media, Buffers and Solutions 
APPENDIX D: Scripts 
167 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
AU 	 (~~, 
REQUEST FOR MOLECULAR STUDIES roNA) .. Lq~"'"tJ . 
I 
Pltol<' It lUMll:SAlt 

Molecular Laboratory 

Division orRuman Genetics 

ht Floor, Anatmny Building 

VCt Medleal School, Observatory 7925 

SOUTH AFRICA 

nl: 27-21- 406 6297 Fax: 27-21. 44m03 
Slli'IllII\\e: 	 FirlItNatI'Ie(s):______________ 
NewFIimiIy: Yes [] NoX (Ifno,plesseflll infilmily name) Flimilynmne: __________________ 
Medieal Aid: Mtdieal Aid No: _____________ 
Sex: M [J II [J Dateofl3irth: Year:__~ .. ~,,_ Month: Day:_~_____ 

Number ofeblldren: _________________ 

Elhl'lie Origin: (please indicate lII\ocatty ofbolhyourinOlher BIId father )_________--.._______ 

~ax: 
OO!lI4Ct~: TOWl\' _________ 	 Tel: 
F6\{:
R.eferringDoctor/Sister: 	 Town: _______= Tel: 
Pax: 
HoSplw or AcIcltess: _____________ ToWl\, ________ Tel: 
Reason fOr Referral (Clinical diaenosis): 
Affeeted [J AtRlsk 0 Camer [] Spouse D QUery C UlIlI!Ieeted [J 
[Jtleclrer Muscular Oys. [J DucheMeMuscularI>ys 0 Colonic Carcinoma 
Frngile.X Syndrome [J BipolarDisorder [J Huntington Oisesae [J 
Retinitis PigmentoM [J Spinocerebellar Ataxia [J Waardenberg Syndrome [J 
AdditionAl disorders (appatentot previbUtlly wated): _______________________ 

Additional family history 

Clinieal Details: 

physical disability [J Mental retardation [J Oeameaa [J Impalred vision [J Night blindness [J 

011\111': ____________________________________________________________________ 

Have samples from this patient been sent to aDNA lab before? (DELETE WHERE NOT APPLICABLE) YES INO I Don't Know 
ffYca.where: ______________________________________________ 
For Lqbprgtgry 1W! onlVi 
_____~_ VoLBlood: (lilt) OtMI': ______DNA nllmber: 

Datt R,ceived: 1,(11': Month: Day: ______ Comput4rlndilt:NIJ•. __________ 

CONSENT FOR DNA ANALYSIS AND STORAGE 
1. 1, ._ "",' ... _ '= , request that an 
attempt be made using genetic material to assess the probability that: I I my child I my unborn child 
(DELETE WH1l.RE NOT APPLICABLE) might have iDh~ It d.istase-causing mutatiOJ:l in the getl.e 
f~:___________________________________________________________ 
2. I understand that the genetic material f~ analysis is to be obtained from: blood cells/skin sample/other (specify) 
(DELETE WHERE NOT APPLICABLE) : 
3. I request that no portiOJ:l ofthe wnple be stored for lAter use. [] (MARK IF APPLICABLE) 
Or 
I request that It portion ofthe santple be stored indefinitely for (DELETE WHERE NOT APPLICABLE): 
( a) possible re-analysis 
( b) analysis tOr the benefit ofmembet$ ofmy inunediate t8rniJ.y 
( c) research purposes, subject to the approval ofthe 'University ofCape Town Research Ethics 
Committee, provided that any information from such research will remain confidential. 
4. The results ofthe analysis carried dill. OJ:I this wnple ofstored biological material will be made known to me, 
via my doct~. in accordance with the relevant protocol, ifand when available. 
In addition, I authorise that they mAy be made known to: (DELETE WHERE NOT APPLICABLE) : 
other doctors involved in illy care 
the following family membet$: 
other: .____~_.~~._.~... 
I S. I authorise I do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) to provide relevant clinical 
details to the Division ofHuman Genetics, VCT. 
I 6. I have been infonned that: 
( a) there are risks IIIld benefits ~atedwith genetic analysis and storage ofbiological material and 
these have been explai.ned to me. 
( b ) the analysis procedure is specific to the genetio condition mentioned above IIIld cannot detennine 
the complete genetio makeup ofan individual. 
( c ) the genetics laboratory is under an obligation to respect medical COIIfidentiality . 
( d ) genetic analysis may not be informative for some families ~ SUnily membet$, 
( e ) even under the best conditions, current technology ofthis type is not perfect and could lead to 
inCorrect results. 
( f) where biological material is used for research purposes, there may be no direct benefit to me. 
7. I understand that I may withdraw my consent for any aspect ofthe above at any time without this affecting my 
future medical care. 
8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND 
AND MY QUESTIONS ANSWERED BY: 
DATE: 
Patient signature _______ Witnessed eonsent 
NOTE· PLEASE INSERT AFAMILY PE))IGREE DRAWING ON THE REVERSE OF THIS FORM 
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APPENDIX B 
Techniques 
B.1 DNA isolation from lymphocytes 
B.2 DNA oligonucleotides 
B.3 Genotype analysis 
B.4 Restriction endonuclease digests 
B.S DNA sequencing 
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USA), dextran blue (Genescan®, PE Applied Biosystems, Foster City, USA) and ROX-500 
size standard (Genescan®, PE Applied Biosystems, Foster City, USA). Samples were heat 
denatured at 95°C for 2min and placed on ice before loading on 12cm (well-to-read) ABI 
plates. 
8.3.2 3100 Genetic Analyzer 
To 11-11 of sample (in 96 well plates) add 81-11 of loading buffer, containing 0.51-11 of ROX-500 size 
standard (Genescan®, PE Applied Biosystems, Foster City, USA) and 8.5 1-11 of Hi-Di formamide 
(Genescan®, PE Applied Biosystems, Foster City, USA). Samples were heat denatured at 95°C for 
2min and placed on ice before loading on the 3100 Genetic Analyzer. 
8.4 Restriction Endonuclease Digestion 
Restriction enzymes were purchased from: 
• 	 Promega, UK 
• 	 New England Biolabs, UK 
• Roche, Germany 
Conditions described by the manufacturers' were followed at all times. 
8.5 DNA Sequencing 
• 	 The PCR product was first separated on a 2% agarose gel, after which the DNA fragment was 
excised from the agarose gel with a clean, sharp scalpel. 
• 	 The DNA was purified in QIAquick spin columns (Qiagen, UK) according to the manufacturer's 
QIAquick Gel extraction protocol. 
• 	 Purified PCR products were sequenced using the BigOye terminator cycle sequencing kit 
(Applied Biosystems, USA), according to the manufacturer's protocol. 
• 	 Centri-Sep Spin Columns (Princeton separations, USA) were used to remove unincorporated 
nucleotides. 
• 	 The sequencing reactions were separated by automated gel electrophoresis using an ABI 
PRISM 377 DNA sequencer (Applied Biosystems, USA). 
Centri-Sep spin column clean-out 
• 	 To hydrate the column, one has to proceed as follows: 
• 	 Gently tap the column to insure that the dry gel has settled in the bottom of the spin column 
• 	 Remove the column cap and reconstitute the column by adding 0.80ml of reagent grade water 
or buffer. Leave the column end stopper in place so the column can stand up by itself. 
Replace the column cap and hydrate the gel by shaking and inverting the column or vortexing 
briefly. It is important to hydrate all of the dry gel 
• 	 Allow at least 30 min of room temperature hydration time before using the columns. 
Reconstituted columns may be stored refrigerated at 4°C for several days. Longer storage 
may be accomplished in 10mM sodium azide 
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APPENDIXC 
Media. Buffers and Solutions 
C.1 10X TBE 
C.2 Agarose loading buffer 
C.3 Formamide loading dye 
CA 6% denaturing polyacrylamide gels 
C.S Silver staining 
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APPENDIX 0 
Scripts 
D.1 reams 
D.2 maketwa.f 
D.3 gaadseript 
D.3.1 vieams 
D.3.2 swap3.f 
D.3.3 extraetline41 . f 
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DOUBLE PRECISION posn(SOO), priO(2000), pri1 (2000), 
+pri2(2000), postO(2000,SOO), post1 (2000,SOO), post2(2000,SOO), 
+dumposn, fpriO(2000), fpri1 (2000), fpri2(2000), 
+fpostO(2000), fpost1 (2000), fpost2(2000), fOO, f01, f02, 
+f10, f11, f12, f20, f21, f22, pOO, pOi, p02, p10, p11, p12, 
+p20, p21,p22 
INTEGER i, j, npairs, nincrs, fam(2000), id1 (2000), id2(2000), 
+ pfam(2000), pid1 (2000), pid2(2000), k, ffam(2000), fid 1 (2000), 
+ fid2(2000), 
+ pffam(2000), pfid 1 (2000), pfid2(2000) 
open(3, file='maketwo.dat', status='old') 

open(4, file = 'firstprior.mpt', status = 'old') 

open{S, file= 'firstposterior.mpt', status= 'old') 

open(6, file = 'secondprior.mpt', status = 'old') 

open(7, file::: 'secondposterior.mpt', status= 'old') 

open( 14, file:::'twoposterior.dat', status:::'unknown') 

open{1S, file='twoprior.dat', status='unknown') 

read(3, *) npairs 

read(3, *) nincrs 

read(4,*) 

read{S,") 

read{6,*) 

read(7, *) 

# assume only one position at first locus, possibly many at second 
# read in data for second locus 
do 100 i=1,npairs 
read(6, *) fam(i), id1 (i), id2(i), priO(i). pri1 (i), pri2(i) 
do 200 j=1 ,nincrs 
read(7, *) pfam(i). posnU), pid 1 (i), pid2(i). postO(i,j}. 

+post1 (i.j), post2(i,j) 
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+({fid1 (i).eq.id2U)).and.(fid2(i).eq.id1 0))))) then 
fOO= fpriO(i)*priOU) 

f01 = fpriO(i)*pri1 U) 

f02= fpriO{i)*pri2U) 

f1 0= fpri1 (i)*priOU) 

f11 = fpri1 (i)*pri1 U) 

f12= fpri1 (i)*pri2U) 

f20= fpri2{i)*priOO) 

f21 = fpri2(i)*pri1 0) 

f22= fpri2(i)*pri20) 

do 500 k=1,nincrs 

pOO= fpostO(i)*postOO,k) 

p01 = fposto(i)*post1 O,k) 

p02= fpostO(i)*post20,k) 

p10= fpost1 (l)*postOO,k) 

p11= fpost1(l)*post10,k) 

p12= fpost1 (i)*post20,k) 

p20= fpost2(i)*postOO,k) 

p21 = fpost2(i)*post1 O,k) 

p22= fpost2(i)*post20,k) 

write(15,999), posn(k), ffam(i), fid1 (i), fid2(i), 
+fOO, f01, f02, f10, f11, f12, f20, f21, f22 
write( 14,999), posn(k), ffam(i), fid1 (i), fid2(i), 
+pOO, p01,p02,p10,p11,p12,p20,p21,p22 
500 continue 
end if 
400 continue 
300 continue 
999 format(fB.3,i12, i12, i12, 9f12.9) 
550 continue 
stop 
end 
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write(*,*) ped, id, pa, rna, sex, 

+aff, (a11 (i), aI2(i), i=1, nloci) 

100 continue 

stop 

end 

0.3.3 extractline41.f 
# This was part 02 goodscript 
# To extract line 41 of the twomls.out from twolocarp 
DOUBLE PRECISION posn, sing, mul, add, gen 
INTEGER i 
do 100 i=1,40 
read(*,*) 
100 continue 
read(*,*) posn, sing, mul, add, gen 

write(", *) posn, sing, mul, add, gen 

stop 

end 
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